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ABSTRACT 
The current system in place to study safety of medicines after introduction on the 
market relies on spontaneous reporting. Adverse events occurring long after initiation 
or cessation of drug use are likely to be missed by this system. In this thesis we 
explore methods to identify signals of long-term, unexpected adverse events and 
methods to evaluate these signals . 
. We utilised data from the UK General Practice Research Database (GPRD), a large 
primary care database. A review of the literature investigating the validity of medical 
diagnoses recorded in this database illustrated that the GPRD is a powerful tool to 
study morbidity in primary care. However, intimate knowledge of the complexities of 
the database is needed to ensure the best use is made of the database. 
Pre-existing hypotheses of drug-induced systemic lupus erythematosus (SLE) were 
evaluated using the GPRD. Associations between risk of SLE and exposure to 
hydralazine, minocycline, and carbamazepine were confirmed using both a matched 
case-control design and the self controlled case series method. Spontaneous reports 
of drug-induced SLE recorded in the UK Yellow Card database indicated that 
symptoms of SLE often resolve after withdrawal of the suspected drug. 
'Using the Smile Plot method to generate signals of drug-induced SLE, we were not 
able to identify known signals of drug-induced lUpus. However, we did identify factors 
strongly associated with treatment of early symptoms of disease. These findings 
indicated a high specificity of the Smile Plot method. To improve sensitivity, better 
hierarchical coding systems for drugs are needed to ensure appropriate grouping. 
Lastly, we utilised the GPRD to provide an example of a systematically performed 
drug safety study. In a small subset of data, we generated hypotheses of drug-
induced drug related hypothyroidism. Associations were subsequently evaluated in a 
larger subset of data. No drugs were clearly associated with risk of drug related 
hypothyroidism. 
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CHAPTER 1. INTRODUCTION 
1.1. DRUG SAFETY 
Prescription medicines undergo a thorough process of preclinical and clinical testing 
before approval for use in patients. The clinical phases of drug development are 
subdivided in Phases I through III. A small number of (usually) healthy individuals is 
for the first time exposed to the drug in Phase I. Phase II trials involve testing the 
drug on a small population of patients of the. target disease. The main aims during 
Phase I and II testing are to obtain information on tolerability, pharmacokinetic 
characteristics of a drug and required dosage and treatment regimen. During Phase 
III, randomised clinical trials are carried out. Due to the relatively small number of 
patients included in these trials, statistical power to detect unexpected and 
uncommon side effects is low. In addition, side effects occurring after a long time of 
use or long after cessation of use are unlikely to be identified due to the relatively 
short duration of these clinical trials. It is not until a drug is introduced on the market 
when the chance of detecting rare adverse drug reactions increases as the number of 
exposed patients and length of therapy increases[l]. 
1.1.1. Adverse Drug Reactions 
Adverse drug reactions (ADR) can be divided into two types. Type A reactions are 
undesirable drug effects that can be explained and predicted based on the 
pharmacologic action of a drug. Type A reactions are relatively common, dependent 
on dose and of mild severity. These reactions are likely to be identified during the 
pre-marketing phases of drug-development. Type B reactions on the other hand are 
unexpected adverse reactions that are usually not dose-related, of rare occurrence 
and more serious in terms of morbidity and mortality. An example of a Type B 
reaction is drug-induced lupus associated with use of procainamide. Because of their 
nature, Type B reactions are unlikely to be identified during Phases I to III of the 
drug development process. 
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1.1.2. Post-Marketing Surveillance 
Because the full safety profile of a di-ug is not known at the time of its approval, 
safety has to be monitored once the drug is on the market. The importance of post-
marketing surveillance is illustrated by public health tragedies such as in the 1960s, 
when an estimated 10,000 babies were born with congenital malformations due to 
exposure to thalidomide in utero[2]. A more recent example is that of cardiovascular 
events associated with selective cyclooxygenase inhibitors[3]. 
Post-marketing surveillance can roughly be divided into two steps[2]. Previously 
unknown adverse drug reactions are identified using signal detection methods. New 
signals are then investigated in further detail in analytical studies, for instance to 
confirm or refute causality, quantify risk, or to identify specific sub-groups of patients 
that are likely to present with the hypothesized adverse event. 
1.1.2.1. Signal Detection 
The current system in place to study safety of medicines after their introduction on 
the market relies predominantly on spontaneous reports. In addition to case reports 
that are published in the medical literature there are several national and 
international systems in which health care professionals (and sometimes consumers) 
have the opportunity to report suspected adverse events. For example, the US Food 
and Drug Administration (FDA) developed a reporting system called MedWatch in 
which standard forms are used by health care professionals to voluntarily report 
adverse events[4]. The largest international database of adverse event reports is 
held by the World Health Organisation (WHO) at the Uppsala Monitoring Centre in 
Sweden[S]. This database, containing case reports from over 60 countries, is 
screened on a regular basis in order to identify new adverse events[6]. As a result of 
~ 
these spontaneous reporting systems several (sometimes serious) adverse events 
have been newly identified, such as sudden cardiac death associated with sertindole 
exposure in 1998[7]. 
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Although spontaneous reports databases have proven to be useful tools to identify 
new adverse drug reactions, the data have a number of limitations. Most importantly, 
there is substantial under-reporting and reporting rates are subject to bias[5]. 
Secondly, the data only provide "numerator" data as the total number of adverse 
events is unknown. The number of available statistical methods to analyse 
spontaneous reports databases is therefore limited. Thirdly, individual case reports 
only contain a limited amount of information. For instance, detailed information on 
pre-existing medical conditions and past drug therapies is often lacking. Assessment 
of causality is therefore almost impossible. 
1.1.2.2. Multiple Comparisons 
In signal generation studies of drug safety, one studies large numbers of drugs which 
are potentially associated with the adverse drug reaction of interest (or alternatively, 
a large number of adverse events that are potentially associated with the drug of 
interest).For each individual drug - adverse event association, the significance level 
equals 100(1-a)% with a usually being 0.05 (i.e. a 95% significance level). However, 
when the number of potential associations being tested increases, the overall 
significance level decreases (e.g. when the number of associations tested is 20, the 
significance level will be 100(1- a)20% = 36% instead of 95%), and the chance to 
reject at least one null hypothesis increases (in the example stated above this chance 
would increase from 5% to 64%). A method commonly used to correct for this 
problem is called the Bo~ferroni correction. This method is extremely conservative 
and when the number of comparisons being made is large, a approaches zero. This 
may result in over-correction and a loss of statistical power whereby only those 
associations that are extremely strong are detected[8]. less conservative methods 
than the Bonferroni correction have been developed for studies with multiple 
comparisons. Examples are family wise error rate (FWER) methods and false 
discovery rate (FOR) methods. In general, FWER methods are utilised when a 
'medium' number of comparisons are made. FWER methods are less conservative 
than the Bonferroni correction, but still result in a approaching zero when a very 
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large number of comparisons are made. In large scale studies such as signal 
generation exercises, FOR methods are more useful to correct for multiple 
comparisons. 
1.1.2.3. The UK Yellow Card System 
In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) and its 
Commission on Human Medicines (CHM) are in charge of the "Yellow Card" scheme. 
It is a system of spontaneous reporting whereby health care professionals report 
suspected adverse events on a "Yellow Card". Health care professionals contributing 
to this scheme are GPs, dentists, hospital pharmacists (since 1997), community 
pharmacists (since 1999)[7] and, since late 2005, patients themselves can report 
suspected adverse drug reactions on a separate yellow card form. Drugs of interest 
are not only prescription drugs, but also vaccines, over the counter medicines, and 
herbal preparations. The "Yellow Card" is a standardised form containing patient 
descriptive information (sex and age), the suspected drug (which drug, dosage, route 
of administration, indication of therapy, start and stop dates of therapy), and details 
on the suspected drug reaction including severity, outcome (recovered or not) and 
dates of start and end of reaction. If known, other drugs taken in the 3 months prior 
to the~ reaction are also listed. The reports are anonymised and collected into a 
central database (formerly ADROIT, Adverse Drug Reactions Online Information and 
Tracking, currently this database is called "Sentinel"). 
Although yearly reporting rates (per million residents) for the Yellow Card scheme 
are known to be high compared to other countries[7J, the database is still subject to 
under-reporting. Only a limited percentage of health care professionals eligible to 
submit reports will actively do so[7J. For instance, an estimated 33% of practicing 
GPs submitted reports in the period from 1992 to 1995[7J. 
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1.1.2.4. Signal Evaluation 
Once adverse drug reactions have been identified, careful evaluation of signals is 
needed. A number of epidemiologic study designs are available to evaluate signals 
(i.e. test hypotheses). 
A commonly used study deSign is the case-control study, in which study subjects are 
selected based on their disease status. The odds of exposure to the suspected drug is 
compared between individuals with and without the outcome of interest (i.e. the 
adverse event). An alternative commonly used observational study design is the 
cohort study, in which study subjects are selected based on their exposure status. 
Subjects are then followed over time and the incidence of the outcome (adverse 
event) in the exposed group is compared to the incidence in the group not exposed 
to the suspected drug. 
An important problem with observational study designs is the potential influence of 
bias and confounding. When information on these factors has been measured, their 
effects can be investigated through statistical analyses. However, some factors (e.g. 
health-seeking behaviour) are difficult to quantify. For studies where unmeasured 
confounding is likely to play an important role, alternative statistical analysis 
." 
approa'C::hes have been developed, Two important methods are the case-crossover 
design and the self-controlled case series. Both methods make within-person 
comparisons, thereby cancelling out the effect of hard to measure factors that are 
likely to vary between the study group and reference group. The case-crossover 
design is derived from the case-control method, and compares prevalence of 
exposure in a predefined time period preceding the event versus prevalence during 
control periods[9]. The self-controlled case series method on the other hand is 
, .. 
derived from the cohort method, The incidence of an outcome during predefined risk 
periods after exposure is compared to the incidence of disease during baseline 
periods[lO]. A detailed explanation of the self-controlled case series method can be 
found in Chapter 3. 
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Intervention (experimental) study designs such as randomised clinical trials can also 
be used to study drug safety. Although well-designed interventional studies are less 
sensitive to bias and confounding than observational studies, the main drawback of 
interventional studies is that they are demanding in terms of time and resources. In 
case of a pressing drug safety issue when a timely answer is needed, interventional 
study designs will generally not be utilised. 
An important advantage of the case-control, cohort study and case-only study 
designs is that existing data sources can be utilised to answer newly arisen 
questions. A number of large health care databases are available to this end. 
Examples are Medicaid and health maintenance organisation (HMO) databases in the 
US. In addition, Pharmaceutical companies often hold their own databases of detailed 
patient information. The intricacies in terms of collection, completeness and quality of 
data are different for the different databases. However, these databases all contain 
computerised patient-level data for large numbers of individuals who are followed up 
for extended periods of time. These databases are therefore excellent data sources 
for drug safety studies, which often investigate uncommon drug exposures and/or 
rare adverse events. 
1.1.2.5. The General Practice Research Database (GPRD) 
The UK-based GPRD is a large primary care database containing anonymised patient 
level data. Over 98% of patients are registered with the UK National Health Service 
(NHS). NHS practices cOl)tributing to the GPRD are broadly representative of all UK 
practices in terms of age and sex distribution of patients, and geog"raphical 
distribution and size of practices[l1]. Patient-level data is collected prospectively by 
each contributing general practice. The quality of data, entered by practice staff and 
anonymised prior to central collection, is checked before and during contribution of 
data to the GPRD. If a number of quality criteria are met a practice is said to be "up-
to-standard"[12]. 
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A typical data set from the GPRD contains several components. Patient level data are 
provided in text format, in four separ~te files; a patient file containing general 
information including a patient's sex, age, date of birth and registration details. In 
the patient file, one row of data represents one unique patient. Medical information is 
recorded in a separate file, which includes dates of consultation and the 
corresponding OXMIS and Read codes for diagnoses and symptoms. In this medical 
file one patient may have several rows of data, depending on the number of consults 
with their GP. Therapy information includes prescriptions using codes from the 
prescription pricing authority (PPA) with corresponding dates, dosages and method of 
administration. Each patient may have several rows of therapy data depending on 
number of prescriptions received. For some patients additional information is 
available regarding vaccinations, weight, height and blood pressure measurements 
and laboratory test results. This information is recorded in a separate file which is 
called the prevention file. All information is entered by practice staff and is 
anonymised prior to central collection. 
Text descriptions of the OXMIS and Read codes for medical diagnoses and symptoms 
are listed in a medical dictionary. For each drug code, information on drug name, 
formulation, strength and a list of up to three British National Formulary (BNF) codes 
are listed in a therapy dictionary. 
1..2. EXAMPLES OF PO TEN TIALL Y DRUG-INDUCED DISEASE 
1.2.1. Systemic Lupus Erythematosus 
Systemic Lupus Erythematosus (SLE) is an autoimmune disease of the connective 
tissue. It is a lifelong disease which can affect multiple organ systems[13]. Around a 
third of patients initially present with a typical butterfly shaped rash in the face. 
Other commonly seen early symptoms of the disease include photosensitivity and 
arthritis [14]. Later in the course of the disease, major organs such as the lungs, 
heart and kidney may be affected, resulting in potentially life-threatening disease 
[13]. The majority of SLE patients have chronically active disease, or a relapsing-
18 
remitting course of disease. Several indices have been developed to monitor SLE 
disease activity and severity of organ damage [15]. SLE can have a major impact on 
quality of life of patients suffering from active disease [14], with fatigue being an 
important characteristic of the disease [16]. 
An important feature of the epidemiology of SLE is the female predominance [14]. 
Onset of disease often takes place in the decade after puberty, i.e. ages 20 to 30 
[14]. However, a study of SLE cases in the GPRD found a peak incidence in women 
aged 50 to 54 years [17]. Certain ethnic groups are of higher risk to develop SLE, 
including African-Americans and African Caribbeans, and Asians [13]. The incidence 
of SLE is generally low, although there are some marked differences in incidence and 
prevalence between different countries across the world [18]. In the UK, the age-
standardised incidence of SLE is estimated to be 7.9 per 100,000 person-years for 
women, and much lower for men, namely 1.5 per 100,000 [17]. 
Making a diagnosis of SLE is a complex process and is based on both clinical 
observation as well as laboratory tests [16]. The American College of Rheumatology 
has developed a list of eleven disease diagnostic criteria that are specific for SLE 
[19]. When at least four criteria are met, a patient is considered to have SLE. A 
number of these criteria are based on laboratory findings such as detection of specific 
autoantibodies, evidence of proteinuria, or hematologic abnormalities (e.g. 
leukopenia, thrombocytopenia, haemolytiC anaemia). Other criteria include a typical 
rash, arthritis, photosensitivity, oral ulcers and arthritis. 
Due to the wide variety of clinical manifestations of SLE, there is no "one size fits all" 
treatment regimen [20]. Because there is no curative therapy available for SLE, 
currently available treatments are targeted at control of disease activity and ideally 
achieving disease remission [21]. Traditionally, SLE is treated with antimalarials (e.g. 
hydroxychloroquine) which are especially useful in the treatment of articular and 
mucocutaneous manifestations of the disease. In addition, azathioprine is used for 
the treatment of a wide range of manifestations. Other traditional treatments include 
treatment with cytotoxic drugs such as cyclophosphamide, corticosteroids, and non-
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steroidal anti-inflammatory drugs (NSAIDs) to suppress inflammatory and immune 
mechanisms. Alternative, newer treatments such as biologicals are becoming more 
important in the treatment of SLE [20]. A number of these traditional and newer 
treatments are associated with serious side effects which can also greatly affect a 
patient's quality of life [14]. 
The pathogeneSiS of SLE is not fully understood. However, it is clear that genetic as 
well as environmental factors are important factors in disease susceptibility [13]. 
Environmental factors important in inducing disease as well as disease flares are 
exposure to ultraviolet light, exogenous and endogenous estrogen, and possibly 
infections (including Hepatitis C, Epstein-Barr Virus), and exposure to silica dust 
[14]. In addition, several prescription medicines have been implicated in the risk of 
SLE. Patients with the drug-induced form of the disease have widely overlapping 
symptoms compared to idiopathic SLE. 
1.2.1.1. Drug-Induced Lupus 
A wide range of prescription drugs has been reported to induce autoimmune disease. 
A search of the medical literature published in 2005 reveals a total of 52 publications 
reporting a drug suspected of inducing an autoimmune condition. The majority of 
these reports (47 out of 52) describe a single case of drug-induced autoimmunity. 
Eight reports (15%) appeared in non-English journals and are therefore less likely to 
reach large numbers of health care professionals world wide. 
The most extensively do'cumented drug-induced autoimmune disease is systemic 
lupus erythematosus (SLE). Since the first reports of procainamide and hydralazine-
induced lupus in the early 1950s, the list of drugs reported to lead to lupus has been 
growing[22]. Table 1-1 is reproduced from Rubin (2005)[23] and is the most recent 
overview of drug~ implicated in risk of lUpus. Therapeutic class and duration of 
treatment varies widely among the different drugs on this list. It is thought that 
drug-induced lupus develOps within one month up to several years after start of 
exposure to the causative drug[24]. In some cases treatment continued for over 10 
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years before the occurrence of clinically apparent disease[25]. 
Table 1-1: Drugs implicated in risk of SLE 
Agent Risk 
Anti-arrhytmics 
Procainamide High After one year of treatment at currently used doses, 
Quinidine Moderate 
Disopyramide Very low 
Propafenone Very low 
approximately 20% of procainamide users and 5 to 
Anti-hypertensives 
Hydralazine High 
8% of hydralazine users develop SLE. For the other 
Methyldopa Low 
Captopril Low 
Acebutolol Low 
drugs included in table 1-1, a much smaller 
Enalapril Very low 
Clonidine Very low percentage of users develops the disease (less than 
Atenolol Very low 
Labetalol Very low 
Pindolol Very low 1 %). Risk levels for these drugs are assessed based on 
Minoxidil Very low 
Prazosin Very low number of reports in the literature. Limited evidence is 
Anti-psychotics 
Chlorpromazine Low 
Phenelzine Very low available for quinidine, sulfasalazine, chlorpromazine, 
Chlorprothixene Very low 
Lithium carbonate Very low penicillamine, methyldopa, carbamazepine, acebutolol, 
Antibiotics 
Isoniazid Low 
Minocycline Low 
isoniazid, captopril, propylthiouracil and minocycline. 
Nitrofurantoin Very low Evidence for other drugs is based on a very small 
Anti-convulsants 
Carbamazepine Low 
Phenytoin· Very low amount of case reports and is these drugs are 
Trimethadione Very low 
Primidone Very low 
Ethosuximide Very low therefore considered to be of "very low" risk. To our 
Anti-thyroidals 
Propylthiouracil Low knowledge, no large analytical studies have been 
Anti-inflammatories 
D-Penicillamine Low 
conducted to confirm suspected associations and to 
Sulfasalazine Low 
Phenylbutazone Very low quantify risks associated with exposure to these drugs. 
Diuretics 
Chlorthalidone Very low 
Hydrochlorothiazide Very low The underlying mechanisms of drug-induced 
Miscellaneous 
Anti-tumor necrosis- 0. Very low 
Lovastatin Very low 
autoimmunity are not clear although it is thought that 
Levodopa Very low 
Aminoglutetheimide Very low 
Interferon- 0. Very low 
oxidative metabolites of the suspected drugs play a 
Timolol e~e-droes Ver~ low 
role in the development of autoimmunity[23]. Many 
reports of drug-induced lupus describe disappearance of symptoms upon withdrawal 
of the suspected drug and in some instances, re-challenge resulted in re-appearance 
of symptoms[22]: Such reports are in support of a causal association between the 
suspected drugs and risk of lupus. 
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1.2.2. Hypothyroid ism 
Hypothyroidism occurs when the thyroid gland is not producing sufficient thyroid 
hormone to maintain normal body functions [26]. This can be due to primary 
hypothyroidism (i.e. when the thyroid gland itself fails to work), or secondary 
hypothyroidism (i.e. when hormones dictating functionality of the thyroid gland are 
deregulated) [27]. The vast majority (up to 95%) of hypothyroidism cases have the 
primary form of the disease [27]. Hypothyroidism can also be classified according to 
the time of disease onset, namely congenital or acquired hypothyroidism. Congenital 
hypothyroidism occurs when the thyroid gland is not or not properly developed 
(agenesis or dysgenesis), or when the synthesis of thyroid hormone is impaired due 
to a genetic defect [28]. Acquired hypothyroidism occurs at a later stage in life and 
can be due to iodine insufficiency, surgical procedures or other medical treatment 
which affect functionality and mass of thyroid gland tissue, destruction of the thyroid 
gland through autoimmune processes, 
Worldwide, the major cause of primary hypothyroidism (including congenital 
hypothyroidism) is dietary iodine insufficiency [26]. However, in geographical areas 
where the diet provides sufficient iodine (such as the United Kingdom), 
hypothyroidism is most often caused by medical procedures affecting the thyroid 
gland (i.e. iatrogenic hypothyroidism), or by autoimmune mechanisms [26]. 
Although the pathogenesis of autoimmune thyroiditis is not fully understood, it is 
clear that genetic predisposition plays an important role. Individuals with a family 
history of autoimmune hypothyroidism have an increased risk of the disease [27]. 
Symptoms of primary acquired hypothyroidism may develop over the course of 
years. These symptoms are often widely variable and can be non-specific, including 
"weight gain and constipation due to impaired metabolism, cold intolerance, dry skin 
and hair, fatigue and slowed mental processing or mental retardation, bradycardia, 
deafness, and a hoarse voice. Infertility and menorrhagia are also common 
manifestations [26, 28, 29]. In children with congenital hypothyroidism, skeletal 
growth and maturation is affected, unless the disease is adequately treated[26]. In 
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addition, sexual maturation can be delayed due to the lack of thyroid hormone [27]. 
Mild anaemia is seen in about a quart~r of untreated hypothyroidism cases, and 
approximately ten percent of cases of autoimmune hypothyroidism are affected with 
pernicious anaemia[26]. Severe cases of hypothyroidism can present with an altered 
state of consciousness and severe hypothermia. This can ultimately lead to 
myxoedema coma which, when not promptly treated, may result in death[26]. 
Both congenital and acquired hypothyroidism are more often diagnosed in women 
than in men [28]. For congenital hypothyroidism, the female to male ratio is 
approximately 2: 1, whereas for acquired hypothyroidism this ratio is approximately 
7: 1 [28]. For women, the risk of developing a transient form of hypothyroidism is 
increased during pregnancy and in the 6 month period directly after delivery [29]. 
This transient form of hypothyroidism is called postpartum hypothyroidism and is 
mediated by autoimmune mechanisms [28]. Approximately 7% of women are 
thought to develop postpartum hypothyroidism after delivery [30]. The incidence of 
hypothyroidism increases with age, with a marked increase in incidence after the 
third decade of life [31, 32]. Not many studies have described the distribution of the 
different subtypes of hypothyroidism in the general population. One recently 
published study by Carle et al[31] found that 84.4% of incident cases of 
hypothyroidism in two areas in Denmark were of spontaneous, primary nature with 
no apparent cause of disease. These cases are generally assumed to be of 
autoimmune origin [28]. The overall incidence of hypothyroidism (all causes) in this 
Danish study was 51.8 'per 100,000 person-years among women, and 14.9 per 
100,000 person-years among men. These estimates are markedly lower than 
previously reported incidence rates for the UK; 350 per 100,000 (for women) and 60 
per 100,000 (for men) were observed in the Whickham study [33] and th Tayside 
study reported an incidence of 498 per 100,000 (for women) and 88 per 100,000 (for 
men)[34]. 
Serum TSH is high in all cases of primary hypothyroidism and measurement of serum 
TSH is therefore an excellent test to diagnose primary hypothyroidism[27]. It is also 
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used to distinguish between primary and secondary hypothyroidism, as TSH is not 
elevated in cases of secondary hypothy~oidism [35]. Instead, serum TSH is low or 
normal with a reduced concentration o~ T4 • A diagnosis of autoimmune 
hypothyroidism is confirmed by a positive laboratory test for thyroid autoantibodies, 
as well as a family history of the disease and/or the presence of other autoimmune 
diseases [27]. Determining other causes of hypothyroidism can be difficult but may 
be facilitated by carefully investigating a patient's medical history [27]. 
Hypothyroidism is treated with thyroid hormone, which is an effective therapy in the 
majority of cases[36]. Patients with hypothyroidism are primarily treated in primary 
care, which makes the disease an excellent candidate to be studied in a primary care 
database such as the GPRD. However, one disadvantage of studying hypothyroidism 
in this database is that it is difficult to assess the cause of hypothyroidism. This is 
due to the fact the laboratory measurements such as presence of autoantibodies, or 
specific histologic characteristics of thyroid gland tissue are not conSistently recorded 
in the database. 
The aetiology of hypothyroidism in iodine replete areas is not fully understood, It has 
been hypothesized that an increase in iodine uptake is associated with an increased 
risk of· the autoimmune form of hypothyroidism [31]. In addition genetiC factors are 
thought to playa role [28]. Environmental factors may also playa role, including 
several commonly used pharmacologic agents which are known to have an effect on 
thyroid function. These include lithium, iodine containing drugs such as amiodarone, 
alpha interferon, propylthiouracil, thionamide, and drugs that interfere with thyroxine 
absorption in treated hypothyroidism[28, 37, 38]. 
'1.3. RA TIONALE FOR RESEARCH 
Drug-induced autoimmunity is a good example of a type B adverse drug reaction as 
its occurrence cannot be predicted based on the pharmacological action of suspected 
drugs. Furthermore, drug-induced autoimmunity is a rare but serious adverse event. 
For instance, the estimated incidence rate of SLE is 7.8 cases per 100,000 person 
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years[39]. Only a fraction of newly diagnosed cases of SLE will be due to exposure to 
a lupus-inducing drug. In addition to b~ing unexpected and rare, duration of drug 
treatment may be months to years before the adverse event occurs. As a result, it is 
questionable whether health care professionals attribute autoimmune disease to drug 
exposure when a new patient presents. 
If long-term unexpected adverse drug reactions remain unrecognised by health care 
professionals, these will not appear in spontaneous reporting databases. However, 
the current system in place to study drug safety relies predominantly on spontaneous 
reports. As a result, long-term unexpected adverse drug reactions are likely to be 
missed by the current system. 
This thesis investigates the use of a data source different from the currently used 
spontaneous reporting databases, namely the General Practice Research Database. 
The adverse event of interest in this thesis is drug-induced autoimmunity. The 
examples given in this introductory chapter, drug-induced lupus and drug-related 
hypothyroidism, may not be very common diseases but they can be potentially life 
threatening. In this thesis, we utilise these potential adverse drug reactions as a tool 
to investigate methods of signal detection and signal evaluation. 
1.4. AIMS AND OBJECTIVES 
1.4.1. Aims 
To determine whether the GPRD can be used to study drug-induced autoimmune 
disease 
To examine and compare statistical methods available for evaluating drug safety 
hypotheses 
To examine a systematic method of signal generation which utilises a large 
healthcare database instead of a spontaneous reporting database 
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To perform a complete drug safety study including a signal generation and a 
signal evaluation phase 
1.4.2. Objectives 
To test pre-existing hypotheses of risk of SLE associated with prescription drugs 
using a case-control method 
To test pre-existing hypotheses of risk of SLE associated with prescription drugs 
using a case-only method 
To compare results obtained by the case-control method with those from the self-
controlled case series method 
To assess whether a novel signal generation method (the Smile Plot method) is 
capable of detecting known associations of prescription drugs and risk of SLE 
To investigate whether other drugs than those identified from the literature are 
associated with risk of SLE. 
To describe suspected adverse drug reactions of drug-induced lupus as reported 
in the UK Yellow Card database of spontaneous reports. 
To identify previously unknown associations of risk of drug related 
hypothyroidism and prescription drugs (grouped by BNF-subchapter) using the 
smile plot method in a subset of data 
To evaluate newly identified signals of drug-induced drug related hypothyroidism 
in a different subset of data 
1.5. OUTLINE OF THESIS 
The present chapter provides an overview of drug safety issues and available 
methods and data sources to study drug safety. Drug-induced autoimmunity is 
described as an example of an unexpected long-term adverse drug reaction. 
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For the purpose of this thesis the General Practice Research Database (GPRD) was 
utilised to study drug-induced autoimmune disease. A review of the literature to 
study the validity of medical diagnoses recorded in the database is presented in 
Chapter 2. 
The association between prescription drugs and risk of autoimmunity was studied in 
different data sources and using different statistical analysis methods. Details of 
these data sources and the methods used are outlined in Chapter 3. 
In Chapter 4, the association between selected prescription drugs and risk of 
systemic lupus erythematosus is investigated. Firstly, GPRD data are analysed in 
order to evaluate existing hypotheses and to determine whether drug-induced 
autoimmunity can be studied using this database. Data are analysed using a case-
control design as well as the self-controlled case series method. Secondly, both 
Yellow Card and GPRD data are analysed to identify potential new signals of drugs 
inducing SLE. 
Chapter 5 investigates risk of drug related hypothyroidism associated with exposure 
to prescription drugs. The total data set of cases with hypothyroid disease and 
controls is split up in two parts; a small subset that is utilised for signal generation 
~ . 
and a larger subset which is used to validate newly identified signals. 
Finally, Chapter 6 summarises and discusses the main findings of this thesis and 
implications for clinical pr,actice and pharmacovigilance. 
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CHAPTER 2. A LITERATURE REVIEW OF THE VALIDITY AND 
VALIDATION OF THE GENERAL PRACTICE RESEARCH DATABASE 
(GPRD) 
2.1. INTRODUCTION 
Computerised databases of medical records are increasingly used in biomedical 
research. The General Practice Research Database (GPRD) is a primary care database 
containing anonymised patient records for about 5% of the UK population. The 
GPRD's strengths as a research tool include its size, representativeness of patient 
and practice characteristics[ 40], and a virtually complete medical history of patients 
due to the recording of referral to secondary care[41]. The GPRD has been widely 
used for observational studies, with over 500 studies published to date including a 
number of high impact papers[42-47]. 
A typical dataset from the GPRD contains general information on a patient's sex, age, 
date of birth and registration details. Medical information includes dates of 
consultation with the corresponding OXMIS and Read codes for diagnoses and 
symptoms. The therapy information includes prescriptions using codes from the 
prescription pricing authority (PPA) with corresponding dates, dosages and method of 
administration. For some patients there is additional information on vaccinations, 
weight and blood pressure measurements and laboratory test results. All information 
is entered by practice staff and is anonymised prior to central collection. 
The validity of research based on GPRD data depends on the quality of data 
recorded. Methods available to check this quality can be divided into two groups, 
internal and external validation. Internal validation uses no information from outside 
"the database". Examples include diagnostic algorithms combining medical codes, 
disease-appropriate drugs and/or disease-specific signs to establish likelihood of 
disease or manual review of computerised records. External validation involves 
, 
comparing information from outside the database, such as the original doctor's notes, 
to the computerised information. This anonymised information is obtained by 
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approaching each practice. Specific validation studies have suggested that diagnostic 
data in GPRD are of high validity[48, 49J. However, there has not been a review of 
the literature of all validation studies to assess the totality of evidence. In order to 
investigate the range of methods used to validate diagnoses in the GPRD, to 
summarise findings of these validation studies and to assess their quality, we 
conducted a review of the literature of studies that assessed quality of morbidity data 
available in the GPRD. 
2.2. METHODS 
2.2.1. Search Strategy 
We searched the databases PubMed and Embase for articles using the GPRD as a 
data source, published between 1987 and February 2004. Publication listings on the 
websites of the GPRD (http://www.gprd.com/info/bibliography.asp) and the Boston 
Collaborative Drug Surveillance Program (http://www.bcdsp.org/publications.html) 
were scrutinised to identify additional articles. International Society of 
Pharmacoepidemiology (ISPE) conference procedures, issues of Health Statistics 
Quarterly, and back issues of Pharmacoepidemiology and Drug Safety that were not 
incorporated into pubMed were hand-searched. Reference lists of identified articles 
were examined. In the first search a comprehensive list of free text terms denoting 
VAMP, General Practice Research Database or UK primary care database was linked 
to a number of free text and exploded thesaurus terms for validation, accuracy and 
reproducibility, together with a number of free text and exploded thesaurus terms for 
patient records, medical records and primary care records. This preliminary search 
showed that in many published papers case validation was a minor component of the 
study and was not mentioned in the title, abstract or index terms. Therefore, we 
broadened our search strategy to identify all epidemiological studies using the GPRD 
as a primary data source. The complete search strategy can be found in Appendix I. 
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2.2.2. Study Selection 
All publications identified via the search"strategy that definitely, or possibly, used the 
GPRD as a data source were retrieved and the full text was examined. A study was 
eligible for the review of the literature when a disease diagnosis was verified. The 
verification process could utilise computerised information only (internal validation), 
and/or use additional information from outside the database (external validation). 
2.2.3. Data Extraction and Quality Assessment 
Data extraction was conducted by one reviewer (Marieke Schoonen) using a 
standardised data extraction sheet (which can be found in Appendix I), and a second 
reviewer (Andy Hall) assessed a random sample of 20% of the articles to verify the 
extraction process. All disagreements were resolved after discussion. Data extracted 
included the disease validated and the method used to identify cases. The specific 
OXMIS, Read or leD codes used to identify each condition were not extracted, as 
describing the validity of a single disease or group of diseases was not the purpose of 
the review. We extracted information about the validation method used and the 
outcome of the validation exercise. Validation methods were classified into: 1) 
manual inspection of computerised records; 2) creation of an algorithm combining 
computerised information into a measure of likelihood of truly having the disease of 
interest; 3) retrieval of original medical records or death certificates; 4) sending a 
questionnaire to the GP; 5) comparison of disease pattern and/or rates to an external 
data source; 6) comparison of internal disease pattern to clinical knowledge of 
disease (e.g. seasonality). Wherever pOSSible, quality of the validation exercise was 
additionally assessed in terms of number and status of independent reviewers, GP 
response rates to requests for information and whether the reviewers were blinded to 
exposure in anarytical studies. 
2.2.4. Data Analysis 
Diseases were grouped by the organ system affected, with additional categories for 
allergy, birth outcome, cancer, death, demography, hospital procedures and 
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miscellaneous diagnoses. Studies were categorised by validation method used, in 
order to describe the usefu lness of different validation methods. 
Figure 2-a: Stream diagram of article search 
11 11 non-duplicate abstracts 
identified from PubMed. 
BABASE, GPRO and BCOSP 
~ 
402 papers ntrieved for full text I 
searching 
78 additional papers idertified 
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searching IS P E conference 
procedures, PO S back 
issues, and HSQ issues 
I 204 papers included in I systemaic review 
~ 
I 266 diagnoses validaed I 
709 ab~ ntt using 
PRO as a data souroe 
excluded 
"1J 
2 76 papers eKcluded 
GPRD, General Practice Research Database (http://www.gprd.com/info/bibliography.asp); 
BCDSP, Boston Collaborative Drug Surveillance Program, 
(http://www.bcdsp.org/publications.html); ISPE, International Society of Pharmacoepidemiology; 
PDS, Pharmacoepidemiology and Drug Safety; HSQ, Health Statistics Quarterly 
2.3. RESUL TS 
We identified a total of 1111 non-duplicate abstracts from the PubMed, EMBASE and 
website searches, of which we excluded 709 after reviewing the title and abstract 
(Fig 2-a) . We identified another 78 abstracts from reviewing papers and from hand-
searching re levant joumals and conference procedures. After reviewing the full text, 
we included 204 of these 480 studies. The main reasons for exclusion were: a 
publication did not validate the diagnosis under investigation, the GPRD was not used 
as a data source, the publication was not an original research article, the study 
reported a va lidation exercise that had al ready been published elsewhere, or no 
diagnosis was investigated (e .g. study of prescriptions). The 204 included papers 
validated 266 diagnoses (i. e. some papers reported more than one validated 
diagnosis). 
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Table 2-1: Characteristics of validation exercises 
Validation method 
Total 
Internal validation methods 
Manually review computerised recordst 
Algorithm'" 
External validation methods 
Times used 
424 
116 
84 
0/0 Diagnoses 
validated* (N-266) 
44 
32 
Retrieve copy of records 117 44 
Original medical records§ 107 40 
Death certificate 10 4 
Questionnaire to GP 55 21 
Compare disease pattern/rates to other data source 46 17 
Other/l 6 2 
*Validation of a diagnosis by use of different methods within one study causes total percentage to be >100 
tManual review: print out of full computer records per case to read 
"'Algorithm: a list of medical codes, or a combination of signs, symptoms, and/or disease appropriate therapies used in 
the database 
§Also includes copies of discharge and referral letters II Other validation methods included: a questionnaire to patients (external) and investigating whether expected 
seasonality could be confirmed (internal) 
Table 2-1 shows the frequency of use of the different validation methods. For internal 
validations, the full computer records were manually reviewed for 44% of the 266 
diagnoses, and an algorithm combining the computerised information was used to 
validate 32% of diagnoses. The GP was asked to provide extra information to verify 
their patients' diagnoses in 145 validation exercises (55%). This external information 
included a questionnaire, copies of original notes (including referral letters and 
discharge letters), or death certificates. In 27 exercises the GP was asked for a 
combination of this information. A total of 95 of these validation exercises (66%) 
reported GP response rates to requests for information - 40-100% of requests were 
met by GPs. A small number of studies that manually reviewed computer records, 
original records, or death certificates hired an expert to review these data. Blinding 
of reviewers to exposure in analytical studies was in general not reported. The 
number of cases validated using additional information varied from 10 to 2820. 
A total of 135 diagnoses were validated by means of only one method. Of these, 
researchers relied most often on creating an algorithm combining the computerised 
information '(42 out of 135 diagnoses, 31%). Comparing disease rates and patterns 
to another data source was the second most frequently used method (22%). Ninety-
six of the total 266 diagnoses (36%) were validated using a combination of both 
.internal and external validation methods. 
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Table 2-2: Number of validation studies ~er disease catego!}' 
Disease definition Proportion considered valid 
sl!ecified {%l*§ 
Based 
Diagnoses No I Range on N No.1 range 
Disease catego!:l validated References* ~es ICDt unclear (%) studies of cases 
Total 266 112 23 127 
Allergy 6 a1-a6 2 4 73 1 120 
Birth outcome / 5 a3 a7-al0 1 4 85 - 100 2 123 
Congenital 
Blood dyscrasia 8 a6 all-a17 3 2 3 25 - 95 4 38 - 59 
Cancer§ 14 a18-a30 6 3 5 88 - 100 8 12 - 316 
Cardiovascular 48 a31-a69 18 5 25 
disease 
Coronary 20 a31-a48 6 3 11 35 - 100 9 10 - 1606 
Cerebrovascular 9 a35 a49-a53 5 4 48 - 77 5 25 - 101 
Venous 19 a38 a43 a54- 7 2 10 54 - 100 6 14 - 170 
thromboembolism a70 
/ hypertension 
Death 13 a35 a56 a71- 7 6 47 - 94 4 20 - 72 
a81 
Dermatology 6 a6 a82-a86 4 2 74 - 100 3 47 - 84 
Endocrinology 11 a4 a43 a60 a87- 2 
a94 
9 42 - 99 2 80 - 86 
Eye disease 7 a95-al00 2 2 3 16 - 97 6 60 - 341 
Gastrointestinal 26 a6 a25 a58 12 2 12 8 - 100 14 21- 860 
disease al0l-a121 
Gynaecology 4 a122-a12S 3 1 87 1 366 
Hepatic disease 15 a6 a91 a124 13 2 13 - 96 10 24 - 2820 
a126-a137 
Hospital procedures 4 a59 a116 a138 NA NA NA 82 1 167 
Mental health 18 a60 a78 a102 8 2 8 52 - 92 8 25 - 318 
a139-a1S0 
Metabolic disease 5 a43 a70 agO 
a138 a151 
3 2 
Musculoskeletal 15 a67 a152-a164 6 4 5 33 - 100 10 38 - 1428 
disease 
Neurology 15 a72 a165-a177 8 2 5 9 -100 6 11 - 100 
Renal 6 a6 al71 a178- 2 4 8 1 59 
a181 
Respiratory 22 a3 a4 a80 a81 7 15 26 - 95 2 20 - 89 
a182-a190 
Systemic 6 a4 a191-a195 2 1 3 66 - 76 2 44 - 151 
Miscellaneous" 12 a140 a196-a204 3 9 8 - 100 7 12-1191 
*More .than one diagnosis within the same disease category may be validated within one publication 
tDisease criteria specified as ICD codes, although the GPRD uses OXMIS and Read codes for recording medical events 
*Numbers given are the range of values that were reported within the disease category. Not all papers reported these 
values §Numbers given are based on validations where the GP was requested to confirm diagnosis or provide copies of records 
"Miscellaneous diagnoses studied were: benign prostatic hyperplasia (1), orchidopexy (1), potentially drug-inducible 
illnesses (4), indication for referral (2), serious adverse event (3), and NSAID-related adverse event (1) 
Table 2-2 shows the number of validation studies per disease category. The definition 
used to select cases was clearly stated for 42% of the diagnoses. In 9% of the 
validated diagnoses only an International Classification of Diseases (ICD) code was 
given. Clarity of disease description was especially low in endocrine and respiratory 
diseases. HepatiC diseases were generally clearly described. The proportion of 
computer-identified cases of a disease confirmed by the GP was highly variable both 
between a'nd within disease categories. Fifty-eight of the 111 studies (52%) that 
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reported a confirmation rate reached over 80% concordance; the 24 with less than 
50% concordance used very strict case criteria. 
2.4. DISCUSSION 
This review identified a large number of studies in which diagnoses were validated. 
The search strategy used is likely to have captured all published studies of 
validations within the GPRD in the specified time period. We found that the most 
frequently used method was external comparison through requesting additional 
information from the GP. These external methods only assess positive diagnoses in 
computer records and therefore measure positive predictive value not specificity 
(which would require a comparison of computer records and GP records without the 
diagnoses). Many authors using this method did not seem to appreciate that that 
they were measuring only positive predictive value and that negative predictive 
value, sensitivity and specificity remained unknown. Positive predictive value varies 
with prevalence of the condition and so care is needed in interpretation when 
geographical variation or change in incidence over time is investigated. 
Validation studies requesting copies of medical notes from the GP showed that the 
proportion of records actually retrieved was highly variable. Low retrieval rates raise 
the question of generalisability of the results of the validation to all cases, especially 
as not all GPs offer this service. Thus, even if compliance in providing records is high, 
this may arise only from a sub-group of practices and therefore of records. For 
instance, in a study by Van Staa et al[50], 719 practices contributed data during the 
study period. Only 295 practices (41%) were known to provide additional 
information, of which 269 (91%) provided the requested information. This may 
introduce selection bias if data from GPs offering the service are of a different quality 
to those not providing the service. Thus the predictive value found may only be 
applicable to the cases coming from these practices. An additional problem with 
record retrieval from GPs is that it is expensive (currently £70 per single set of 
notes). This frequently limits the number of records that can be retrieved, leading to 
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small sample sizes. Very few studies gave confidence intervals around their estimates 
of positive predictive value. 
The second most frequent method used was a manual examination of the 
computerised record. Very few studies specified the criteria used in this examination 
to determine "true" cases. Judgements from individual physicians may vary over time 
and between physicians. Without case criteria specified, there is scope for bias 
arising from these individual judgements. In addition, manual inspection of 
computerised records is time consuming and takes away much of the advantage of 
having automated data. 
The use of specified internal diagnostic algorithms overcomes this concern, 
particularly since these are clearly described in the studies. This allows the reader to 
decide whether or not they agree with the judgements made. However, GPs in the 
GPRD are asked to record a diagnostic code following consultations where a new 
diagnosis was made or a new treatment initiated[ 40]. For other consultations, a 
symptom or sign may be entered instead. For chronic diseases this means the 
absolute number of diagnostic codes will not necessarily be a proxy for disease 
severity or natural history. Inclusion of disease-specific therapy and/or symptoms in 
the algorithm may increase probability of the diagnosis. This cou"fd however result in 
omission of less severe cases who do not require treatment. Differential diagnoses 
may be recorded before the definite diagnosis[51], leading to misclassification. If an 
algorithm relies on cod~s for symptoms, people with overlapping symptoms from a 
different disease may be included. 
Finally some validations compared the disease pattern (sex ratio, symptomatology) 
or incidence/prevalence rates with estimates from studies not using the GPRD. These 
are reassuring for descriptive purposes but of course do not exclude the possibility 
that a balanced misclassification between different diagnoses occurs, i.e. the 
situation sometimes seen in death certification where the loss of deaths from cause A 
because of misclassification is balanced by the inclusion of people truly dying of 
cause B but who are misclassified to cause A. Results of these types of validations 
35 
should therefore be treated with caution when used in analytical studies where the 
precise individual diagnosis is critical. 
Information provided in the papers was often limited in terms of the methodology 
used for the validation. For example patient characteristics such as age may 
influence data quality but this was rarely explored. In particular manual inspection of 
the records was poorly described. 
Validation of prescription data is of lesser importance than validation of morbidity 
data, as the GP uses the computer to generate prescriptions. This makes the therapy 
file virtually complete (except for prescriptions issued in secondary care). Hollowell et 
al[S2] confirmed there is excellent agreement between prescribing data from the 
GPRD and national data from the UK Prescription Pricing Authority. 
In defining diagnoses, research groups use their own sets of criteria and medical 
codes to select cases. Occasionally, medical codes from the GPRD coding system 
(OXMIS and Read codes) were mapped onto ICD codes. However, for many diseases 
it is not clear which codes from the GPRD correspond to specific ICD codes. It is 
desirable that a table of the medical OXMIS and Read codes used for diagnosis or the 
mapp}ng of these codes to specific ICD codes be made available at the time of 
publication, so that others studying the disease can use the same method. 
When conducting a case-control study using the GPRD, it is important to apply the 
same inclusion and eX,elusion criteria to cases and controls. However, because 
validation studies typically focus solely on cases, they may produce more detailed 
criteria for cases compared to controls. For example, a study of Garcia Rodriguez et 
al[S3] established the relation between exposure to nonsteroidal anti-inflammatory 
drugs and acute liver injury. Cases with acute liver injury were validated by 
retrieving original medical records. Based on the validation study, 16 of 166 potential 
cases (10%) were exeluded from further analyses due to alcoholism. No validation 
was carried out for controls, and so no further details on alcohol consumption were 
identified. This may have led to bias and potentially a false association. 
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In our review of GPRD validation studies used we made every effort to include all 
published studies that matched our ineiusion criteria. Despite our extensive search 
strategy and additional hand searches, there is still a possibility we missed out on 
some publications that should have been included in this review. An additional 
limitation of our review is that we did not attempt to assess the quality of each the 
validation studies. Appraisal of quality of included studies is a characteristic of a 
systematic review, as described in further detail in the Handbook for systematic 
reviews by the Cochrane Collaboration[54]. 
The implications from this review for researchers are that although validation studies 
have shown good predictive value for the majority of diseases studied there needs to 
be a much clearer description of the methods and case criteria - with disease codes 
and mapping to ICD where appropriate - to allow the researcher to fully judge the 
appropriateness and generalisability of the method and to replicate it if desired. We 
suggest that the careful use of algorithms is likely to be the most cost-effective 
method of identifying valid cases. It is likely that results from clinical investigations 
and letters from specialists will be captured in future electronic records - this will 
greatly strengthen this method of validation and is likely to improve the quality of the 
data (with fewer data entry errors). It is also clear that most studies should carry out 
some form of validation, since the positive predictive value of ~ set of diagnostic 
codes may change over time and use of historical validations may therefore not be 
justified. 
In conclusion, the GPRD is an enormously powerful tool for the study of morbidity in 
primary care. Its use is likely to increase, particularly with the recent agreement 
between GPRD and the Medical Research Council (MRC) that the data can be made 
available to academic researchers at no (or low) cost[55]. However, intimate 
knowledge of the use of coding in General Practice and of the complexities of the 
database is needed to ensure that the best use is made of it. 
37 
CHAPTER 3. METHODOLOGY 
The association between prescription Clrugs and risk of autoimmunity was studied 
using a variety of statistical analysis methods. Details of these methods are outlined 
in the current chapter. 
3.1. STUDY POPULATION 
3.1.1. The Yellow Card Database 
We received permission to analyse a subset of Yellow Card data for the purpose of 
this thesis. The subset comprised of reports submitted to the Commission on Human 
Medicines (CHM) between July 1963 and 10 January 2006 that mentioned SLE as an 
adverse drug reaction. Detailed reports were received of drugs for which a suspected 
association with lupus was reported at least 9 times. We did not receive detailed 
reports of drugs with less than 9 reports. 
Detailed reports contained the following information: description of all adverse drug 
reaction(s) diagnosed in individual, drug suspected of causing the reaction, age 
range and sex of case, duration of treatment, outcome of reaction (recovered or 
recov.ering after treatment or after drug withdrawal, not recovered, fatal, not 
known), reaction onset time, and names of other drugs also taken by the patient in 
the past 3 months (if known). Although information on dosage and method of 
administration may be available for the suspected drug on the original Yellow Card 
report, this was not included in our data set. For drugs taken concurrently with the 
suspected drug there was no information on duration of treatment, dosage, and 
method of administration. 
The Yellow Card data set was provided in a Microsoft Excel file format. After adding a 
unique patient identifier for each report, data were converted to a Stata data set 
(Stata software Version 9, Statacorp, Texas) to summarise data and perform 
descriptive analyses. All detailed descriptions of adverse drug reactions were 
assigned an SLE likelihood code. An SLE likelihood of 1 was assigned to reports with 
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a definite diagnosis of SLE. Possible SLE symptoms and signs were assigned a 
likelihood of 2. All other adverse -drug reactions reported (e.g. pneumonia, 
depression, dry mouth) were not of i~terest to us and therefore excluded in further 
analyses. An overview of ADRs included in our study is given in Table 3-1. 
Table 3-1: Adverse drug reactions listed on Yellow Card reports and their SLE 
likelihood 
Adverse drug reaction listed on report 
Lupus-like syndrome 
Systemic lupus erythematosus 
Systemic lupus erythematosus rash 
Glomerulonephritis proliferative 
Antinuclear antibody positive 
Histone antibody positive 
Photosensitivity reaction 
Rash erythematous 
Cutaneous lupus erythematosus 
*Likelihood-l for definite and 2 for possible SLE 
Likelihood 
of SLE* 
1 
1 
1 
2 
2 
2 
2 
2 
2 
All cases with at least one adverse drug reaction with a likelihood of 1 were included 
in the study. Cases with only a likelihood of 2, such as those with cutaneous lupus 
erythematosus were excluded. Simple frequency tables were generated to explore 
and describe the Yellow Card data. 
3.1.2. The General Practice Research Database 
A detailed description of the General Practice Research Database (GPRD) can be 
found in Chapters 1 and 2. The base population included all patients registered with a 
general practice that was contributing data to the GPRD between 1987, the start date 
of the GRPD, and 2001. A comprehensive list of medical codes for autoimmune 
diseases was compiled by a team of clinicians and a rheumatology epidemiologist 
prior to the onset of this project. All subjects with a medical code for an autoimmune 
disease included in this list were selected from the base population as potential 
cases. Control subjects originated from the same base population but did not have a 
record of a medical code for an autoimmune disease at any point in time. Details of 
case definition, and inclusion and exclusion criteria are outlined under "outcome 
definition" (SLE, 3.3.1; drug related hypothyroidism, 3.3.2). 
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Further sections of this chapter describe methodology specific for analysis of the 
GPRD data. 
3.2. DATA MANAGEMENT 
Computerised patient-level data go through a number of quality checks before being 
added to the GPRD[12]. Despite these checks the data are not flawless. Prior to data 
analysis, our data were cleaned and the values of calendar dates were verified. Data 
cleaning steps are described in sections 3.2.1 and 3.2.2. Matching of control subjects 
to autoimmune cases involved additional steps after eligible controls were identified. 
These additional steps are outlined in sections 3.3.4, 3.3.5 and 3.3.6. 
3.2.1. Missing and Incomplete Calendar Dates 
Data entered by a GP or practice staff may be incomplete or missing. Missing 
calendar dates appear as 1 January 1900 in some but not all GPRD records. In order 
to ensure these missing dates were not used as non-missing values in data analyses, 
all instances of 1 January 1900 were reset to missing C.) in SAS and Stata. A list of 
outlying calendar date values for prescriptions as well as doctor's visits was 
scrutinised. 11 November 1911 was identified as an alternative value for missing 
date and all instances of this date were also reset to missing. 
Incomplete calendar dates with a missing day and month were reset to midpoint of 
the non-missing year, i.e. 1 July. Calendar dates with missing day and non-missing 
month and year were reset to the midpoint of the month, i.e. day 15. In addition an 
indicator variable was created to flag all calendar dates with estimated day and/or 
month. This indicator variable was used for the self-controlled case series method to 
determine whe~her Ca) diagnosis date was estimated or Cb) prescription date was 
estimated. 
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3.2.2. Data Cleaning 
Codes for medical diagnoses and symptoms may be erroneous or incomplete. 
Merging the patient-level medical records with a medical dictionary enabled us to 
identify these codes, for which a text description was not available. A list of 
incomplete or erroneous codes was scrutinised in order to identify obvious errors 
(e.g. where the first or last letter of a code was missing) but no obvious errors were 
found. Incomplete and erroneous medical codes were reset to missing and the record 
was retained, as these records represented consultations for unknown symptoms or 
with unknown outcomes. Similarly, incomplete and erroneous codes for therapy 
records were identified by merging therapy files with the therapy dictionary. These 
drug codes were reset to missing but the record was retained as a prescription to 
unknown drug. 
Duplicate medical codes, i.e. identical codes that were recorded on the same day for 
the same patient, were removed. Duplicates of prescriptions for the same drug on 
the same day to the same patient were also removed. 
3.3. OUTCOME DEFINITION 
3.3.1. Systemic Lupus Erythematosus 
3.3.1.1. Case Definition 
OXMIS and Read codes for SLE were identified from a coding dictionary by four 
investigators (3 physician epidemiologists and 1 rheumatic disease epidemiologist), 
and verified by a rheumatologist whose subspecialty is SLE. A full list of codes can be 
found in Appendix II. Patients with at least one SLE code in their medical history 
were identified~ With the exception of subacute cutaneous lupus (SCLE), codes for 
cutaneous variants of lupus were not considered to represent SLE. SCLE was 
retained since a high proportion of SCLE cases develop SLE. 
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For all statistical analyses utilising matched case-control data (described in further 
detail in sections 3.5.1 and 3.5.3), we excluded cases with a medical code for a 
comorbid autoimmune disease anywhere in their records. The reason for this 
exclusion criterion was that none of the controls had an autoimmune disease in their 
records either. Details on control definition and matching can be found in section 
3.3.3 and onwards. 
3.3.1.2. Case Validation 
None of the cases were validated by review of original medical records due to 
financial and time constraints. Case validation based on laboratory test results on 
ANA and anti-DNA antibody positivity was not feasible as this information was 
recorded for 19 cases only «1%). In clinical practice, the diagnosis of lupus is 
usually based on criteria formulated by the American College of Rheumatology[19]. 
It is thought that drug-induced lupus, which develops in previously asymptomatic 
individuals and usually disappears upon discontinuation of the drug is different from 
idiopathic SLE, which is a life-long disease[23]. Criteria for diagnosis of drug-induced 
lupus are less strict than those for diagnosis of idiopathic SLE[25]. In our study the 
diagnosis of SLE was not validated for each case individually and laboratory test 
results for ANA or anti-DNA antibody positivity were not available for the majority of 
cases. However this was not considered a critical limitation of our study, because of 
the less strict diagnostic criteria for drug-induced lUpus. In addition, a high 
proportion of our case population received prescriptions for drugs used for the 
treatment of lupus (79% non-steroidal anti-inflammatory drugs, 10% corticosteroids, 
48% anti-malarials and/or immunosuppressives[17]) and incidence rates based on 
our data are consistent with other published estimates[17]. We therefore believe the 
lupus diagnostic codes were valid. 
3.3.1.3. Diagnosis Date 
The date corresponding to the first SLE record represented the date of diagnosis for 
the cases. This date served as index date for the matched controls. Further 
characteristics of control subjects are described in paragr~ph 3.3.3, 3.3.4 and 3.3.5. 
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3.3.2. Drug related hypothyroidism 
The risk of hypothyroidism associated 'with prescription drugs was investigated, using 
GPRD data, in two ways. Firstly, new signals of drug-induced hypothyroidism were 
generated using a subset of cases and their matched controls. These signals were 
subsequently evaluated in the remainder of hypothyroidism cases and controls. 
3.3.2.1. Definition of Data Subsets 
Data were split by geographical area. Practices contributing to the GPRD are located 
in 11 geographical areas which cover England, Wales, Scotland and Northern Ireland. 
Incident cases with hypothyroid disease were observed in practices from each of 
these areas. Cases and their matched controls registered with a practice in the 
regions "Northern England & Yorkshire", "Eastern England" and "West Midlands" were 
included in the signal generation data set and patients from practices in Scotland, 
Wales, Northern Ireland and all other regions of England were included in the signal 
evaluation data set. Random splitting of data was not considered appropriate as this 
would have resulted in similar results for signal generation and evaluation. 
Decisions on the size of each data subset were based on type II error rate 
con~iderations. A type II error is made in the case of a false n.egative study finding; 
i.e. to conclude there is no association between drug exposure and risk of drug 
related hypothyroidism when in fact there is one. This type of error was considered of 
less importance in the context of signal generation (where minimising the number of 
false positive signals i~ of highest importance). However for signal evaluation type II 
error was considered to be particularly important. Type II error rate is dependent on 
a number of factors, including study sample size: larger sample sizes result in 
decreased type II error rates. We therefore included the majority of incident cases 
with hypothyroid disease (11873 out of the 17791, 66.7%) in the signal evaluation 
data set. Further details on sample size and power considerations for the signal 
evaluation study can be found in Section 3.5.1.1. The sample size for the signal 
generation data set was 5918 incident cases. In order to minimize type I error rate, 
we utilised a family-wise procedure which is further outli~ed in Section 3.5.3. 
43 
3.3.2.2. Case Definition 
The list of diagnostic codes for hypothyroidism (including autoimmuine thyroiditis) 
can be found in Appendix III. Cases were defined as patients with at least one 
occurrence of an code for hypothyroidism in their medical records and at least one 
code for disease specific treatment (i.e. thyroid hormone). Therefore all included 
cases were treated, symptomatic drug related hypothyroidism cases. We searched 
the computerised medical case records for codes indicating thyroidectomy or radio-
iodine therapy (Appendix IV). Cases with an occurrence of such codes prior to drug 
related hypothyroidism diagnosis were likely to have iatrogenic instead of 
autoimmune mediated disease and were therefore excluded from the analyses. 
3.3.2.3. Case Validation 
Cases were not individually validated by review of medical records due to financial 
and time constraints. Case validation based on laboratory test results on auto-
antibody positivity was not feasible as this information was recorded for 1.3% of the 
cases. 
3.3.2.4. Diagnosis Date 
The date corresponding to the first medical record of drug related hypothyroidism 
represented the date of diagnosis for the cases. This date served as index date for 
the matched controls. Further characteristics of control subjects are described in 
paragraph 3.3.3, 3.3.4 and 3.3.5. 
3.3.3. Control Definition 
Control subjects were selected from the same base population as the cases and did 
not have a medical code for any autoimmune disease in their records. Exclusion 
criteria that were applied to cases were also applied to their matched controls: 
Controls matched to drug related hypothyroidism cases were excluded if they had a 
positive history of thyroidectomy or radio-iodine therapy prior to the index date. 
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3.3.4. Control Matching 
Each case was matched to up to five non-autoimmune disease controls based on sex, 
age, practice and calendar year. Case diagnosis date, which was determined as 
described in further detail below, served as the index date for matched controls. A 
subject was eligible as a control when the index date occurred during the period of 
up-to-standard data collection. If no suitable control subject born in the same year as 
the case was identified, a subject of one year older or one year younger was sought. 
If still no suitable control was identified, the age difference was expanded to two 
years older of younger. This process was repeated up to a maximum age difference 
of 9 years. If there were still no suitable controls, the case was left unmatched or 
matched to less than 5 controls. 
When a matched case was diagnosed with two or more autoimmune diseases, the 
index date for the earliest autoimmune disease served as the index date at which 
controls had to contribute data to the database. If at the time of diagnosis of a later 
autoimmune disease a matched control had left the practice, this control no longer 
contributed data and was therefore excluded from analyses of the later autoimmune 
disease. 
3.3.5. Inactive Controls 
Control subjects not showing any activity in medical, therapy or prevention records in 
the three years before the index date were assumed to be inactive. Inactive controls 
may represent healthy subjects who truly don't receive any prescriptions. However, 
some inactive control subjects are likely to have transferred out of the practice or are 
seeking medical care elsewhere. We decided to exclude inactive controls from further 
analyses because including these inactive controls as unexposed to drugs of interest 
would have, potentially erroneously, strengthened drug-disease associations. 
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3.3.6. Incident and Prevalent Cases 
Cases were eligible as incident if the date of diagnosis occurred during the study 
period (1987 to 2001), and while the patient was registered with a practice 
contributing data to the GPRD. Diagnoses recorded on or shortly after registration 
with a practice may represent diagnoses for pre-existing medical conditions. For a 
number of acute and chronic diseases, Lewis et al[S6] demonstrated there is an 
inflated incidence rate in the period after registration. The length of time needed for 
incidence rates to return to baseline varies by disease. In general, the time period is 
4 to 6 months for acute conditions, and 10 to 12 months for chronic diseases. In 
order to avoid misclassification between prevalent and incident conditions, we 
excluded cases diagnosed within the first 12 months of having UTS data. 
Similarly to the cases, the index date of the matched controls occurred at least 12 
months after the start of up-to-standard data collection. Controls with less than 12 
months of data before the index date were excluded from the analyses. 
3.4. EXPOSURE DEFINITION 
If a study subject received a prescription for a drug of interest a minimum of one 
week before diagnosis or index date, this subject was conside-red to be exposed. No 
maximum time limit between prescription and diagnosis was set to ensure that all 
potential exposure time windows were included. The agreement between prescribing 
data from the GPRP and national data from the UK Prescription Pricing Authority 
(PPA) is known to be very high[S2]. As the prescription data are considered of 
particularly high quality, it was decided to also include prescriptions from outside the 
up-to-standard period in the analyses. 
3.4.1. Exposures of Interest for Signal Generation 
In signal generation studies, all drug exposures are considered potential risk factors 
for disease (in contrast to signal evaluation studies in which pre-existing hypotheses 
are tested). 
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In the GPRD, drug exposures are recorded as numerical codes which are linked to a 
prescription dictionary. One code represents only one drug name listed in the British 
National Formulary (BNF), but there can be several different codes that represent the 
same drug name. There were 41990 codes representing 10310 different drug names 
that were listed in the BNF during our study period. 
As well as being linked to a GPRD drug code, drug names are linked to BNF codes. 
The BNF is divided into 15 chapters, each of which relate to a body system (e.g. the 
gastro-intestinal or cardiovascular system) or a therapeutic area (e.g. infections, 
anaesthesia). BNF chapters are further divided into subchapters, sub-subchapters, 
and paragraphs. A BNF code consists of four two-digit numbers and is based on the 
BNF chapter, subchapter, sub-subchapter and paragraph under which a drug is listed. 
For instance, the code for amoxicillin (05.01.01.03) is compiled as follows: 
Chapter 05 Infections 
Subchapter 01 Antibacterial drugs 
Sub-subchapter 01 Penicillins 
Paragraph 03 Broad-spectrum penicillins 
5Qme drugs are listed under more than one BNF chapter, for instance: aspirin is used 
as an antiplatelet drug for the cardiovascular system, and it is also used as an anti-
inflammatory for musculoskeletal and joint diseases. Drug names can be linked to a 
maximum of three different BNF codes. 
Instead of studying risk of 5LE or drug related hypothyroidism associated with each 
of the 10310 drug names individually, we grouped the drug exposures by BNF 
subchapters, i.e. by the first four digits of the BNF codes. At a later stage in the 
signal generation analysis we refined our grouping by using the full BNF code. Drugs 
included in more than one BNF chapter and/or subchapter were counted once in each 
of their respective groups. Grouping of exposures resulted in an increase in potential 
risk factors to which both cases and controls were exposed. In relation to 'that, 
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grouping of drugs increased the proportion of subjects exposed to the potential risk 
factor, which dramatically increased study power. 
3.4.2. Exposures of Interest for SLE Signal Evaluation 
We obtained a list of drugs hypothesised to be associated with risk of SLE from the 
literature. A list of exposures of interest can be found in Table 1-1. The drugs in this 
table are reported to have 'low', 'moderate' and 'high' approximate risk levels based 
on available Iiterature[22]. Drugs thought to be of very low risk, such as those where 
there is only one case report available, were not studied. Risks associated with 
exposure to drugs reported to exacerbate pre-existing lupus or to initiate lupus 
flares[23] were also not studied because in the clinical data available in the GPRD, 
exacerbations of existing disease are difficult to assess reliably. 
3.4.2.1. Control Drugs 
A selection of drugs that are not known to be linked to risk of SLE were included as 
'control drugs' to investigate whether any observed effects were specific to the drugs 
of interest. Control drugs were chosen based on a number of characteristics. Firstly, 
drugs commonly prescribed in general practice were chosen, to ensure sufficient 
statistical power. Secondly, we ensured that use of the drug did not reflect a 
forthcoming diagnosis of SLE by selecting drugs which are not prescribed for 
symptoms overlapping with early SLE symptoms. Lastly, therapeutic class played a 
role in the selection of appropriate control drugs. Inclusion of a control drug of similar 
therapeutic class as a drug known to induce lupus enabled us to investigate whether 
effects were class-wide or drug-specific. Trimethoprim was included as a 'control' 
drug because it is of the same therapeutic class as the SLE-inducing drug minocycline 
(i.e. an· antibiotic). The 'control' drug diazepam is an antiepileptic, as is 
carbamazepine. The third 'control' drug, the asthma drug salbutamol, is of a different 
therapeutic class from any of the lupus-inducing drugs but it was chosen because 
asthma" symptoms do not overlap with early SLE symptoms and prescription of the 
drug should occur independently of case or control status. 
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3.4.3. Exposures of Interest for Signal Evaluation investigating Drug 
Related Hypothyroidism 
During the signal evaluation phase of our study of risk of drug related 
hypothyroidism associated with prescription drugs, we investigated new hypotheses 
which were identified during the signal generation phase. 
3.5. STA TISTICAL ANAL YSES 
3.S.1. Conditional Logistic Regression 
Conditional logistic regression was performed to model the risk of SLE (or drug 
related hypothyroidism) associated with exposure to drugs of interest during the 
study period and 1 week or more before diagnosis date (index date for the matched 
controls). Odds Ratios (ORs) and 95% Confidence Intervals (CIs) were calculated 
using Stata Software Version 9.0 (StataCorp, Texas). When there were sufficient 
numbers of exposed study subjects, a drug was studied in further detail by 
investigating the effect of number of prescriptions (as a proxy for cumulative dose), 
time between first and last prescription (as a proxy for duration of exposure) and 
time since cessation of the drug. In all analyses, unexposed subjects served as the 
reference category. Categorisation of variables was based on their frequency 
distribution in the control group. For instance, number of prescriptions was 
categorised into four groups; unexposed individuals served as the reference group 
and those exposed were categorised into three groups based on tertiles of number of 
prescriptions in the controls. Years of available prescription data before diagnosis 
date was also categorised into 4 groups with cut-off pOints based on quartiles in the 
controls. However, values were rounded off to the nearest year or 6 months for ease 
of interpret~tion. Similarly, number of consultations in the year before diagnosis was 
categorised into four groups based on quartile values in the controls. No missing 
values were observed for the categorised variables, hence sample size was not 
affected in analyses which included categorised variables in the model (e.g. 
conditional logistic regression models that were adjusted for confounding variables). 
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We investigated potential trends in risk of SLE (or drug related hypothyroidism) with 
increasing number of prescriptions in two ways. Firstly, we performed a test for trend 
by adding the grouped variable for "number of prescriptions to the conditional logistic 
regression model as a continuous variable. The p-value relating to the risk estimate 
for this 'continuous' variable served as the p for trend. This test for trend assumes 
linearity of the underlying (ungrouped) continuous variable for number of 
prescriptions. When the odds ratios for the separate categories of number of 
prescriptions are suggesting a non-linear trend, but the p for trend suggests 
statistical significance, interpretation can be difficult. This situation may occur when 
individual categories contain a limited number of subjects, or when the risk estimate 
for one specific category has an extreme value relative to the other categories. A 
more informative measure in that case is the risk of SLE (or drug related 
hypothyroidism) per 10 prescriptions for the drug of interest. In order to calculate 
this risk, we grouped number of prescriptions in an alternative way; unexposed cases 
and .. controls remained the reference category and every 10 prescriptions were 
combined into a new group. For instance, the maximum number of prescriptions for 
anxiolytics (BNF code 04.01.02.00) was 514, hence there were 52 exposure 
categories. The regrouped variable for number of prescriptions was added in the 
model as a continuous variable to obtain risk of disease per 10 prescriptions. 
The potential confounders age, sex, practice and calendar time were included in the 
study design as matching variables. Two additional factors were added to the model 
" 
as a priori confounding factors: Years of available prescription data before diagnosis 
date (index date for the controls) was included because with more years of available 
prescription data, a study subject is more likely to receive a prescription for a drug of 
interest and more likely to be diagnosed with SLE; Number of consultations in the 
year preceding diagnosis date (index date for the controls) was included as a 
confounder because with more consultations a study subject is more likely to receive 
a prescription· for any drug, including a drug of interest and more likely to be 
diagnosed with SLE (or drug related hypothyroidism). 
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Age at diagnosis was categorised into younger and older age based on the median 
value for each disease «45 years or ~45 years for the SLE data and <55 or ~55 for 
the drug related hypothyroidism data, respectively). Age at diagnosis and sex were 
then investigated in two ways. Firstly, potential effect-modifying effects were 
examined. Stratum-specific DRs for men and women and for younger and older age 
were calculated and a test for interaction was performed. Secondly, age- and sex 
distributions of exposed subjects were compared to those of unexposed subjects, to 
identify whether drug-induced lupus (drug-induced drug related hypothyroidism) can 
be distinguished from idiopathic lupus by means of its age- and sex distribution. For 
age, a two-sided t-test was performed to compare the mean age in exposed versus 
unexposed cases and separately for controls. A chi-squared test was performed to 
investigate differences in the proportions of males and females for exposed and 
unexposed cases and separately for controls. When expected values were less than 
five, a Fisher's Exact test was performed instead of a chi-squared test. 
3.5.1.1. Statistical Power 
The GPRD data set obtained for this project included all possible autoimmune cases 
diagnosed between 1987, when data collection of the GPRD was initiated, and 2001. 
This data set included approximately 1500 matched incident cases of SLE and 
approximately 18000 matched incident cases of drug related hypothyroidism. The 
total number of cases with hypothyroid disease was divided in two subsets as 
described in paragraph 3.3.2.1. This resulted in a sample size of about 6000 cases 
for signal generation and 12000 for signal evaluation. 
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Using the formula below (from Schlesselman[57]), power curves were generated in 
order to assess the minimum relative risk we would be able to detect with the sample 
size available to us. 
where 
N = Number of cases needed for the study sample 
Za = Value of Z in a standard normal distribution where (l = 0.05 
c = Number of controls per case 
Po = Proportion of controls exposed 
qo = Proportion of controls unexposed 
R = Minimum risk to be detected 
" PI + cPo P= l+c 
q'=I- P' 
Z = Value of Z in standard normal distribution where f3 = 1- power 
p -
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Figure 3-a: Power curves for variouS levels of exposure in control subjects 
Figure 3-a depicts power curves for four different levels of drug exposure in controls 
(0.01 %, 0.1 o/~, 1% and 10%), at an a of 0.05. For each level of exposure, power 
associated with four levels of risk (RR=2, RR=2.5, RR=4 and RR=8) was calculated. 
Study power of 80% was considered sufficient. 
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For the signal evaluation study of drug related hypothyroidism (sample size :::: 
12000), there was sufficient study' power to detect a relative risk of >4 associated 
with drugs of low exposure prevalence (i.e. used by 0.01% of the controls). For 
drugs with higher exposure prevalence (0.1 % and higher) there was sufficient power 
to detect a relative risk of 2 or higher. 
Study power for risk of SLE was insufficient when 0.01% of the controls were 
exposed to the exposure of interest. Study power was limited to relative risks of >4 
for drugs with a relatively low exposure prevalence of 0.1%. There was sufficient 
power to detect relative risks of 2 or more for drugs with exposure an prevalence of 
1% or more. 
3.5.2. Self-Controlled Case Series 
The case series method is derived from the cohort method and compares, within an 
individual, the incidence of an outcome during (exposed) risk periods versus the 
incidence during (unexposed) periods which serve as baseline time[10]. Individuals 
without the outcome of interest (control subjects) do not contribute information to 
the risk estimate. Unexposed cases also do not contribute information regarding the 
association between exposure and risk of disease. However, unexposed cases may be 
included to adjust for confounding by age. It is particularly important to include 
unexposed cases when those who are exposed are all of the same age, e.g. when 
investigating risk of intussusception associated with oral polio vaccination[58] . 
.. 
Because the case series method makes comparisons within one person, factors that 
are difficult to measure (e.g. consultation behaviour), or vary between individuals 
(e.g. coexistence of other autoimmune diseases), do not affect the risk estimates. 
We utilised the self-controlled case series method to investigate the association 
between risk of lupus and exposure to a variety of prescription drugs. Definition of 
outcome and exposure, and details of the statistical analysis methods are provided 
below. 
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3.5.2.1. Outcome Definition 
Cases were identified by selecting patients with at least one code for SLE in their 
medical history (for further details, see section 3.3.1.1). In order to avoid 
misclassification between prevalent and incident conditions, we excluded cases 
diagnosed within the first 12 months of having UTS data (see paragraph 3.3.6 for 
further detail). Case inclusion and exclusion criteria for the self-controlled case series 
analysis were the same as described for the matched case-control analysis (section 
3.3.1.1), with the exception that cases with comorbid autoimmune disease were 
included in the SCCS analyses. In the case-control analyses these cases were 
excluded to avoid confounding. 
3.5.2.2. Exposure Definition 
Exposures of interest were drugs known to be associated with risk of SLE, as well as 
three 'control drugs'. A more detailed description of exposures of interest and control 
drugs can be found in paragraph 3.4.2. Because we observed a wide variation in age 
among the exposed cases (see also table 4-5), it was not necessary to include 
unexposed cases for adjustment of confounding by age. Our analyses were therefore 
based on exposed cases only. For each drug of interest, a separate data set was 
created containing only cases who received one or more prescriptions for the drug. 
Prescriptions issued on the same day for the same drug were combined to represent 
one exposure. Because timing is very important in the case series method (see 
Whitaker et al[59] and section 3.5.2.3), we double checked that none of the 
prescriptions for the drugs of interest had a missing or estimated diagnosis date. In 
the whole of our data set, there were three missing prescription dates. These missing 
dates were not in association with the drugs of interest. 
3.5.2.3. Definition of Exposure time 
The start of an individual's GPRD record was defined as the first date on which a 
patient's practice was considered to contribute up-to-standard data, or the date on 
which a patient registered with the practice (whichever occurred latest). The end of 
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an individual's record was defined as the date on which the patient transferred out of 
their general practice or the date oi the last data upload of the practice to the GPRD 
(whichever came earliest). The total observation time, running from the start to the 
end of the GPRD record, was divided into intervals of defined length. There were 
three types of intervals, namely: risk periods, washout periods, and baseline periods. 
Figure 3-b: Graphic representation of the case series method 
r 
First prescription for 
drug of interest 
1 
Diagnosis of SLE 
1 
Time 
r 
Start GPRD 
record 
• = Baseline time 
End GPRD 
record 
= 30-day risk period 
D = 60-day washout period 
The figure shows an example of one individual who received two prescriptions for the drug of 
interest during the observation period. A 30 day risk period started on the day of the first 
prescription, and a further 50 day washout period followed the risk period. All other observation 
time served as reference time in which the individual was not exposed. In this example, SLE was 
diagnosed within the 50-day washout period after receiving the second prescription. 
A risk period started on the day a prescription for a drug of interest was issued and 
ended 30 days later. New risk periods started on the issue dates of each subsequent 
prescription for the drug of interest, i.e. a case had as many 3~-day risk periods as 
the number of issued prescriptions during the observation time. The length of the 
risk period was chosen somewhat arbitrarily because the time lag between taking a 
drug and developing SLE is not known. We chose 30 days to reflect the usual 
prescription length for all drugs of interest. The median value for prescription length 
was 28 days (inter-quartile range, 5 to 30). 
An additional 60-day washout period, starting on day 31 after each prescription was 
issued and ending on day 90, was included in the analyses. The reason to include the 
washout period was twofold; we did not know the exact date on which a patient 
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started and ended taking a drug of interest (we only know the date a prescription 
was issued). In addition, when a patient is on long term medication for a chronic 
condition, a GP sometimes chooses to issue repeat prescriptions that cover several 
months instead of a limited time period of one month. The length of the washout 
period was again based on the distribution of prescription length for all drugs of 
interest: 99% of prescriptions had a duration of 90 days or less so we were 
reasonably certain that patients would have stopped taking the drug by the end of 
the washout period. However, 32% of all prescriptions for drugs of interest had 
missing information regarding length of prescription. 
All observation time outside of the risk and washout periods was defined as baseline 
time and served as the comparison period. Individuals were assumed to be 
unexposed to the drug of interest during baseline time. Figure 3-b provides an 
illustration of an individual's total observation time divided into the above described 
time periods. Data were pre-processed to calculate age (in days) on the days a risk, 
washout and baseline period started and ended. 
3.5.2.4. Statistical Analysis 
We compared the incidence rate of SLE during high risk and washout periods to the 
t· .. -
rate during baseline periods. All observation time, including the period after diagnosis 
of SLE, was included to estimate these relative incidence rate ratios (IRR) (Figure 3-
b). We adjusted for age using 5-year age bands. For risk associated with exposure to 
carbamazepine we' stratified the analysis by. sex to investigate its effect on risk of 
disease. All analyses were performed in Stata using the "xtpoisson" command for 
conditional Poisson regression. 
3.S.3. Signal Generation Using the ~'Smile Plot" Method 
A smile plot is a graph of p-values plotted against risk estimates corresponding to 
these. p-values. The smileplot package was developed by R Newson[60] in order to 
facilitate the interpretation of multiple test procedures. The package is downloadable 
from (http://www.stata-journal.com/software/sj3-2) as an add-in to the statistical 
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software package Stata (from version 7, Statacorp, Texas). An example of a smile 
plot can be seen in Figure 3-c. Observations in the upper right hand corner of Figure 
3-c represent drugs with a large estimated risk and strong evidence for an 
association with the disease of interest. 
Figure 3-c: Example of a smile plot 
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From: Newson et al [60]. This figure presents correlation between oily fish consumption and red blood cell fatty acid 
percentages, expressed in Somers' O. The labels in this graph represent different fatty acids. The vertical line represents 
the null (i.e. no correlation); the p-values corresponding to correlation estimates are on the y-axis (on a reverse 
logarithmic scale). In addition to the x-axis, which lists Somers' 0, there are two horizontal lines. One is marked ".05" and 
represents the uncorrected level of significance. The top horizontal line (in this graph marked with ".00183") represents 
the 'new' significance level: a stricter level obtained using defined criteria to correct for multiple comparisons. In our 
study of drug-induced autoimmune disease the graph will contain the following elements; the x-axis will list odds ratios 
instead of Somers' 0, and the labels in the graph will represent individual BNF subchapters instead of fatty acids. The 
yertical reference line will represent the null (OR=l, i.e. no risk). All other elements of the graph will be the same as 
presented here. 
The basis for each smile plot is an input data set. This data set contains a unique id 
variable for each exposure of interest, a risk .estimate for each exposure, and p-value 
corresponding to each risk estimate. The risk estimates may be univariable or may 
be adjusted for confounding factors. Additional measures such as 95% confidence 
limits for the risk estimates and number of individuals exposed to each risk factor 
may be incorporated in the input data set, but these are not used to generate the 
graph. 
Once the input data set has been created, one has to choose a method of controlling 
for multiple comparisons. A range of multiple test procedures is available in the smile 
plot package. These can be divided into family wise error rate (FWER) and false 
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discovery rate (FDR) methods (see also section 1.1.2.2). The methods calculate a 
corrected significance level. For one comparison, the significance level a is 0.05. With 
an increasing number of comparisons, the significance level becomes 'stricter', i.e. 
the corrected p value below which a null hypothesis is rejected is smaller than 0.05. 
To create smile plots of risk of autoimmune disease associated with prescription 
drugs, we analysed the GPRD autoimmune case-control data using conditional 
logistic regression (as described in section 3.5.1). Exposures of interest were drugs 
grouped by BNF subchapter or full BNF code (see Paragraph 3.4.1 and Appendix V for 
a list of BNF subchapters). For each exposure, we estimated risk of SLE (or drug 
related hypothyroidism), adjusted for confounding factors, and the p value 
corresponding to the risk estimate. We also recorded the number of cases and 
controls exposed to each BNF subchapter, the 95% confidence limits corresponding 
to each Odds Ratio, as well a unique identifier for each exposure. The risk estimates, 
p values and additional variables were then compiled in a new data set (the input 
data set). 
Smile plots were generated for each input data set. We explored all step-up FDR 
methods available in the smile plot package to correct for multiple comparisons, 
.' 
namely: the Simes, Yekutieli, and Krieger methods. We decided to use the method 
resulting in conservative corrected p values, which was the Yekutieli method. 
Separate smile plots (and thus input data sets) were generated to investigate the 
effect of time between exposure and onset of disease. One input data set contained 
risk estimates and p values based on all exposures up to one week before diagnosis 
of SLE (or drug related hypothyroidism). We also generated an input data set based 
on exposures that took place one year or more before diagnosis. 
The effect of sex and age at diagnosis was investigated by means of stratification. 
Separate smile plots were generated for women and men, and for younger and older 
age at diagnosis. The cut point to divide age at diagnosis in 'younger' and 'older' age 
groups was based on the median age at diagnosis for each disease «45 years or 
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~45 years for the SLE data and <55 or ~55 for the drug related hypothyroidism 
data, respectively). 
3.5.4. Signal Evaluation 
Our study of prescription drugs and risk of drug related hypothyroidism consisted of 
two phases: firstly, we generated new signals using the smile plot method as 
described above. Potential signals were subsequently evaluated in a larger data 
subset. A description of how the total drug related hypothyroidism case-control data 
were divided in subsets can be found in section 3.3.2.1. 
.' 
Signals were evaluated using conditional logistic regression (see section 3.5.1). Each 
BNF subchapter was divided in BNF codes and risk of drug related hypothyroidism 
was determined for each individual BNF code. In addition, risk associated with 
number of prescriptions (grouped) was investigated in order to assess a potential 
dose-response relationship. Potential effect modification by sex was investigated by 
performing stratified analyses (see section 3.5.1 for further detail). 
60 
CHAPTER 4. RISK OF SYSTEMIC LUPUS ERYTHEMATOSUS 
(SLE) ASSOCIATED WITH PRESCRIPTION MEDICINE 
Exposure to a wide range of prescription drugs has been linked to the induction of 
auto-antibodies and, to a lesser extent, clinically apparent autoimmune disease. The 
,most extenSively documented drug-induced autoimmune disease is systemic lupus 
erythematosus (SLE). Prescription drugs from several therapeutic classes have been 
reported to lead to lupus[22]. To date there has not been a large observational study 
to confirm the findings of these case reports or to quantify risks associated with 
exposure to the drugs of interest. 
In this chapter, the risk of lupus associated with prescription drugs is investigated. 
Two separate data sources are utilised: Firstly, existing hypotheses are evaluated in 
GPRD data using a case-control and a case-only approach. A new method to 
generate new hypotheses is presented, also using GPRD data. Secondly, a subset of 
Yellow Card spontaneous reports is described. 
4.1. MATCHED CASE-CONTROL STUDY 
We identified 875 incident cases of lupus with 3632 matched controls (Table 4-1). 
82.8% of the cases were female with a mean age. at diagnosis of 44.2 years (sd, 
15.1). Male cases were on average 6.6 years older at diagnosis (mean age 50.9 
years, sd 15.5, p" < 0.0001). Control subjects had a mean age of 45.3 years (sd, 
15.1). 
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Table 4-1: Demographic characteristics and univariable Odds Ratios (ORs) with 95% Confidence Intervals (CIs) for the 
association between selected variables and risk of lupus 
Study subjects (%) 
Case Control 
(N=875) (N=3632) 
Sext Female 721 (82.4%) 3012 (82.9%) 
Age at diagnosis, yearst Age (SD) 45.4 (15.1) 45.3 (15.1) 
Range 4.5 - 85.5 4.5 - 88.4 
Time in database, yearM 1 - 3 209 (23.9) 1112 (30.6) 
3 - 4.5 165 (18.9) 770 (21.2) 
4.5 - 7 246 (28.1) 950 (26.2) 
>7 255 (29.1) 800 (22.0) 
. Consultation rate§ 0-6 55 (6.29) 1060 (29.19) 
7 - 12 105 (12.00) 672 (18.50) 
13 - 24 194 (22.17) 826 (22.74) 
> 24 521 (59.54) 1074 (29.57) 
* Univariable OR for risk of SLE 
t Variable used to match cases and controls, therefore univariable OR is not reported 
* Time (in years) in database before diagnosis 
OR*(95% CI) 
1.00 (reference) 
1.37 (1.03 - 1.83) 
2.43 (1. 79 - 3.30) 
4.27 (3.03 - 6.02) 
P < 0.001 
1. 00 (reference) 
4.27 (2.95 - 6.18) 
8.51 (5.95 - 12.2) 
28.2 (19.4 - 40.8) 
P < 0.001 
§ Number of consultations per year in the year preceding diagnosis date (index date for the controls) .' 
The observation period from study entry to index date was longer for cases than 
controls, the mean for cases being 5.5 years and for controls being 4.9 years. Cases 
consulted their general practitioners more frequently in the year prior to the index 
date. The mean number of consultations for cases in the year before the index date 
was 40.4, while for controls the average number was 21.2. 
Conditional logistic regression was used to examine the association between lupus 
.and exposure to drugs at any point up to one week before the diagnosis or index 
date. Crude and adjusted ORs are shown in Table 4-2. Neither cases nor controls 
were exposed to procainamide, propylthiouracil, or acebutolol therefore risk 
associated with these drugs could not be estimated. For isoniazid, only cases were 
exposed. Very fe~ subjects were exposed to a further five drugs of interest, resulting 
in wide confidence intervals (e.g. hydralazine, OR = -6.62, 95% CI 1.03 - 42.74). For 
three drugs of interest more than 10 cases and controls were exposed. Large 
numbers of both cases and controls were exposed to the 'control' drugs. 
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Table 4-2: Crude and adjusted Odds Ratios (ORs) and 95% Confidence Intervals (CIs) for the association between lupus 
and exposure to selected drugs before diagnosis or index date 
Study Subjects 
Case Control 
Drug name (N=875) (N=3632) 
Drugs thought to induce SLE§ 
Hydralazine 4 
Minocycline 50 
Carbamazepine 28 
Quinidine 2 
Methyldopa 2 
Captopril 11 
Chlorpromazine 7 
Procainamide a 
Propylthiouracil a 
Acebutolol a 
Isoniazid 3 
Drugs not thought to induce SLE 
2 
49 
49 
2 
7 
24 
16 
a 
a 
a 
a 
Trimethoprim 201 583 
Diazepam 86 228 
Salbutamol 135 411 
*Reference category is the unexposed group for each drug 
Unadjusted OR* 
(95% CI) 
8.91 (1.62 - 48.94) 
4.35 (2.90 - 6.52) 
2.39 (1.48 - 3.85) 
3.94 (0.55 - 28.17) 
1.39 (0.29 - 6.70) 
1.97 (0.95 - 4.09) 
1.95 (0.78 - 4.87) 
1.63 (1.35 - 1.97) 
1.66 (1.26 - 2.18) 
1.44 (1.16 - 1. 79) 
Adjusted OR*t* 
(95% CI) 
6.62 (1.03 - 42.74) 
4.23 (2.65 - 6.75) 
1.88 (1.09 - 3.22) 
1.41 (0.17 - 11.95) 
1.40 (0.28 - 7.11) 
1.30 (0.57 - 2.96) 
0.86 (0.32 - 2.33) 
1.00 (0.80 - 1.24) 
0.92 (0.68 - 1.26) 
0.96 (0.76 - 1.22) 
tORs adjusted for time (in years) in database before diagnosis, and number of consultations in the year preceding 
diagnosis or index date 
*Control drugs additionally adjusted for exposure to SLE-inducing drug 
§Drugs are reported to have high, moderate or low risk of inducing lupus [22] 
For hydralazine, minocycline, carbamazepine and quinidine, drugs thought to induce 
lupus based on the literature, the crude ORs were greater than 2 and were 
statistically significant apart from quinidine. Exposure to methyldopa, captopril and 
chlorpromazine was not clearly associated with risks of lupus (ORs not statistically 
significant with values between 1 and 2). Simultaneous adjustment for number of 
consultations in the year preceding diagnosis or index date, and for number of years 
of available therapy data before diagnosis or index date, generally reduced the ORs. 
After adjustment for confounding factors a more than twofold increased risk was 
.. .-
seen for two of the drugs thought to induce SLE (hydralazine, OR = 6.62, 95% CI 
1.03 - 42.7; minocycline, OR = 4.23, 95% CI 2.65 - .6.75). 
Exposure to carba,mazepine was associated with a significantly increased risk. Risks 
associated with use of quinidine, methyldopa and captopril were slightly, but not 
significantly, increased (ORs between 1.00 and 2.00). The estimate for 
chlorpromazine shifted from an increased to a slightly decreased risk after 
adjustment for confounding factors. 
In general, crude ORs for the 'control' drugs trimethoprim, diazepam and salbutamol 
showed an increased risk of lupus of less than double compared to unexposed 
individuals. However, after adjustment for confounding factors (including use of 
lupus-inducing drugs) these associations were no lo~ger apparent. 
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The stratum-specific estimates for men and women are shown in Table 4-3. Very few 
men were both diagnosed with lupus and exposed to the drugs of interest. The sex-
specific estimates were different from the overall adjusted ORs for hydralazine, 
carbamazepine, captopril and chlorpromazine. For hydralazine, both women and men 
had an increased risk of SLE. Although the OR for men was higher than for women 
there was little evidence of effect modification (p for interaction = 0.387). For 
. carbamazepine, women had an increased risk of SLE whereas there was no evidence 
of an association in men. The test for interaction suggested the effect of 
carbamazepine varied with gender (p = 0.047). A test for interaction between 
captopril use and sex was not significant (p = 0.203). The male : female ratio for 
cases exposed to chlorpromazine was significantly different from the ratio among 
unexposed cases (ratio exposed 1 : 0.77, ratio unexposed 1 : 4.7, p = 0.027). There 
was no clear association observed for the 'control' drugs in women or men. 
Table 4-3: Sex-specific adjusted Odds Ratios (ORs) and 95% Confidence Intervals (CIs) for the association between 
lu~us and ex~osure to selected drugs before diagnosis or index date 
Women Men 
Case Control Case Control 
Drug name (N=721) (N=3012) OR (95% CI)*U (N=154) (N=620) OR (95% CI)*U 
Drugs reported to induce SLE§ 
Hydralazine 2 1 2.87 (0.26 - 31.71) 2 1 13.1 (1.04 - 166) 
Minocycline 45 44 4.29 (2.61 - 7.06) 5 5 4.47 (1.08 - 18.58) 
Carbamazepine 25 39 2.47 (1.37 - 4.48) 3 10 0.60 (0.15 - 2.38) 
Quinidine 2 2 1.36 (0.16 - 11.65) 0 0 
Methyldopa 2 7 1.43 (0.28 - 7.26) 0 0 
Captopril 9 16 1.84 (0.71 - 4.76) 2 8 0.53 (0.09 - 3.21) 
Chlorpromazine 3 12 0.51 (0.12 - 2.15) 4 4 1. 75 (0.40 - 7.69) 
'Control' drugs; not known to induce SLE 
Trimethoprim '190 541 1.05 (0.84 - ~.32) 11 42 0.59 (0.28 - 1.26) 
Diazepam 73 203 0.87 (0.62 - 1.21) 13 25 1.34 (0.59 - 3.03) 
Salbutamol 105 335 0.88 (0.68 - 1.15) 30 76 1.29 (0.75 - 2.22) 
*Reference category is the unexposed group for each drug 
tORs adjusted for time (in years) in database before diagnosis, and number of consultations in the year preceding 
diagnosis or index date 
*Control drugs additionally adjusted for exposure to SLE-inducing drug 
§Drugs are reported to have high, moderate or low risk of inducing lupus [22] 
Stratum-specific estimates for younger and older age at diagnosis could not be 
obtained for all drugs because of the small number of exposed subjects (data not 
shown). The highest number of minocycline users was amongst those less than 45 
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years old (34/446 cases exposed, 41/1849 controls). Risk of lupus in this group was 
3.38 (95% CI 1.94 - 5.90). In contrast, the older age group of ~45 years had fewer 
minocycline users (16/429 cases and 8/1783 controls) but a suggestion of a higher 
risk was observed (OR=7.93, 95% CI 3.12 - 20.17, p interaction = 0.117). Cases 
using captopril before diagnosis were on average 13 years older than non-users 
(mean age 58.1 (sd 11.3), p = 0.0058) but the risk estimate for the older age group 
was similar to the overall risk estimate (data not shown). Risk associated with 
captopril in the younger age group could not be estimated as only one case was 
exposed and no controls. 
Table 4-4: Odds Ratios (OR) and 95% Confidence Intervals (CI) for number of I2rescril2tions and risk of SLE 
Stud}! subjects 
No. of prescriptions* Case Control Unadjusted OR Drug name N=875 N=3632 {95% CIl 
Drugs thought to induce SLE 
Minocycline unexposed 825 3583 1.00 (Reference) 
1 17 22 3.43 (1.81 - 6.51) 
2-3 13 12 4.31 (1. 94 - 9.60) 
>=4 20 15 5.67 (2.88 - 11.14) 
P < 0.001 
Carbamazepine unexposed 847 3583 1.00 (Reference) 
1 9 16 2.39 (1.05 - 5.45) 
2-6 4 17 0.96 (0.32 - 2.89) 
>=7 15 16 3.83 (1.88 - 7.80) 
P < 0.001 
Captopril unexposed 864 3608 1.00 (Reference) 
1-13 Rx 8 13 2.58 (1.06 - 6.26) 
>=14 Rx 3 11 1.20 (0.32 - 4.40) 
P = 0.180 
Chlorpromazine unexposed 868 3616 1. 00 (Reference) 
1 Rx 4 11 1.60 (0.49 - 5.27) 
>=2 Rx 3 5 2.65 (0.63 - 11.2) 
p = 0.124 
Drugs not known to induce SLE 
Trimethoprim unexposed 674 3049 1.00 (Reference) 
1 Rx 121 385 1.47 (1.17 - 1.84) 
2 Rx 40 105 1.85 (1.26 - 2.70) 
>=3 Rx 40 93 2.13 (1.43 - 3.18) 
P < 0.001 
Diazepam .. unexposed 789 3404 1. 00 (Reference) 
1 50 118 1.85 (1.30 - 2.62 
2-3 19 53 1.64 (0.96 - 2.81) 
>=4 17 57 1.28 (0.74 - 2.23) 
P = 0.009 
Salbutamol unexposed 740 3221 1.00 (Reference) 
1 Rx 40 161 1.08 (0.75 - 1.56) 
2-6 Rx 52 126 1.85 (1.31 - 2.59) 
>=7 Rx 43 124 1.49 (1.04 - 2.15) 
12 < 0.001 
* Categorisation no. of prescriptions based on distribution in controls 
t Adjusted for years in database before diagnosis and no. of consultations in year prior diagnosis 
:1= Drugs not known to induce SLE additionally adjusted for use of SLE drug yes/no 
Adjusted OR H 
{95% CIl 
1.00 (Reference) 
3.03 (1.49 - 6.17) 
6.10 (2.20 - 16.93) 
5.00 (2.37 - 10.51) 
P < 0.001 
1.00 (Reference) 
1.55 (0.62 - 3.84) 
0.94 (0.27 - 3.25) 
3.04 (1.34 - 6.85) 
P = 0.011 
1.00 (Reference) 
2.13 (0.79 - 5.73) 
0.56 (0.14 - 2.29) 
P = 0.970 
1. 00 (Reference) 
0.63 (0.17 - 2.26) 
1.48 (0.29 - 7.42) 
P = 0.987 
1. 00 (Reference) 
0.97 (0.75 - 1.25) 
1.10 (0.72 - 1.67) 
1.00 (0.64 - 1.56) 
P = 0.918 
1. 00 (Reference) 
1.10 (0.74 - 1.63) 
0.79 (0.44 - 1.42) 
0.73 (0.40 - 1.33) 
P = 0.297 
1. 00 (Reference) 
0.85 (0.57 - 1.26) 
1.23 (0.84 - 1.79) 
0.83 (0.55 - 1.25) 
12 = 0.744 
For drugs where there were sufficient numbers of cases and controls exposed, the 
effect of number of prescriptions on risk of lupus was investigated (Table 4-4). For 
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minocycline there was a clear trend of increasing risk with increasing number of 
prescriptions (adjusted OR per 10 prescriptions 3.10, 95% CI 2.10 - 4.55, P for trend 
< 0.001). For carbamazepine there was some evidence of a trend in DRs for grouped 
number of prescriptions (adjusted OR per 10 prescriptions 1.27, 95% CI 1.04 - 1.57, 
P for trend = 0.011). For chlorpromazine there was a suggestion of increasing risk 
with increasing number of prescriptions, however the OR per 10 prescriptions and the 
'test for trend did not confirm this association (adjusted OR per 10 prescriptions 1.18, 
95% CI 0.64 - 2.20), P for trend = 0.987). Number of prescriptions for captopril did 
not show a clear association with risk of SLE nor did the 'control' drugs. Results for 
time between first and last prescription as a proxy for duration are very similar to 
cumulative dose (data not shown). 
Current use of minocycline was associated with a 4-fold increased risk (OR = 4.05, 
95% CI 1.04 - 15.76) and current use of chlorpromazine was associated with a 2-fold 
increased risk (OR = 2.27, 95% CI 0.27 - 19.02). Increasing time since cessation of 
drug use was associated with a decreased risk of lupus for minocycline and 
chlorpromazine, which was confirmed by a test for trend (minocycline p = 0.009, 
chlorpromazine p = 0.031). For carbamazepine there was a suggestion of a decrease 
.in risk of lupus with increasing time since cessation but, a test for trend did not 
confirm this association (p = 0.120). Time since cessation of use of captopril and all 
of the 'control' drugs was not clearly associated with· risk of lupus (data not shown). 
4.2. SELF-CONTROLLED CASE SERIES METHOD 
The matched case-control analyses (results described in section 4.1) included 875 
incident cases of SLE. Although there were a further 632 incident cases identified 
from the GPRD, these were unsuitable for the case-control analyses because there 
was no suitable control available (N= 135) and/or the case was diagnosed with 
another autoimmune disease (N=567). For the self-controlled case series analyses, 
all incident cases were eligible for inclusion i,n the analyses. Table 4-5 summarises 
the characteristics of cases exposed to the drugs of interest. Due to the limited 
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number of exposed cases for each drug, we chose to report median values and the 
inter-quartile range (instead of 'means and standard deviations) for length of 
observation time, number of repeat prescriptions and age. 
Table 4-5: Self-Controlled Case Series: characteristics of SLE cases and their exposures 
No. of exposed cases 
at timing of first 
prescription* Median length 
of observation 
timet, year 
No, of repeat 
prescriptions 
Drug name Pre (%) 
Drugs thought to induce SLE§ 
Hydralazine 7 (100) 
Minocycline 38 (67) 
Carbamazepine 34 (56) 
Methyldopa 1 (100) 
Captopril 15 (60) 
Chlorpromazine 8 (40) 
Propylthiouracil 1 (100) 
Acebutolol 3 (100) 
Isoniazid 3 (43) 
Penicillamine 6 (67) 
Sulfasalazine 38 (63) 
Drugs not thought to induce SLE 
Post (%) 
0(0) 
19 (33) 
27 (44) 
0(0) 
10 (40) 
12 (60) 
0(0) 
0(0) 
4 (57) 
3 (33) 
22 (37) 
3.5 (2.1 - 6.5) 
5.2 (2.6 - 8.0) 
4.3 ( 2.8 - 6.8) 
6.0 
4.6 (2.1 - 6.3) 
6.6 (3.3 - 9.1) 
8.5 
8.2 (3.4 - 9.3) 
4.4 (1.4 - 7.6) 
4.7 (3.4 - 7.5) 
4.8 (3.2 - 7.7) 
Mediant Max* 
6 (3 - 26) 49 
3 (1 - 6) 73 
10 (2 - 28) 94 
40 
13(4-29) 103 
2(1-13) 48 
18 
10(1-99) 99 
6 (1 - 7) 10 
4 (2 - 6) 22 
5 (2 - 12.5) 77 
Trimethoprim 124 (36) 220 (64) 5.3 (3.3 - 7.6) 1 (1 - 2) 23 
Diazepam 61 (41) 89 (59) 5.3 (3.1 - 8.0) 2 (1 - 4) 167 
Salbutamol 142 (54) 122 (46) 4.4 (2.7 - 7.0) 3 (1 - 10) 357 
*Number of exposed cases who received their first prescription before or after diagnosis of SLE 
tNumbers in parentheses: inter-quartile range 
*Max, maximum 
§Drugs are reported to have high, moderate or low risk of inducing lupus[22] 
Median age at 
first 
prescriptiont, 
year 
68 (64 - 72) 
38 (30 - 47) 
46 (35 - 57) 
73 
66 (54 - 74) 
44 (39 - 61) 
42 
67 (52 - 72) 
38 (34 - 60) 
51 (49 - 61) 
47 (37 - 54) 
50 (37 - 62) 
50 (40 - 61) 
49 (38 - 60) 
For drugs thought to induce SLE[22], the majority of cases received their first 
prescription before onset of SLE, apart from chlorpromazine (12 out of 20 exposed 
cases received their first prescription after diagnosis of SLE), and isoniazid (4 out of 7 
'cases received their first prescription after diagnosis of SLE). For the 'control drugs' 
trimethoprim and diazepam however, the majority of cases received their first 
prescription after diagnosis of SLE. For the 'control 'drug' salbutamol, the proportion 
of cases receiving"their first prescription before diagnosis was approximately equal to 
those receiving their first prescription after diagnosis of SLE (54% versus 46%, 
respectively). Observation time was of similar length for all studied drugs, apart from 
chlorpromazine. Although the inter-quartile range overlapped with the range for all 
other drugs, chlorpromazine users had on average a slightly longer observation time. 
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Table 4-6: Incidence Rate Ratios (IRR) of SLE associated with prescription drug exposure during defined time periods 
Exposure period* No. of SLE 
(No. of exposed cases) diagnoses IRRt (9S% eI) 
Drugs thought to induce SLE* 
Hydralazine (N=7) 
Unexposed period 
0-30 
31 - 90 
Minocycline (N=57) 
Unexposed period 
0-30 
31 - 90 
Carbamazepine (N=61) 
Unexposed period 
0-30 
31 - 90 
Captopril (N=25) 
Unexposed period 
0-30 
31 - 90 
Chlorpromazine (N=20) 
Unexposed period 
0-30 
31 - 90 
Isoniazid (N=7) 
Unexposed period 
0-30 
31 - 90 
Penicillamine (N=9) 
Unexposed period 
0-30 
31 - 90 
Sulfasalazine (N=60) 
Unexposed period 
0-30 
31 - 90 
Drugs thought not to induce SLE 
Trimethoprim (N=344) 
Unexposed period 
0-30 
31 - 90 
. Diazepam (N=149) 
Unexposed period 
0-30 
31 - 90 
Salbutamol (N=264) 
2 
1 
4 
36 
8 
13 
31 
12 
18 
15 
1 
9 
15 
2 
3 
6 
0 
1 
7 
0 
2 
39 
5 
16 
316 
9 
19 
114 
13 
22 
Unexposed period 179 
0-30 34 
31-90 51 
*Period expressed in days since prescription was issued 
tIRR = Incidence Rate Ratio 
1.00 (Reference) 
1.42 (0.10 - 20.54) 
4.23 (0.57 - 31.34) 
1. 00 (Reference) 
2.14 (0.90 - 5.09) 
2.57 (1.25 - 5.27) 
1. 00 (Reference) 
1.60 (0.66 - 3.87) 
1.93 (0.87 - 4.26) 
1. 00 (Reference) 
0.09 (0.01 - 0.85) 
0.77 (0.20 - 2.91) 
1. 00 (Reference) 
1.28 (0.19 - 8.48) 
1.58 (0.34 - 7.27) 
1.00 (Reference) 
0.34 (0.02 - 5.66) 
1.00 (Reference) 
2.20 (0.30 - 15.9) 
1.00 (Reference) 
0.77 (0.27 - 2.19) 
2.26 (1.12 - 4.56) 
1. 00 (Reference) 
0.80 (0.41 - 1.58) 
0.94 (0.58 - 1.51) 
1.00 (Reference) 
1.63 (0.83 - 3.20) 
1.86 (1.06 - 3.23) 
1.00 (Reference) 
1.43 (0.92 - 2.23) 
1.59 (1.09 - 2.33) 
=1= Drugs are reported to have high, moderate or low risk of induCing lupus[22J 
, 
Cases exposed to carbamazepine and captopril received a substantial number of 
prescripti<?ns, whereas cases exposed to minocycline and chlorpromazine as well as 
the 'control drugs' generally received a limited number of prescriptions. Median age 
at first prescription again varied between the different drugs. These differences 
mostly reflect the indications for which the drugs are prescribed. For instance: 
hydralazine, methyldopa and captopril are drugs prescribed for high blood pressure; 
a condition that is mostly diagnosed in an older population. 
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In Table 4-5, the values for acebutolol, methyldopa, and propylthiouracil are based 
on only three exposed cases and random variation is likely to playa large role in any 
observed differences in observation time, number of repeat prescriptions and median 
age at first prescription. 
Table 4-6 summarises the results of the self-controlled case series analyses.' A 
. limited number of cases were diagnosed with SLE during the defined risk period for 
most drugs thought to induce lupus[22]. This resulted in wide confidence intervals. 
In the case population exposed to isoniaZid and penicillamine, no SLE diagnoses were 
made during the defined 30-day risk period and we could therefore not estimate the 
incidence rate ratio in this period. All risk estimates for the washout period, including 
those for the 'control drugs' were higher than those for the risk periods. 
Among users of hydralazine, no increased risk of SLE was seen during the risk 
period. However, a 4-fold increased risk was observed during the washout period. 
The 95% confidence interval included one. For minocycline, risk during both of the 
exposed periods was twofold compared to unexposed time. For carbamazepine, there 
was a suggestion of a moderately increased risk in both the risk and washout 
periods, but the IRRs were not statistically significant. When the analysis was 
stratified by sex, risk estimates for women were similar to the overall results (IRRrisk 
period = 1.30, 95% CI 0.50 - 3.42; IRRwashout period = 1.74, 95% CI 0.74 - 4.11). The 
risk estimates for the seven exposed men however were substantially higher. Two 
men were diagnosed with SLE during the risk period and two during the washout 
period. The diagnosis date for the other three -men occurred during baseline 
(unexposed) time. This resulted in the following risk estimates: IRRrisk period = 7.43 
(95% CI 0.81 - 68.1), IRRwashout period = 4.29 (95% CI 0.50 - 36.53). Although these 
estimates-are based on a small number of exposed men (and, consequently, have 
very wide confidence intervals), their magnitude is in support of a true increase of 
risk, especially during the period immediately after receiving a prescription. 
There was a suggestion of a moderately increased risk of SLE (IRR less than 2) 
associated with use of chlorpromazine. An approximately twofold increase in risk was 
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observed during the washout period for penicillamine and sulfasalazine. Risk of SLE 
associated with use of captopril a'ppeared to be decreased in both the 30-day risk 
period and the washout period. 
We did not observe an increased risk of SLE during the washout period for 
trimethoprim. However, for the other two 'control drugs' a modest but statistically 
, significant increase in risk of SLE was observed during the washout period. 
4.3. SIGNAL GENERA TION USING "SMILE PLOTS" 
For the signal generation analyses, we used the same cases and controls as for the 
matched case-control study. Characteristics of the 875 cases and 3632 matched 
controls can be found in Paragraph 4.1 and Table 4-1. 
4.3.1. Exposure to Drugs Prescribed One Week or More Before Diagnosis 
Firstly, we investigated risk of SLE associated with exposure to drugs, grouped by 
BNF subchapter, one week or more before diagnosis. Further details of the BNF 
subchapters can be found in Appendix V. There were 87 subchapters to which both 
cases and controls were exposed. Conditional logistic regression was performed to 
'obtain adjusted risk estimates for each of these subchapters. A graphical 
presentation of the risk estimates and corresponding P-values can be found in Figure 
4-a. 
There was a suggestion of an increased risk of SLE, with P-values smaller than the 
corrected overall critical P-value, for twelve BNF subchapters (located in the upper 
right corner of Figure 4-a). Five of these twelve signals were subchapters of BNF 
chapter 13, which covers drugs for the skin. Furthermore, seven of the twelve signals 
were subchapters containing drugs prescribed to reduce inflammation such as 
corticosteroids and aspirin (subchapters 1304, 603, 1001, 504, 1306, 103 and 407). 
Further details of the twelve signals can be found in Table 4-7. 
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Figure 4-a: Smile plot of Odds Ratios (OR) and corresponding P-values for risk of SLE associated with exposure to BNF 
subchapters one week or more before diagnosis date 
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Odds Ratios (OR) are adjusted for time in database (in years) before diagnosis date, and consultation rate 
in the year before diagnosis. Method used to correct for multiple comparisons: Yekutieli; Uncorrected 
overall critica l P-va lue : 0.05; Number of P-values: 87; Corrected overall critical P-value: 0.00136596; 
Number of rejected P-values: 12. 
Table 4-7: Odds Ratios (OR), 95% Confidence Intervals (CI) and P-va lues for the risk of 
BNF subchapters one week or more before diagnosis date 
SLE associated with exposure to 
Label BNF subchapter * 
( BNF chapter) 
1308 Sunscreens and camouflagers (Skin) 
208 Anticoagu lants and protamine 
(Cardiovascular system) 
1304 Topica l local corticosteroids (Skin) 
603 Corticosteroids (Endocrine system) 
1001 Drugs used in rheumatic diseases and gout 
(Musculoskeletal and joint diseases) 
504 Antiprotozoal drugs (Infections) 
304 Antihistamines, hyposensitisation, and 
allergic emergencies (Respiratory system) 
1306 Acne and rosacea (Skin) 
103 Ulcer-healing drugs (Gastrointestina l 
system) 
1302 Emoll ient and barrier preparations (Skin) 
1310 Anti-infective skin preparations (Skin) 
407 Analgesics (Central nervous system) 
Case 
(N =875) 
63 
29 
489 
1(58 
586 
228 
290 
267 
181 
135 
370 
571 
* BNF subchapters identified as signals in smi le plot ana lysis 
t OR for exposures up to one week before diagnosis date 
Control 
(N =3632) 
OR ( 95% CI ) t:!: P va lue'll 
10 24.5 (11.4 - 52 .9) 2.22E-16 
26 2.81 (1.50 - 5.26) 1.27E-03 
1099 2.23 (1.87 - 2.66) 2.22E-16 
238 2.14 (1.68 - 2.73) 1.12E-09 
1504 1.91 (1.58 - 2.30) 1.34E-11 
469 1.82 (1.47 - 2.24) 2.57E-08 
617 1.73 (1.42 - 2.10) 3.48E-08 
609 1.66 (1.37 - 2.03) 4 .13E-07 
371 1.66 (1.32 - 2.09) 1.84E-05 
273 1.57 (1.21 - 2.04) 7.39E-04 
943 
1586 
1.55 (1.30 - 1.85) 
1.48 (1.23 - 1.79) 
1.50E-06 
3.48E-05 
* OR adjusted for time in database (in years) before diagnosis, and number of consultations in the year before diagnosis 
~Corrected overall critical P-value : 1.37E-03 
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For two BNF subchapters, the 95% confidence intervals suggested reduced risks of 
SLE: 74 cases and 271 controls were exposed to drugs for acute diarrhoea 
(subchapter 104, OR = 0.70, 95% CI 0.52 - 0.94) and 68 cases and 225 controls 
were exposed to local preparations for anal and rectal disorders (subchapter 107, OR 
= 0.71, 95% CI 0.51 - 0.98). Although a reduced risk was suggested based on the 
95% confidence intervals, the P-values for these estimates exceeded the critical P-
value corrected for multiple comparisons (Pcorrected = 0.001366). There was no clear 
association with risk of SLE for 63 of the 87 BNF subchapters tested (72%), with the 
95% confidence intervals including 1 (data not shown) and P-values exceeding the 
corrected overall critical P-value. In total, 62 of the 87 point estimates were greater 
than 1 (71%). Exposure to subchapter 802 (drugs affecting the immune response for 
malignant disease and immunosuppression) was associated with a high risk (OR = 
12.0, 95% CI: 2.46 - 58.8). This estimate was based on 12 exposed cases and 2 
exposed controls, and the P-value exceeded the corrected overall critical P-value (P = 
2.03E-03, Pcorrected = 1.37E-03). 
Table 4-8: Odds Ratios (OR), 95% Confidence Intervals (CI) and P-values for the risk of SLE associated with exposure to 
BNF subchapters one week or more before diagnosis date for male cases and controls 
. Case Control 
Label BNF subchapter* (BNF chapter) (N=154) (N=620) OR (95% CI)t:I: 
1302 Emollient and barrier preparations (Skin) 28 27 4.08 (1.92 - 8.69) 
1304 Topical local corticosteroids (Skin) 89 163 3.67 (2.34 - 5.75) 
1501 General anaesthesia (Anaesthesia) 35' 39 3.04 (1.75 - 5.30) 
504 Antiprotozoal drugs (Infections) 28 37 2.91 (1.59 - 5.32) 
2.65E-04 
1.52E-08 
8.50E-05 
5.37E-04 
401 Hypnotics and anxiolytics (Central nervous system) 44 59 2.46 (1.47 - 4.11) 6.02E-04 
*BNF subchapters identified as signals in smile plot analysis . 
tOR for exposures up to one week before diagnosis date 
*OR adjusted for time in database (in years) before diagnosis, and number of consultations in the year before diagnosis 
~Corrected overall critical P-value: 6.69E-04 
In the sex-stratified analyses, we found similar results for women as compared to the 
overall. results (data not shown). For men, less signals were identified but two 
previously undetected BNF subchapters were among the identified signals: BNF 
subchapter 401 (hypnotics and anxiolytics) and BNF subchapter 1501 (general 
anaesthesia) (Figure 4-b and Table 4-8). Apart from the four drugs temazepam, 
diazepam, lorazepam and butobarbitone/promethazi~e hydrochloride which are listed 
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in subchapter 401 as well as 1501, there are no further similarities between the two 
subchapters. Eight cases and one. control were exposed to sunscreens and 
camouflagers (BNF subchapter 130S,' OR = 42 .9, 95% CI, 4.05 - 455). Although the 
point estimate and 95% confidence interval for subchapter 130S suggested a strong 
association with risk of SLE, the P-value (P= 1.S0E-03) exceeded the corrected overall 
critical P-value (Pcorrected = 6.S0E-04). Similarly, exposure to herbal preparations for 
the skin (subchapter 1314) was associated with an increased risk of SLE (OR = 16.9, 
95% CI: 1.27 - 224). The estimate was based on three exposed cases and one 
exposed control, and the P-value (P=3.24E-02) again exceeded the corrected overall 
critical P-value of 6.S0E-04. 
Figure 4-b : Smile plot of Odds Ratios (OR) and corresponding P· values for risk of SLE associated with exposure to BNF 
subchapters one week or more before diagnosis date in men 
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ORs are adjusted for time in database (in years) before diagnosis date, and consultation rate in the year 
before diagnosis. Method used to correct for multiple comparisons: Yekutieli ; Uncorrected overall criti cal P-
va lue: 0.05; Number of P-values: 76; Corrected overall critical P-value: 0.0006801 ; Number of rej ected P-
values: 5 
Stratifying the data by age at diagnosis gave similar results for cases and controls 
diagnosed at age 45 and over, compared to the overall results (data not shown). 
Although subchapters 103, 20S and 407 were not identified as signals in the older 
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cases and controls, the point estimates and 95% confidence intervals for these 
subchapters did suggest an increased· risk of SLE. Among the signals for older cases 
and contro ls, there was one subchapter that was not identified in the full data set: 60 
older cases and 112 older controls were exposed to subchapter 1104 (corticosteroids 
and other ant i- inflammatory preparations for the eye, OR = 1.97, 95% CI : 1.35 -
2.87, P = 4.49E-04, Pcorrected = 1.isE-03). 
Figure 4-c: Smile plot of Odds Ratios (OR) and corresponding P-values for risk of SLE associated with exposure to BNF 
subchapters one week or more before diagnosis date for individuals under 45 years old 
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ORs are adjusted for time in database (in years) before diagnosis date, and consultation rate in the year 
before diagnosis. Method used to correct for multiple comparisons: Yekutieli; Uncorrected overall critical P-
value : 0.05; Number of P-values: 85; Corrected overall critica l P-value : 0.0012875; Number of rejected P-
values: 11 
The results for younger cases and controls (diagnosed before the age of 45) can be 
found in Figure 4-c and Table 4-9. The majority of signals for younger study subjects 
were si~ilar to signals observed in the full data set. However, we observed three 
new signals, all of the BNF chapter of treatments for the cardiovascular system 
(subchapter 206: nitrates, calcium-channel blockers and other antianginal drugs, 
subchapter 208: anticoagulants and protamine and subchapter 209: antiplatelet 
drugs). Subchapter 209 contains aspirin, which has anti - inflammatory properties in 
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addition to its antiplatelet action. Two other identified signals are also subchapters 
that include aspirin (subchapters 407 _and 1001). 
Table 4-9: Odds Ratios (OR), 95% Confidence Intervals (CI) and P-values for the risk of SLE associated with exposure to 
BNF subchapters one week or more before diagnosis in cases and controls under the age of 45 
Case Control 
Label BNF subchapter* (BNF chapter) (N=446) (N=1849) ORt:!: (95% CI) P-valuell 
1308 Sunscreens and camouflagers (Skin) 21 3 29.2 (7.79 - 110) 5.71E-07 
208 Anticoagulants and protamine (Cardiovascular 16 4 9.70 (2.86 - 33.0) 2.69E-04 
system) 
209 Antiplatelet drugs (Cardiovascular system) 17 12 4.80 (1.98 - 11.6) 5.30E-04 
206 Nitrates, calcium-channel blockers and other 30 28 3.18 (1.70 - 5.94) 2.99E-04 
antianginal drugs (Cardiovascular system) 
603 Corticosteroids (Endocrine system) 69 99 2.35 (1.60 - 3.47) 1.55E-05 
1001 Drugs used in rheumatic diseases and gout 279 640 2.20 (1.69 - 2.87) 4.73E-09 
(Musculoskeletal and joint diseases) 
103 Ulcer-healing drugs (Gastrointestinal system) 71 107 2.18 (1.47 - 3.22) 9.50E-05 
1304 Topical local corticosteroids (Skin) 236 561 2.00 (1.56 - 2.57) 6.19E-08 
504 Antiprotozoal drugs (Infections) 115 257 1.67 (1.25 - 2.24) 5.91E-04 
407 Analgesics (Central nervous system) 281 706 1.66 (1.28 - 2.16) 1.26E-04 
304 Antihistamines, hyposensitisation, and allergic 152 352 1.61 (1.23 - 2.12) 6.37E-04 
emergencies (Respiratory system) 
*BNF subchapters identified as signals in smile plot analysis 
tOR for exposures up to one week before diagnosis date 
*OR adjusted for time in database (in years) before diagnosis, and number of consultations in the year before diagnosis 
lICorrected overall critical P-value: 6.69E-04 
In addition to investigating risk of SLE associated with exposure to BNF subchapters, 
we investigated risk of SLE using a more refined grouping of drugs, i.e. grouping by 
the full BNF code. Odds ratios, 95% confidence intervals and P-values were 
calculated for exposure to BNF codes one week or more before diagnosis date. Risk 
estimates and corresponding P-values for all BNF codes are presented in a smile plot 
(Figure 4-d). There were 264 BNF codes to which both cases and controls were 
exposed. Seventeen of these (6.4%) were identified as signals because the P-value 
was smaller than the overall corrected critical P-value. 
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Figure 4-d: Smile plot of Odds Ra t ios (OR) and corresponding P-values for r isk of SLE associated w'th e t B 
codes one week or more before diagnosis date I xposure 0 NF 
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Appendix VI provides lists of drugs for the BNF codes that were identified as signals. 
Seven of the identified signals were codes of BNF chapter 13, which covers drugs for 
the skin. A further three signals were BNF codes of chapter 10 (drugs for 
musculoskeletal and j oint diseases). The signals identified when using the more 
refined grouping of drugs by BNF code (Table 4-10) are similar to those based on 
grouping drugs by subchapter presented in Table 4-7. Fifteen of the seventeen BNF 
code signals were derived from BNF subchapters listed in Table 4-7. The risk 
estimates of twelve of those were higher than the risk estimates for the associated 
subchapter and the confidence intervals were wider. Two signals, BNF code 
5.01.03.00 and 5.01.05 .00, had not been identified in the previous analysis although 
both were from the same BNF subchapter (501, antibacterial drugs). 
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Table 4-10: Odds Ratios (OR), 95% Confidence Intervals (CI) and P-values for the risk of SLE associated with exposure 
to BNF code one week or more before diagnosis date. 
Cases Controls 
BNF code* Description of BNF chapter (N=875) (N=3632) ORH (95% CI) P value~ 
13.08.01.01 Drugs for the skin 21 1 52.6 (6.68 - 415) 1.68E-04 
13.08.01.00 Drugs for the skin 47 7 25.7 (10.7 - 61.9) 4.38E-13 
10.01.03.00 Drugs for musculoskeletal and 81 20 12.1 (7.03 - 20.7) 4.38E-13 
joint diseases 
5.04.01.00 Drugs for infections 134 182 2.77 (2.09 - 3.67) 1.64E-12 
13.06.01.02 Drugs for the skin 44 70 2.26 (1.45 - 3.52) 3.12E-04 
13.04.00.00 Drugs for the skin 489 1099 2.23 (1.87 - 2.66) 4.38E-13 
6.03.02.00 Drugs for the endocrine system 168 238 2.14 (1.68 - 2.73) 1.12E-09 
1.03.05.00 Drugs for the gastrointestinal 76 128 1.89 (1.32 - 2.71) 4.98E-04 
system 
10.01.01.00 Drugs for musculoskeletal and 566 1461 1.82 (1.51 - 2.19) 2.51E-l0 
joint diseases 
13.10.01.02 Drugs for the skin 87 159 1.78 (1.30 - 2.43) 2.94E-04 
10.01.04.01 Drugs for musculoskeletal and 218 430 1.68 (1.35 - 2.08) 2.75E-06 
joint diseases 
3.04.01.01 Drugs for the respiratory 235 502 1.64 (1.34 - 2.02) 2.51E-06 
system 
5.01.03.00 Drugs for infections 292 673 1.56 (1.29 - 1.90) 6.90E-06 
13.06.02.01 Drugs for the skin 226 526 1.53 (1.25 - 1.89) 5.61E-05 
5.01.05.00 Drugs for infections 282 688 1.50 (1.24 - 1.82) 4.08E-05 
4.07.01.00 Drugs for the central nervous 473 1228 1.46 (1.21 - 1.75) S.93E-05 
system 
13.10.02.00 Drugs for the skin 211 492 1.45 (1.18 - 1.79) 4.98E-04 
*BNF codes identified as signals in the smile plot analysis 
tOR for exposures up to one week before diagnosis date 
*OR adjusted for time in database (in years) before diagnosis, and number of consultations in the year before diagnosis 
~Corrected overall critical P-value: 5.23E-04 
For a further 31 BNF codes there was a suggestion of an increased risk of SLE based 
on the 95% confidence intervals. However, the P-values for these estimates 
exceeded the corrected overall critical P-value (data not shown). There was also one 
BNF code for which a decreased risk of SLE was 'suggested based on the 95% 
confidence interval..(BNF code 1.02.01.00, 40 cases and 158 controls exposed, OR = 
0.58, 95% CI: 0.39 - 0.87). Again the P-value for this BNF code exceeded the critical 
P-value corrected for multiple comparisons. 
In the sex-stratified analyses we identified similar signals for women as compared to 
the overall results (data not shown). For men, only three BNF codes were identified 
as signals. BNF code 13.04.00.00 (topical local corticosteroids for the skin) was 
identified as a signal both in men and in the overall analysis. The other two BNF 
codes identified as signals in men, codes 13.02.01.02 (non-proprietary emollient 
preparations) and 15.01.04.01 (Sedative and analge~ic peri-operative drugs), did not 
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arise in the overall analysis but appeared to be strongly associated with risk of SLE 
since the risk estimates were large. -Further details of BNF code signals in men are 
listed in Table 4-11. 
Table 4-11: Odds ratios (OR), 95% Confidence Intervals (CI) and P-values for exposure to BNF codes one week or more 
before diagnosis in men 
Cases Controls 
BNF code* (N=154) (N=620) 
13.02.01.02 28 25 
13.04.00.00 89 163 
15.01.04.01 35 38 
*BNF codes identified as signals in smile plot analysis 
tOR for exposures up to one week before diagnosis date 
ORH (95% CI) P-value~ 
4.87 (2.18 - 10.9) 1.16E-04 
3.67 (2.34 - 5.75) 1.52E-08 
3.20 (1.82 - 5.61) 4.96E-05 
:tOR adjusted for time in database (in years) before diagnosis, and number of consultations in the year before diagnosis .-
~Corrected overall critical P-value: 1.55E-04 
When data were stratified by younger and older age at diagnosis, results for those 
aged less than 45 years at the time of diagnosis (index) date were similar to the 
overall analysis (data not shown). This was in contrast to the signal generation 
results for BNF subchapters, when we identified three signals of drugs aimed at the 
cardiovascular system in the younger cases and controls (subchapters 206, 208 and 
209. See also Table 4-9). 
For those aged 45 and older at diagnosis, one new BNF code was identified as a 
signal: 38 older cases and 49 controls were exposed to BNF code 11.04.02.00 (OR= 
2.58 95% CI: 1.58 - 4.21, P = 1.58E-04, Pcorrected = 3·.52E-04). This is in line with the 
results for older study subjects exposed to BNF subchapters where subchapter 1104 
was identified as a signal. 
78 
Table 4-12: Odds Ratios (OR), 95% Confidence Intervals (CI) and P-values for the risk of SLE associated with exposure 
to BNF codes for s~ecific drugs one week or more before diagnosis date 
Drug name* Cases Controls 
BNF code {N=875 l {N=3632l ORH {95% Cll P-valuell 
Carbamazepine 
4.02.03.00 30 59 1.65 (0.99 - 2.77) 5.63E-02 
4.07.03.00 135 303 1.25 (0.97 - 1.61) 7.99E-02 
4.08.01.00 44 84 1.61 (1.05 - 2.47) 2.82E-02 
Minocycline 
5.01.03.00 292 673 1.56 (1.29 - 1.90) 6.90E-06§ 
12.03.02.00 46 84 1.41 (0.94 - 2.12) 9.89E-02 
13.06.02.01 226 526 1.53 (1.25 - 1.89) 5.61E-05§ 
Trimethoprim 
5.01.08.00 267 770 1.07 (0.88 - 1.29) 5.07E-Ol 
11.03.01.00 157 402 1.25 (0.99 - 1.58) 5.68E-02 
Diazepam 
4.01.02.00 126 300 1.17 (0.90 - 1.52) 2.41E-Ol 
4.08.02.00 2 2 1.32 (0.15 - 12.0) 8.03E-Ol 
4.08.03.00 1 1 0.66 (0.04 - 11.0) 7.71E-Ol 
10.02.02.00 122 302 1.11 (0.85 - 1.45) 4.37E-Ol 
15.01.04.01 173 396 1.32 (1.05 - 1.66) 1.80E-02 
Salbutamol 
3.01.01.01 153 455 0.97 (0.78 - 1.22) 8.03E-Ol 
3.01.04.00 4 10 1.38 (0.36 - 5.31) 6.41E-Ol 
3.01.05.02 23 61 0.91 (0.52 - 1.61) 7.52E-Ol 
3.02.00.00 81 227 0.95 (0.70 - 1.28) 7.25E-Ol 
7.01.03.00 17 57 0.82 (0.45 - 1.50) 5.14E-Ol 
*Choice of drugs further explained in section 4.1 
tOR for exposures one week or more before diagnosis date 
*OR adjusted for time in database (in years) before diagnosis, and number of consultations in the year before diagnosis 
lICorrected overall critical P-value = 5.23E-04 
§ P-value < 5.23E-04, therefore BNF code identified as signal 
In sections 4.1 and 4.2 of this thesis we presented results for risk of SLE associated 
with specific drugs (instead of drugs grouped by BNF code). In Table 4-12, signal 
generation results are presented for the BNF codes representing these drugs. Both 
carbamazepine and minocycline were identified as risk factors for SLE in section 4.1. 
However, the BNF codes representing carbamazepine are not identified as signals 
using the smile plot method. For minocycline 'on the other hand, two of the three BNF 
codes are identified as signals. There were five BNF codes representing the 'control 
drug' diazepam or combined preparations that included diazepam. None of these BNF 
codes were identified as signals. However, the point estimates for four of the five 
codes 'were greater than 1, and the 95% confidence interval for BNF code 
15.01.04.01 suggested an increased risk of SLE. BNF codes representing the 'control 
drug' salbutamol were not identified as signals. The pOint estimates were less than 1 
apart from one code to which few cases and controls were exposed. Two BNF codes 
represented trimethoprim. The point estimate and 95% confidence interval of one of 
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these codes (11.03.01.00) suggested an increased risk of SLE. However, the P-value 
exceeded the value of the corrected ·overall critical P-value. 
4.3.2. Exposure to Drugs One Year or More Before Diagnosis 
Initial symptoms of SLE may be vague and overlapping with a number of other 
conditions. Therefore, considerable amounts of time may pass before the GP 
identifies the patient's symptoms as SLE. In the signal generation analyses described 
above, we investigated exposures as recent as one week before diagnosis. Drugs 
prescribed for early symptoms of SLE may have been identified as signals. Below we 
describe the results of signal generation in which recent exposures, i.e. drugs 
prescribed in the year before diagnosis, were excluded from the analyses. 
When excluding recent exposures, five subchapters were identified as signals. All of 
these subchapters were also identified as Signals when including recent exposures of 
up to one week before diagnosis (Figure 4-e and Table 4-13). The risk estimates 
were of similar magnitude to those obtained when including recent exposures. 
Table 4-13: Odds Ratios (OR), 95% Confidence Intervals (CI) and P-values for the risk of SLE associated with exposure 
to BNF subchapters one year or more before diagnosis date 
BNF subchapter* (BNF Cases 
Label chapter) (N=875) 
1308 Sunscreens and camouflagers 35 
1304 
304 
(Skin) 
Topical local corticosteroids (Skin) 
Antihistamines, hyposensitisation, 
and allergic emergencies 
(Respiratory system) 
393 
236 
504 Antiprotozoal drugs (Infections) 173 
1306 Acne and rosacea (Skin) 219 
*BNF subchapters identified as signal in smile plot analysis 
tOR for exposures up to one week before diagnosis date 
Controls 
(N=3632) 
9 
932 
520 
381 
516 
ORtt (95% CI) 
15.4 (6.74 - 35.4) 
1.80 (1.51 - 2.16) 
1.58 (1.28 - 1.94) 
1.57 (1.25 - 1.97) 
1.50 (1.22 - 1.86) 
P-value'!l 
1.00E-10 
1.55E-10 
1.66E-05 
1.31E-04 
1.37E-04 
*OR adjusted for time in database (in years) before diagnosis, and number of consultations in the year before diagnosis 
~Corrected overall critical P-value: 5.69E-04 
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Compared to the signal generation analyses that included recent exposures, we 
identified less signals but those identified were from the same subchapters. The risk 
estimates were lower and confidence intervals were wider compared to estimates 
obtained when including recent exposures. The same pattern was seen for sex- and 
age-stratified analyses. 
Figure 4-e: Smile plot of Odds Ratios (OR) and corresponding P-values for risk of SLE associated with exposure to BNF 
subchapters one year or more before diagnosis 
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In Figure 4-f and Table 4-14, results are p~esented for signal generation of full BNF 
codes, excluding recent exposures from the analyses. We identified fewer signals as 
compared to the analyses that included recent exposures. The observed associations 
with risk of SLE are weaker as compared to the analyses that include recent 
exposures. 
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Table 4-14: Odds Ratios (OR), 95% Confidence Intervals (CI) and P-values for the risk of SLE associated with exposure 
to BNF codes one year or more before diagnosis date 
Description BNF chapter Cases 
BNF code* (N=875) 
13.08.01.00 Drugs for the skin 27 
10.01.03 .00 Drugs for musculoskeletal and 42 
joint diseases 
5.04.01.00 Drugs for infections 84 
13.04.00.00 Drugs for the skin 393 
5.01.05.00 Drugs for infections 243 
* BNF codes identified as signals in smile plot analysis 
t OR for exposures up to one week before diagnosis date 
Controls 
(N=3632) ORU (95% el) P-value~ 
6 20.94 (7.60 - 57 .71) 4.05E-09 
19 6.70 (3.63 - 12.34) 1.10E-09 
144 1.90 (1.37 - 2.62) 1.12E-04 
932 1.80 (1.51 - 2.16) 1.55E-10 
576 1.50 (1.22 - 1.84) 1.28E-04 
:Io OR adjusted for time in database (in years) before diagnosis, and number of consultations in the year before diagnosis 
~Corrected overall critical P-value = 1.59E-04 
Figure 4-f: Smile plot of Odds Ratios (OR) and corresponding P-values for the ri sk of SLE associated with exposure to 
BNF codes one year or more before diagnosis date 
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4.4. DESCRIPTION OF SIGNALS IN THE YELLOW CARD DATABASE 
A total of 528480 Yellow Card reports were submitted between July 1963 and 10 
January 2006 by health care professionals and, since recently, patients. SLE or SLE-
like disease was the reported adverse drug reaction on 859 of these (0.16%). We 
received detailed records for 446 of the 859 reports (Figure 4-g). After inspection we 
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excluded 25 of the 446 detailed records, because the recorded adverse event was 
cutaneous lupus, which is not considered a form of SLE. The drug terbinafine was 
listed as the suspected drug on all of these 25 excluded reports. A further six reports 
were excluded because they concerned conditions other than SLE, namely: 
rheumatoid arthritis (N=2, suspected drugs: minocycline and procainamide), 
arthropathy (N=1, suspected drug: labetalol), arthritis (N=1, suspected drug: 
. minocycline), myalgia (N=1, suspected drug: procainamide) and pneumonia (N=1, 
suspected drug: procainamide). 
Figure 4-g: Stream diagram of Yellow Card reports 
Total number of Yellow 
N=528480 Card reports submitted 
by 11 January 2006 
Yellow Card 
N=859 Reports of SLE or 
SLE -like disease 
Has the specific combination of 
drug and adverse event been 
reported 9 times or more? 
No 
No further 
N=413 information 
received 
No 
Exclude from 
N=31 analyses 
Yes 
Detailed 
information N=446 
received 
Does the detailed report 
contain a diagnosis of SLE 
or SLE-like disease? 
Yes 
I Include I N=415 
.' 
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Table 4-15 lists the total number of included reports for each drug. The drug with the 
largest number of reports of a suspected association with SLE was hydralazine (42% 
of the total number of reports). The male to female ratio of reports for each drug can 
also be found in Table 4-15. An equal number of Yellow Cards reporting procainamide 
in association with SLE were submitted for men and women. For sulfasalazine and 
.. 
penicillamine on the other hand, the majority of reports were for female cases, and 
. all twelve reports submitted for infliximab involved female cases. 
, 
Table 4-15: Number and sex distribution of Yellow Cards re(2orting SLE or SLE-like disease by sus(2ected drug 
Outcome of disease Time to onset of SLE, da~s§ 
Male: Reeo- Not 
Suspected No. of Female vered/ reeo- Not Median time 
drug* reports ratiot reeo-vering vered Fatal known* {rangelll 
Hydralazine 173 1 : 2.1 127 1 4 4 639 (3 - 2268) 
Minocycline~ 138 1 : 2.9 105 18 0 14 161 (1 - 6570) 
Practolol 21 1 : 2.0 15 0 0 6 
Procainamide 20 1 : 1.0 10 0 0 10 (189,480, 848) 
Sulfasalazine 17 1: 7.5 14 0 0 3 
Ca rba mazepi ne 17 1:2.4 8 1 0 8 (1,49, 80, 114) 
Infliximab 12 4 2 0 6 (68, 186, 207, 277) 
Penicillamine 9 1: 8.0 6 1 0 2 (1460) 
Labetalol** 8 1: 6.0 6 0 0 2 (12) 
Overall (%) 415 1 : 2.5 295 (71.1) 23 (5.5) 4 (1.0) 92 (22.2) 
*Drugs for which at least 9 reports of drug-induced SLE were submitted 
t4 reports of unknown gender for hydralazine, and one report of unknown gender for minocycline and labetalol 
*The outcome was reported to be Unot known", i.e. information on the outcome of disease was not missing 
§Time from initiation of therapy to diagnosis of SLE 
IIWhen the total of reported values 4 or less, the list of values is given instead of the range 
~One report for minocycline had missing information on outcome of disease 
**One of the 9 reports for labetalol reported arthropathy rather than SLE and was excluded 
0/0 Missing 
82.7 
80.4 
100.0 
85.0 
100.0 
76.5 
66.7 
88.9 
87.5 
Information on outcome of disease was available for 414 of the 415 reports. The 
majority of cases recovered or was recovering at the time of submission of the Yellow 
Card. Four cases had a fatal outcome of disease, all of whom were exposed to 
hydralazine. 
Information on time between initiation of therapy and onset of SLE was missing on 
the maj~rity of reports (Table 4-15). In addition, information on duration of therapy 
was missing on 72% of reports (data not shown). However, we did have information 
on both duration and time to onset of SLE for 27 of the 173 hydralazine reports. 
Seventeen of the 27 cases continued to take hydralazine for 1 up to 522 days after 
onset of SLE symptoms. A further five cases stopped taking hydralazine on the day 
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that SLE symptoms started. The remaining 5 cases developed SLE symptoms after 
cessation of hydralazine use. Time since cessation ranged from 4 days to nearly 4 
years. Of these 27 cases, 23 recovered from SLE or were recovering at the time of 
submission of the Yellow Card report. Four cases had an unknown outcome of 
disease. 
Table 4-16 presents the number of reports for each drug by age category. Overall, 
27% of reports did not contain information on age of the case. The majority of cases 
taking minocycline (an antibiotic which is primarily prescribed for acne) were aged 15 
to 44. All reports concerning cases aged 75 and over were for exposure to 
hydralazine which is an anti-hypertensive. 
Table 4-16: Age distribution of Qatients for each drug susQected of inducing SLE 
Age group (years) 
Number of 
75+ Missing Suspected drug* re~orts 1-4 5-14 15-44 45-54 55-64 65-74 
Hydralazine 173 0 0 12 31 45 33 6 46 
Minocycline 138 0 3 119 4 1 0 0 11 
Practolol 21 0 0 0 1 4 0 0 16 
Procainamide 20 0 0 0 2 2 2 0 14 
Sulfasalazine 17 0 0 5 0 4 2 0 6 
Carbamazepine 17 1 1 7 3 0 0 0 5 
Infliximab 12 0 0 3 2 2 0 0 5 
Penicillamine 9 0 0 2 3 0 1 0 3 
Labetalolt 8 0 0 1 0 1 1 0 5 
Overall 415 1 4 149 . 46 59 39 6 111 
(%) (0.2) (1.0) (35.9) (11.1) (14.2) (9.4) (1.4) (26.7) 
*Drugs for which at least 9 reports of drug-induced SLE were submitted 
tOne of the 9 reports for labetalol reported arthropathy rather than SLE and was excluded 
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CHAPTER 5. RISK OF HYPOTHYROIDISM ASSOCIATED WITH 
PRESCRIPTION MEDICINE 
We investigated risk of drug related hypothyroidism associated with exposure to 
prescription drugs. The total GPRD data set of hypothyroid cases and matched 
controls was divided in two. Firstly, a small subset was analysed to generate 
potential signals of drug-induced drug related hypothyroidism. Subsequently, the 
remainder of the data were analysed to evaluate newly identified signals. Results of 
the analyses are described in this chapter. 
5.1. SIGNAL GENERATION USING THE "SMILE PLOT" METHOD 
Initial analyses demonstrated that exposure to one particular BNF subchapter was 
associated with an extreme increased risk of drug related hypothyroidism: seven 
cases and none of the controls were exposed to subchapter 350, which resulted in an 
odds ratio of 5.83E+09 (confidence limits approaching zero to infinity). BNF 
subchapter 350 included non-pharmacologic care products for the throat such as a 
tracheostomy protector, dressing and brush. The specific subchapter was in use in 
earlier versions of the BNF, but in the most recent version (March 2007) it is no 
IO[lger included. Further examination of the seven cases exp~sed to subchapter 350 
revealed that these cases had undergone surgical operations or had been diagnosed 
with malignant neoplasms in the anatomical proximity of the thyroid gland, (e.g. 
laryngectomy, malignant neoplasms of the larynx). The medical codes referring to 
these conditions were considered to be indicative of potentially iatrogenic thyroid 
disease and cases and controls with an occurrence of such codes in their records 
were excluded from the analyses (see Appendix IV under "Further medical codes for 
potentially iatrogenic drug related hypothyroidism"). 
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Figure 5-a: Smile plot of Odds Ratios (OR) and corresponding P-values for risk of drug related hypothyroidism associated 
with exposure to BNF subchapters one week or more before diagnosis date 
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Odds Ratios are adjusted for time in database (in yea rs) before diagnosis date, and consultation rate in the 
year before diagnosis. Method used to correct for multiple comparisons: Yekutieli; Uncorrected overall 
critica l P-value: 0.05 ; Number of P-values : 93; Corrected overall critica l P-value: 0.0056915; Number of 
rejected P-values: 2. A description of all value labels in the plot (i.e. BNF subchapters) can be found in 
Appendix V. 
After applying these refined case and control exclusion criteria, we re-ran the 
analyses. Overall results (i.e. data including both male and female subjects of all 
ages at diagnosis) are presented in Figure 5-a. 
Two BNF subchapters were clearly associated with drug related hypothyroidism, 
namely the subchapter containing thyroid and antithyroid drugs (subchapter 602), 
and the subchapter containing drugs for anaemias and some other blood disorders 
(subchapter 901) . 1221 cases and 763 controls were exposed to subchapter 602, 
resulting in an OR of 7.17 (95% CI: 6.42 - 8.01) . 710 cases and 1937 controls were 
exposed to subchapter 901, resulting in an OR of 1.25 (95% CI: 1.11 - 1.37). 
Results were consistent throughout the age- and sex stratified analyses (data not 
shown). 
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The drug thyroxine is a thyroid hormone which is categorised under BNF subchapter 
602 and prescribed for hypothyroid conditions such as drug related hypothyroidism. 
The drug is not prescribed for any o~her conditions and it is therefore unlikely that 
non-hypothyroid control subjects would receive a prescription for thyroid hormones. 
We suspected that the strong association we observed between drug related 
hypothyroidism and BNF subchapter 602 was not of causal nature, but that it was 
observed because a number of cases received one or more thyroid hormone 
prescriptions before drug related hypothyroidism was recorded in their medical 
records. This may occur for instance when a GP prescribes thyroxine as part of the 
diagnostic process, or when a prevalent case is misclassified as incident. 
To establish whether the identified signal for subchapter 602 was indeed due to 
thyroid hormone prescriptions issued before hypothyroidism diagnosis date, we 
examined the case and control therapy files in further detail. BNF subchapter 602 
consists of two different BNF codes, namely 06.02.01.00 (thyroid hormones) and 
06.02.02.00 (antithyroid drugs). No controls received prescriptions for thyroid 
hormones. Of the 5918 incident drug related hypothyroidism cases in the signal 
generation data set, 1514 cases (26%) received their first thyroid hormone 
prescription before diagnosis of drug related hypothyroidism. The median number of 
days this first prescription preceded the diagnosis date was 373.5 (inter-quartile 
range, 67 to 1285). 763 cases (4.3% of the 5918 incident cases) received their first 
thyroid hormone prescription more than one year before diagnosis. The median 
number of prescriptions issued before diagnosis date was 6 (inter-quartile range: 1 
to 23). 396 cases received only one prescrip~ion for thyroid hormone before their 
drug related hypothyroidism diagnosis was recorded. More than half of the cases 
(58%) received their first thyroid hormone prescription on the same date as the first 
code for drug related hypothyroidism was recorded in their medical records. All other 
cases (16%) received a thyroid hormone prescription after diagnosis of drug related 
hypothyroidism. For those receiving a prescription after diagnosis date, the median 
time between diagnosis and prescription was 21 days (inter-quartile range, 7 to 62). 
Overall, for 5091 cases (86%) their first thyroid hormone prescription was no more 
88 
than one year apart from the first recorded medical code for drug related 
hypothyroidism. These results confirmed our hypothesis that thyroid hormone 
prescription is a strong marker of d~~g related hypothyroidism and not a cause of 
disease. Therefore, instead of considering thyroid hormone prescription as a potential 
risk factor for disease, we incorporated the date of first prescription in the definition 
of the diagnosis date. We re-defined diagnosis date as the first occurrence of a code 
for drug related hypothyroidism in the medical records, or the first occurrence of a 
thyroid hormone prescription in the therapy records, whichever came earliest. 
Table 5-1: Demographic characteristics and univariable Odds Ratios (DRs) with 95% Confidence Intervals (CIs) for the 
association between selected variables and risk of drug related hypothyroidism in the signal generation data set 
Study subjects (%) 
Case Control 
(N=4,088) (N=16,945) 
Sext Female 3432 (84.4) 14300 (83.9) 
Mean age at diagnosis, yearst Age (SD) 55.1 (17.1) 54.5 (16.6) 
Range 
Time in database, years* 1 - 3 638 (15.6) 3791 (22.4) 
3 - 4.5 1141 (27.9) 5114 (30.2) 
4.5 - 7 1251 (30.6) 4597 (27.1) 
>7 1058 (25.9) 3443 (20.3) 
Consultation rate§ 0-1 346 (8.5) 4596 (27.1) 
2-3 704 (17.2) 3896 (23.0) 
4-6 1112 (27.2) 3660 (21.6) 
>6 1926 (47.1) 4793 (28.3) 
* Univariable OR for risk of drug related hypothyroidism 
t Variable used to match cases and controls, therefore univariable OR is not reported 
OR*(95% CI) 
1.00 (reference) 
1.70 (1.48 - 1.95) 
2.97 (2.56 - 3.45) 
4.16 (3.53 - 4.90) 
P < 0.001 
1.00 (reference) 
2.62 (2.28 - 3.02) 
4.59 (4.01 - 5.25) 
6.36 (5.58 - 7.24) 
P < 0.001 
* Time (in years) in database before diagnosis .' . . 
§ Number of consultations per year in the year preceding diagnosIs date (Index date for the controls) 
USing these 'new' diagnoses dates, we reassessed whether cases were incident or 
prevalent. Originally, we had identified a total of 17791 incident cases of drug related 
hypothyroidism. After applying the new definition of diagnosis date, there were a 
total of 18606 incident cases. The total of incident cases was divided in 2 subsets 
based on geographical location of the practice as described in Section 3.3.2.1. 
Results for signal generation using the smaller subset of data are described below. 
The final signal generation data subset contained 4088 incident cases with 
hypothyroid disease and 16945 matched controls. The demographic characteristics of 
cases and controls included in this final data set are summarised in Table 5-1. 
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Fi.9ure 5-b: Smile plot of Odds Ratios (OR) and corresponding P-values for risk of drug related hypothyroidism associ at d 
with exposure to BNF subchapters one week or more before 'new' diagnosis date e 
.00011---------f-------------L.0001051 
A401 
.001 A1501 
Q) 
::J 
ro A209 
> A703 c... A905 
"0 Q) 
.01 ....-u A50~409 ~ A606 
.... A901 
0 A~0fjl~201 u 
c 
:::> .05 
.1 
A308 
A605 
A904 
A109 Aae2 107 
A1300 
1 
.5 1 1.5 2 2.5 3 
Odds Ratio 
Diagnosis date defined as the earliest of: a first occurrence of a medical code for Hashimoto's Disease or 
a first occurrence of a prescription for thyroxine. Odds Ratios (OR) are adjusted for time in database (in 
years) before diagnosis date, and consultation rate in the year before diagnosis. Method used to correct 
for multiple comparisons : Yekutieli; Uncorrected overall critical P-value: 0.05; Number of P-values: 93 ; 
Corrected overa ll critical P-value : 0.00010511 ; Number of rejected P-values: O. 
Figure 5-b presents the association between drug related hypothyroidism and 
exposure to prescription drugs, grouped by BNF subchapter, one week or more 
before diagnosis date. Of the 93 BNF subchapters investigated, none of the P-values 
were smaller than the critical P-value corrected for multiple comparisons; i.e. no BNF 
subchapter was clearly associated with risk of drug related hypothyroidism. This 
pattern was consistent throughout the sex- and age-specific analyses (data not 
shown). In addition, none of the BNF subchapters were found to be strongly 
associated with risk of drug related hypothyroidism (i.e an Odds Ratio of greater than 
5 or less than 0.2, regardless of whether the P-value did or did not exceed the overall 
corrected critical p-value). Results were consistent across the sex- and age-stratified 
analyses '(data not shown). 
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Table 5-2: Odds Ratios (OR) and 95% Confidence Intervals (CI) for the association between selected BNF 
subchapters and risk of drug related hypothyroidism in the signal generation data subset 
Label 
OR> 1 
201 
209 
203 
901 
1201 
OR < 1 
1105 
606 
905 
503 
409 
.703 
1501 
401 
BNF subchapter (BNF chapter)* 
Positive inotropic drugs (Cardiovascular system) 
Antiplatelet drugs (Cardiovascular system) 
Anti-arrhytmic drugs (Cardiovascular system) 
Anaemias and some other blood disorders 
(Nutrition and blood) . 
Drugs acting on the ear (Ear, nose and 
oropharynx) 
Mydratics and cycloplegics (Eye) 
Drugs affecting bone metabolism (Endocrine 
system) 
Minerals (Nutrition and blood) 
Antiviral drugs (Infections) 
Drugs used in Parkinsonism (Central nervous 
system) 
(Obstetrics, gynaecology and urinary tract 
disorders) 
General anaesthesia (Anaesthesia) 
Hypnotics and Anxiolytics (Central nervous 
system) 
Case Control 
N=4,088 N=16,945 
105 
402 
334 
627 
1115 
10 
26 
63 
66 
154 
623 
646 
882 
263 
1068 
893 
1824 
3522 
57 
122 
260 
283 
616 
2471 
2278 
3111 
ORH (95% CI) 
1.31 (1.02 - 1.69) 
1.24 (1.08 - 1.42) 
1.18 (1.02 - 1.36) 
1.14 (1.02 - 1.27) 
1.10 (1.01 - 1.20) 
0.48 (0.24 - 0.99) 
0.57 (0.36 - 0.90) 
0.65 (0.49 - 0.88) 
0.70 (0.53 - 0.93) 
0.79 (0.65 - 0.95) 
0.82 (0.72 - 0.94) 
0.84 (0.76 - 0.93) 
0.85 (0.78 - 0.93) 
302 Corticosteroids (Respiratory system) 361 1267 0.86 (0.76 - 0.98) 
309 Cough preparations (Respiratory system) 570 1940 0.88 (0.79 - 0.99) 
501 Antibacterial products (Infections) 3310 12551 0.89 (0.81 - 0.98) 
*BNF subchapters were not associated with risk of drug related hypothyroidism after correction for multiple comparisons 
tOR for exposures up to one week before diagnosis date 
=IoOR adjusted for time in database (in years) before diagnosis, and number of consultations in the year before diagnosis 
Table 5-2 lists all BNF subchapters that were found to have a 95% confidence 
interval excluding the null in the signal generation exercise. In Figure 5-b, these 
subchapters are located in the upper half (in between the horizontal line for P=O.05 
and the line for the overall critical P-value corrected for multiple comparisons, 
P=1.05E-04). Although all confidence intervals for BNF subchapters listed in Table 5-
2 suggest statistical significance, these subchapters were not identified as signals in 
the signal generation exercise because of the threshold we defined to take account of 
multiple comparisons. Table 5-2 was compiled to facilitate the Signal evaluation 
exercise which will be described in section 5.2. 
5.2. SIGNAL EVALUATION 
When we originally designed our study to investigate associations between 
prescription drugs and risk of drug related hypothyroidism, we expected to observe 
signals of drug-induced hypothyroidism during the signal evaluation phase. We 
planned to subsequently evaluate these newly generated hypotheses in a larger 
subset of the data. Because no signals were observed during Signal generation, we 
selected alternative BNF subchapters to evaluate in the second phase of this study. 
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An obvious alternative choice of BNF subchapters would have been those that were 
strongly associated with risk of disease (i.e. an OR greater than 5 or less than 0.2) 
but for which no statistical signifi~ance was observed. The larger number of 
individuals included the signal evaluation data subset (described in section 3.3.2.1) 
ensured greater statistical power to evaluate associations, i.e. to have more certainty 
when accepting a null hypothesis ("there is no association between BNF subchapter X 
and risk of drug related hypothyroidism"). However, in Phase I of our study we also 
did not observe any such strong associations. We therefore decided to evaluate BNF 
subchapters that were associated with risk of drug related hypothyroidism based on 
their 95% confidence interval, but were not identified as a signal because the P-
values exceeded the threshold value we set to adjust for multiple comparisons. All· 
BNF subchapters meeting these requirements are listed in Table 5-2. Of these, we 
selected two to evaluate in further detail: subchapter 901 (drugs for anaemias and 
some other blood disorders) for which there was a suggestion of a mildly increased 
risk of drug related hypothyroidism (OR = 1.14, 95% CI 1.02 - 1.27), and 
subchapter 401 (hypnotics and anxiolytics) for which there was a suggestion of a 
decreased risk of drug related hypothyroidism (OR = 0.85, 95% CI 0.78 - 0.93) in 
the Signal generation phase of this study. 
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The signal evaluation data set contained 8,199 cases with a code for hypothyroidism 
and 33,950 matched controls (Table 5-3). 83.8% of the cases were female with a 
mean age at diagnosis of 55.1 years ~Id (sd = 17.4). Male cases were on average 5.9 
years older at diagnosis (mean age: 61.0, sd 17.3, p < 0.0001). The observation 
period from study entry to index date was on average 34 weeks longer for cases than 
controls (p < 0.001). Cases consulted their GP significantly more often in the year 
before diagnosis than the matched controls. 
Table 5-3: Demographic characteristics and univariable Odds Ratios (ORs) with 95% Confidence Intervals (CIs) for the 
association between selected variables and risk of drug related hypothyroidism in the signal evaluation data set 
Study subjects (%) 
Case Control 
~~ ________________ ~~~ ______ ~(~N~=~8,~1~99~)~ ____ (~N~=~3~3~,9~5~O~) ______ ~O~R~*~(9~5~~~o~C~I)~ __ .. 
5ext Female 6872 (83.8) 28569 (84.2) 
Age (SO) 56.1 (17.5) 55.6 (17.2) 
Mean age at diagnosis, yearst Range 2 - 99 2 - 101 
Time in database, years* 1 - 3 1,389 (16.9) 8,224 (24.2) 
3 - 4.5 2,478 (30.2) 10,853 (32.0) 
4.5 - 7 2,523 (30.8) 9,233 (27.2) 
>7 1,809 (22.1) 5,640 (16.6) 
Consultation rate§ 0-1 731 (8.9) 9,529 (28.1) 
2-3 1,467 (17.9) 7,335 (21.6) 
4-6 2,148 (26.2) 7,318 (21.6) 
>6 3,853 (47.0) 9,768 (28.8) 
* Univariable OR for risk of drug related hypothyroidism 
t Variable used to match cases and controls, therefore univariable OR is not reported 
'" Time (in years) in database before diagnosis 
1. 00 (reference) 
1.85 (1.68 - 2.04) 
3.19 (2.87 - 3.55) 
4.56 (4.04 - 5.14) 
P < 0.001 
1.00 (reference) 
2.79 (2.53 - 3.07) 
4.29 (3.91 - 4.71) 
6.17 (5.64 - 6.75) 
P < 0.001 
§ Number of consultations per year in the year preceding diagnosis date (index date for the controls) 
Using conditional logistic regression, we investigated risk of drug related 
hypothyroidism associated with exposure to two BNF subchapters one week or more 
before diagnosis. We investigated exposure to the individual BNF codes classified 
under the subchapter of interest. Crude and adjusted odds ratios and 95% 
confidence intervals are listed in Table 5-4. Of the exposures categorized under BNF 
subchapter 901, the code for oral iron had the highest exposure rate (approximately 
10% of controls) and approximately 2 percent of control subjects was exposed to 
"Drugs used in megaloblastic anaemia". Among exposures grouped under subchapter 
401, both the BNF codes for hypnotics and for anxiolytics had relatively high 
exposure rates of over 10% in the control subjects. As can be seen in the power 
curves in section 3-a, statistical power in this study was sufficient (i.e. > 80%) to 
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detect odds ratios of 1.5 or more for oral iron, "Drugs used in megaloblastic 
anaemias", hypnotics, and anxiolytics. 
Table 5-4: Odds Ratios (OR) and 95% Confidence Intervals (CI) for the risk of drug related hypothyroidism associated 
with selected BNF codes 
. Case Control 
BNF code Description N=8,199 N=33,950 
Drugs for anaemias and some other blood disorders (subchapter 901) 
09.01.01.01 Oral iron 1267 3533 
09.01.01.02 Parenteral iron 18 37 
09.01.02.00 Drugs used in megaloblastic 222 626 
anaemias 
09.01.03.00 Drugs used in hypoplastic, 
haemolytic and renal anaemias 
Hypnotics and anxiolytics (subchapter 401) 
40 
04.01.01.00 Hypnotics 1273 
04.01.02.00 Anxiolytics 1080 
04.01.03.00 Barbiturates 9 
*Reference category is the unexposed group for each drug 
111 
4249 
3594 
23 
Crude OR * 
(95% CI) 
1.67 (1.55 - 1.80) 
2.01 (1.14 - 3.55) 
1.49 (1.27 - 1.76) 
1.48 (1.02 - 2.15) 
1.25 (1.16 - 1.35) 
1.31 (1.22 - 1.41) 
1.55 (0.71 - 3.40) 
Adjusted OR*t 
(95% CI) 
1.26 (1.17 - 1.37) 
1.36 (0.75 - 2.46) 
1.14 (0.96 - 1.36) 
1.18 (0.80 - 1.74) 
0.94 (0.88 - 1.02) 
0.91 (0.84 - 0.98) 
1.18 (0.52 - 2.67) 
tORs adjusted for time (in years) in database before diagnosis, and number of consultations in the year preceding 
diagnosis or index date 
Crude od~s ratios suggested a mildly increased risk of drug related hypothyroidism 
associated with all BNF codes included in subchapters 901 and 401. However, after 
correction for confounding factors, the association was no longer apparent for BNF 
codes included in subchapter 901 ("Drugs for anaemias and some other blood 
disorders") apart from oral iron (code 09.01.01.01). As for BNF codes included in 
subchapter 401 (hypnotics and anxiolytics), the direction of the association shifted to 
a slightly decreased risk of drug related hypothyroidism after adjustment for 
confounding factors. Results of the sex-stratified analyses showed a similar pattern 
(data not shown). The sex-specific risk estimates were of similar magnitude with the 
exception of one BNF code: Among the male study subjects, 29 cases and 41 
controls were exposed to "Drugs used in megaloblastiC anaemias". After adjustment 
for confounding factors, we observed a more than twofold increased risk in men (OR 
= 2.47, 95% CI: 1.47 to 4.15). Results for women were similar to the overall results 
(data not shown). A test for interaction did not confirm that the effect of BNF 
subchapter 09.01.02.00 varied with gender (p=0.501). 
Risk of d'rug related hypothyroidism associated with number of prescriptions (as a 
proxy for cumulative dose) is summarised in Table 5-5. Although the odds ratios for 
categorised number of prescriptions for oral iron did not show a clear pattern of 
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increasing risk with increasing cumulative dose, we did observe a trend (adjusted OR 
per 10 prescriptions 1.11,95% CI 1.06 - 1.17, P for trend < 0.001). Sex-stratified 
analyses showed a similar pattern (data not shown). When we stratified our data by 
younger «55 years) and older (~55 years) age at diagnosis, a clear pattern was 
observed for younger cases. 
Table 5-5: Odds Ratios and 95% Confidence Intervals (eI) for the risk of drug related hypothyroidism associated with 
grouped number of prescriptions for selected BNF codes 
Number of Case Control 
BNF code prescriptions* N=8,199 N=33,950 
Crude OR 
(95% CI) 
Adjusted OR t 
(95% CI) 
Drugs for anaemias and some other blood disorders (subchapter 901) 
09.01.01.01 Unexposed 6932 30417 1.00 (Reference) 1. 00 (Reference) 
1.28 (1.14 - 1.43) 
1.34 (1.18 - 1.52) 
1.17 (1.02 -1.33) 
1 491 1430 1.60 (1.43 - 1.78) 
2 to 3 416 1077 1.83 (1.62 - 2.07) 
> 3 360 1026 1.61 (1.42 - 1.84) 
Ptrend < 0.001 Ptrend < 0.001 
09.01.01.02 Unexposed 8181 33913 1. 00 (Reference) 1. 00 (Reference) 
1 13 21 2.53 (1.25 - 5.10) 1.82 (0.87 - 3.80) 
2 to 4 1 10 0.45 (0.06 - 3.52) 0.33 (0.04 - 2.62) 
>4 4 6 2.66 (0.75 - 9.50) 1.46 (0.40 - 5.28) 
Ptrend = 0.054 Ptrend = 0.554 
09.01.02.00 Unexposed 7977 33324 1.00 (Reference) 1. 00 (Reference) 
1 92 290 1. 36 (1.06 - 1. 75) 1.06 (0.82 - 1.38) 
2 to 5 72 178 1.74 (1.31 - 2.31) 1.34 (0.99 - 1.80) 
>5 58 158 1.45 (1.07 - 1.98) 1.08 (0.78 - 1.49) 
Ptrend < 0.001 Ptrend = 0.135 
09.01.03.00 Unexposed 8159 33839 1. 00 (Reference) 1.00 (Reference) 
1 to 2 19 52 1.51 (0.89 - 2.58) 1.20 (0.69 - 2.10) 
3 to 15 16 32 2.08 (1.13 - 3.86) 1.69 (0.89 - 3.21) 
> 15 5 27 0.67 (0.23 - 1.94) 0.53 (0.18 - 1.55) 
Ptrend = 0.144 Ptrend = 0.718 
Hypnotics and anxiolytics (subchapter 401) 
04.01.01.00 
04.01.02.00 
04.01.03.00 
Unexposed 
1-2 Rx 
3-18 Rx 
>18 Rx 
Unexposed 
1-2 Rx 
3-10 Rx 
>10 Rx 
Unexposed 
1-12 Rx 
13-40 Rx 
>40 Rx 
6926 
538 
363 
372 
7119 
541 
291 
248 
8190 
5 
2 
2 
29701 
1742 
1291 
1216 
30356 
1,807 
925 
862 
33927 
7 
8 
8 
1.00 (Reference) 1. 00 (Reference) 
1.35 (1.22 - 1.50) 1.01 (0.91 - 1.12) 
1.22 (1.08 - 1.38) 0.88 (0.78 - 1.00) 
1.29 (1.14 - 1.46) 0.91 (0.80 - 1.04) 
Ptrend < 0.001 Ptrend = 0.047 
1.00 (Reference) 1. 00 (Reference) 
1.31 (1.18 - 1.45) 0.94 (0.84 - 1.04) 
1.38 (1.20 - 1.58) 0.91 (0.79 - 1.05) 
1. 24 (1.07 - 1.44) 0.85 (0.72 - 0.99) 
Ptrend < 0.001 Ptrend = 0.01 
1. 00 (Reference) 1. 00 (Reference) 
2.83 (0.88 - 9.16) 2.04 (0.60 - 6.96) 
1.04 (0.22 - 4.98) 0.85 (0.16 - 4.54) 
0.96 (0.20 - 4.60) 0.75 (0.16 - 3.56) 
Ptrend = 0.611 Ptrend = 0.954 
* Data categorised based on tertiles of number of prescriptions in the control group, with the unexposed as the reference 
category 
tORs adjusted for time (in years) in database before diagnosis, and number of consultations in the year preceding 
diagnosis or index date 
Results for risk of drug related hypothyroidism associated with exposure to oral iron 
in the younger cases can be found in Table 5-6. Risk in the grouped variable of 
number 'of prescriptions for oral iron increased with increasing number of 
prescriptions. In addition, the p for trend and the adjusted odds ratio per 10 
prescriptions were statistically significant in this younger case population. A test for 
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interaction confirmed effect modification by age at diagnosis: the interaction term for 
the highest exposure category (4 or more prescriptions) was statistically significant 
(p=0.005), with no interaction in the_ other two exposure categories (1 prescription: 
p for interaction = 0.649, 2 or 3 prescriptions: p for interaction = 0.970). This effect 
modification was largely confined to the female population, as there were only 14 
male cases and 15 male controls exposed to oral iron in the younger age group. 
Table 5-6: Crude and adjusted Odds Ratios (OR) and 95% Confidence intervals for the association between oral iron and 
exposure and risk of drug related hypothyroidism in cases diagnosed before age 55. 
Exposure to oral iron* 
Exposed before diagnosis date 
Number of prescriptions 
Unexposed 
1 
2-3 
4 or more 
Case Control Crude OR 
(N=4039) (N=17,179) (95% CI) 
822 2311 1.77 (1.60-1.94) 
3,217 
314 
295 
213 
14,868 
984 
793 
534 
1. 00 (Reference) 
1.56 (1.36-1.79) 
1.87 (1.61-2.16) 
2.05 (1.72-2.44) 
Ptrend < 0.001 
Adjusted ORt 
(95% CI) 
1.34 (1.21-1.48) 
1. 00 (Reference) 
1.27 (1.10 - 1.47 ) 
1.36 (1.17 - 1.59) 
1.41 (1.18 - 1.70) 
Ptrend < 0.001 
OR per 10 prescriptions 1.63 (1.49-1.78) 1.26 (1.16 - 1.39) 
*The unexposed category served as the reference group in all analyses 
tOdds ratios adjusted for time (in years) in database before diagnosis, and number of consultations in the year preceding 
diagnosis or index date 
There was a suggestion of a decreased risk of drug related hypothyroidism with an 
increasing number of prescriptions for anxiolytics (BNF code 04.01.02.00). This trend 
remained after adjustment for confounding factors (P for trend = 0.01): risk in the 
highest exposure category (more than 10 prescriptions) was significantly lower 
compared to unexposed individuals (OR = 0.85, 95% CI 0.7:( - 0.99). However, the 
adjusted OR per 10 prescriptions did not confirm this association (OR = 0.99, 95% CI 
0.97 - 1.00). Number of prescriptions for any of the other BNF codes classified under 
subchapter 401 (hypnotics and anxiolytics) was not associated with risk of drug 
related hypothyroidism. 
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CHAPTER 6. DISCUSSION 
6.1. RISK OF SLE ASSOCIATED WITH PRESCRIPTION DRUGS 
The risk of Systemic Lupus Erythematosus associated with exposure to prescription 
drugs was investigated using two data sources and a variety of analysis methods. 
Firstly, we evaluated existing hypotheses (identified from the literature) in GPRD 
data, for which we used a case-control and a case-only approach. Secondly, we 
performed signal generation using the Smile Plot method which had not previously 
been utilised for the purpose of drug safety. We also described findings on Yellow 
Card spontaneous reports of suspected cases of drug-induced lUpus. In this chapter, 
we will present and discuss the key findings of these studies. 
6.1.1. Matched Case-Control Study 
6.1.1.1. Main Findings 
In our large matched case-control study investigating the association between lupus 
and exposure to prescription drugs, we found statistically significant risks for 
exposure to hydralazine, minocycline and carbamazepine. For the latter two a 
cumulative dose - response relationship was observed. Gender influenced the 
association between use of carbamazepine and risk of lUpus. 
6.1.1.2. Discussion 
This matched case - control study was the first large observational study to 
investigate risk of SLE associated with prescription medicines thought to induce the 
disease. We showed a sex-specific effect of carbamazepine which has not previously 
been reported. Comparison studies using a different data source are not available to 
this date. However, associations between drugs and risk of SLE that have been 
hypothesised- in case reports were confirmed in our study. This led us to believe the 
GPRD is a useful data source to study drug-induced SLE. However when both the 
disease and the exposures (i.e. drug prescriptions) of interest are uncommon, study 
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power to detect moderately increased risks or to perform relevant subgroup analyses 
is limited, even in this very large data set. 
In clinical practice, the diagnosis of idiopathic lupus is based on criteria formulated by 
the ACR[19]. It is thought that drug-induced lupus, which develops in previously 
asymptomatic individuals and usually disappears upon discontinuation of the drug, is 
different from idiopathic SLE, which is a life-long disease[23]. Criteria for diagnosis of 
drug-induced lupus are less strict than those for diagnosis of idiopathic SLE[25]. In 
our study the diagnosis of SLE was not validated for each case individually and 
laboratory test results for ANA or anti-DNA antibody positivity were not available for 
the majority of cases. However this was not considered an important limitation of our 
study, because of the less strict diagnostic criteria for drug-induced lUpus. In 
addition, a high proportion of our case population received prescriptions for drugs 
used for the treatment of lupus (79% non-steroidal anti-inflammatory drugs, 10% 
corticosteroids, 48% anti-malarials and/or immunosuppressives[17]) and incidence 
rates based on our data are consistent with other published estimates[17]. 
Risk of SLE associated with sulfasalazine exposure and penicillamine exposure could 
not be studied in our study population because of the selection criteria for cases and 
controls. Study subjects were not diagnosed with other autoimmune diseases and 
would therefore by definition not receive drugs which are prescribed specifically for 
autoimmune conditions, such as sulfasalazine and penicillamine. We did. note that 5 
cases and 3 controls received prescriptions for sulfasalazine, which may be the result 
of misclassification of an autoimmune disease as non-autoimmune. 
Although causality can not be determined on the basis of our findings, the magnitude 
of the risks observed for hydralazine and minocycline as well as the cumulative dose-
response relationship observed for minocycline and carbamazepine are in support of 
a causal relationship. We ensured that drug exposures took place before onset of SLE 
by excluding prevalent cases. Symptoms are reported to disappear after cessation of 
drug use in a number of drug-induced lupus patients[61] and occasionally re-
challenge with the drug results in reappearance of symptoms[25, 62]. Because the 
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GPRD does not contain codes for recovery from disease we were not able to 
investigate causality in this manner. However, we did note that use of hydralazine 
was discontinued upon diagnosis in th~ee of the four cases using the drug. 
We included consultation behaviour as a confounding factor in our models, even 
though one could argue it is on the causal pathway between drug exposure and 
induction of SLE. We believe it was correct to adjust for consultation behaviour as 
after adjustment, the increased risk of lupus disappeared for the 'control' drugs, but 
not for the drugs thought to induce SLE. 
A GPRD-based study of minocycline-induced lupus in a population of acne 
patients[63] reported an 8.S-fold increased risk of lupus for use of minocycline at the 
time of SLE diagnosis. Excluding past users of minocycline from our study results in a 
similar unadjusted 8-fold increased risk. Adjustment for confounders reduced this 
risk to 4, highlighting the importance of including consultation behaviour and length 
of therapy history in analyses of drug-induced disease utilising the GPRD. 
Numerous previous case reports have suggested that lupus can be induced by a 
range of prescription medications. To our knowledge no sufficiently large 
observational studies assessing such associations have been published. We observed 
a substantially increased risk of lupus associated with exposure to hydralazine and 
minocycline and moderately increased risk for carbamazepine, quinidine, methyldopa 
and captopril. This study provides evidence that the increased risks observed are 
likely to be causal given the lack of an increased risk observed with deliberately 
selected 'control' drugs. For several other drugs previously suggested to increase the 
risk of lupus, we lacked statistical power to reliably confirm or exclude an effect even 
utilising a database that includes over 20 million person years of observation. 
6.1.2. Self-Controlled Case Series 
In the previous section of this thesis we discussed the association between risk of 
SLE and exposure to prescription drugs, based on results from a matched case-
control study. In the current section, we will discuss the same hypothesized 
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associations between prescription drugs and risk of SLE. This discussion will be based 
on findings resulting from a different statistical analysis method, namely a self-
controlled case series. In both the case-control and case series methods we utilised 
incident cases of SLE who were identified from the GPRD. In the previously discussed 
case-control study the reference group consisted of individually matched control 
subjects. Some factors, such as health-seeking behaviour, were likely to have varied 
between cases and their matched controls. If these factors were associated with both 
risk of SLE and the chance of receiving a prescription for a drug of interest, bias may 
have affected SLE risk estimates. In addition, the matched controls in this case-
control study were defined as those not having an autoimmune disease, and 
therefore by definition did not receive medication specific for autoimmune conditions 
other than SLE (some of which have been implicated in risk of SLE). In contrast, the 
self-control'led case series utilised within-person comparisons to obtain risk estimates 
of drug-induced SLE. Factors such as health-seeking behaviour or coexistence of 
other autoimmune conditions were assumed to be constant within each person 
during the observation time and did therefore not bias the results. In theory, factors 
that change over time within one individual, such as disease severity and symptoms, 
may still confound the associations investigated in a self-controlled case series. 
6.1.2.1. Main Findings 
In this case series investigating relative incidence of SLE associated with exposure to 
prescription drugs we found a suggestion of a positive association for hydralazine, 
minocycline, carbamazepine, penicillamine and sulfasalazine. The effects of these 
drugs did not appear to be immediate. In the washout period of 30 to 60 days after 
receiving a prescription for minocycline and sulfasalazine, the relative incidence of 
SLE was more than double compared to baseline (unexposed) periods. For 
hydralazine, the relative incidence rate during the washout period was more than 
four-fold compared to baseline. 
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6.1.2.2. Discussion 
No large observational studies have previously quantified the time between exposure 
to drugs of interest and the development of clinically apparent SLE. In our large data 
set of incident SLE cases, the number of subjects exposed to the drugs of interest 
was limited, resulting in limited statistical power. Although incidence rates in pre-
specified time intervals after receiving a prescription could not be estimated with 
great precision, we did observe an increased risk for a number of drugs implicated 
with risk of SLE. 
The main strength of this study is that we estimated relative incidence rates of SLE 
by making within-person comparisons. Unlike studies that make inter-person 
comparisons such as our previously described matched case-control study of SLE and 
prescription drugs (described in further detail in sections 4.1 and 6.1.1), risk 
estimates of this case series were not affected by confounders such as comorbid 
autoimmune disease or health-seeking behaviour[59]. However, our results may still 
have been affected by factors that change over time within one individual, such as 
SLE symptoms and severity. Because the majority of drugs of interest were indicated 
for conditions that are independent of SLE symptoms and severity (for instance: 
hyralazine is indicated for hypertension, minocycline is indicated for acne), we 
believe the extent of confounding in our anlayses is limited. Compared to our 
. .-
matched case-control study, risk estimates of the case series were lower, suggesting 
that residual confounding may have resulted in an overestimation of risk in the case-
control study. 
A number of limitations of both the study design and our data have to be taken into 
account when interpreting the results of the self-controlled case series of SLE. In 
terms of limitations of the data, we have already mentioned the limited number of 
cases exposed to the drugs of interest. This limitation can not be overcome at the 
current time, because the database used in our study, the GPRD, is the largest 
longitudinal patient-level database available for pharmacoepidemiology research[12]. 
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In the future, when more data will have been recorded in the GPRD, we will be able 
to expand our study including additional exposed cases. 
One disadvantage of our data was the "difficulty of assessing the exact date on which 
SLE became clinically apparent. In our self-controlled case series we used the first 
occurrence of a medical code for SLE as the diagnosis date. In reality however, a 
patient may have had symptoms for a number of weeks (or even months) before this 
patient consulted with their GP, and/or before a GP ruled out all other potential 
disease diagnoses. This may have resulted in a substantial delay between onset of 
symptoms and a computerised medical record of an SLE diagnosis. While 
computerised information for prescriptions and prescription dates is known to be 
accurate[52] [40], this accuracy may not always be the case for the SLE diagnosis 
date. If the diagnosis of SLE is recorded at a later date than the actual onset of the 
disease, but prescription dates are correct, then the relative incidence rate of SLE 
may have appeared to be higher in a period later than our pre-specified 'high risk' 
period. This may explain why, for all drugs of interest, the relative incidence rate 
during the 'washout' period (i.e. 31 to 90 days after receiving a prescription) was 
higher compared to the relative incidence rate in the 'high risk' period (the 30 day 
period after issuing a prescription) as well as the baseline period. This pattern was 
seen for drugs implicated in risk of SLE, as well as the 'control drugs' which are 
thought not to induce SLE. These results had not been anticipated at the analysis 
stage of our study and we therefore did not include further 'high risk' or 'washout' 
periods in our design. 
Some limitations with regard to the statistical aOnalysis method should be noted. The 
self-controlled case series method was originally designed to study adverse events 
following vaccination[64]. A major underlying assumption of the method is that the 
probability of: exposure (i.e. receiving a prescription for a drug of interest) is 
independent of the outcome (i.e. a diagnosis of lupus)[59]. In our study of drug-
induced SLE several scenarios are plausible in which this independence may not be 
present. o· For instance, the increased risk of SLE associated with exposure to 
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minocycline has been reported in a number of international peer-reviewed papers 
and autoimmune disease textbooks[22, 23, 25, 61-63, 65-68]. If a GP is aware of 
these publications and observes a pa~ient on minocycline to develop symptoms of 
SLE, the GP may switch the patient over to an alternative anti-acne treatment, 
thereby influencing this patient's chance of receiving further minocycline 
prescriptions. The potential effect on risk estimates is dependent on the timing of a 
GP's decision to switch a patient over. For instance, if the patient stops receiving 
prescriptions for minocycline as soon as their GP suspects a diagnosis of SLE (but the 
actual diagnosis has not yet been recorded in the database), the patient would no 
longer have a chance to have their SLE diagnosis recorded while they are receiving 
minocycline and we may find an artificially low incidence rate of SLE during exposed " 
periods. 
An adapted method of the self-controlled case series method is currently being 
developed to investigate 'censoring events', i.e. events for which the occurrence (e.g. 
diagnosis of SLE) influences the chance of being subsequently exposed to a risk 
factor of interest (e.g. drug prescription). This adapted method takes account of 
missing exposure data and has been shown to work in simple situations where the 
number of cases is relatively large and the number of repeat exposures is limited 
(Farrington et ai, in press). We performed some preliminary analyses using this 
adapted method in close collaboration with those who developed it. With our sparse 
yet complex data due to the large number of repeat prescriptions, the method is not 
yet operational and needs further development. When the method is finalised it 
would be interesting to apply to our data and compare risk estimates to those 
obtained using the original self-controlled case series method. If results are markedly 
different, this would mean a GP indeed changes his or her prescribing behaviour after 
occurrence of an SLE diagnosis and we would have to treat prescriptions issued after 
diagnosis date as censored (Farrington et ai, in press). We are looking forward to 
collaborating closely with Dr. Whitaker and Prof. Farrington to further develop this 
method in the near future. 
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In the self-controlled case series analyses reported here we assumed that risk of SLE 
returned to baseline at the end of each washout period. This assumption may not 
have been correct: it has been reporte9 that patients on hydralazine are at increased 
risk of developing SLE when exposed to a cumulative dose of 100g or more[65]. An 
adapted version of the self-controlled case series method is available to take account 
of cumulative exposure levels[59]. Instead of assuming that risk returns to baseline 
at the end of each washout period and before the next prescription, this adapted 
method calculates relative incidence rates separately for each risk, washout, and 'in 
between' period (which we previously called baseline period). The time prior to the 
first prescription serves as baseline (unexposed) time. When we applied this adapted 
method to our data, the model was not able to calculate risk estimates, most likely," 
due to the low number of exposed subjects who each had large numbers of repeat 
prescriptions. We were unable to investigate the effect of cumulative exposures on 
the risk of SLE using the self-controlled case series approach. 
In this case-only approach we were able to investigate risk of SLE associated with 
exposure to drugs prescribed for comorbid autoimmune conditions. Associations have 
been hypothesized in the literature for sulfasalazine and penicillamine, which are 
both used for the treatment of Rheumatoid Arthritis[65] [23]. Quantitative risk 
measures and/or estimates of time to onset of SLE after exposure to these drugs 
have not been previously reported. Our results suggest an approximately twofold 
increased risk of SLE associated with penicillamine and sulfasalazine exposure. 
In the self-controlled case series, individuals without the outcome of interest and 
without the exposure of interest do not contribute information to the risk estimate. In 
addition, incident cases who are on drugs taken daily for many years continuously 
also do not contribute any information to the risk estimate, because these cases will 
not have any baseline (unexposed) comparison time. Similarly, when repeat 
prescriptions are a limited number of days apart, but long enough for a risk and 
washout period to pass by, the amount of baseline time will be limited. In this 
situation; the cases do contribute information to the risk estimates. However, 
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analyses are likely to be less robust as compared to analyses in which substantial 
amounts of unexposed time was available to calculate baseline incidence. 
The majority of drugs implicated in "the risk of SLE are used to treat lifelong 
conditions (or prevent exacerbations) and users of these drugs are likely to be 
exposed during the majority of observation time. For instance, carbamazepine is an 
anti-epileptic drug and it prevents the occurrence of epileptic seizures by maintaining 
a certain dose at all times[69]. Other drugs implicated in risk of SLE that may be 
used on a continuous basis are hydralazine, methyldopa, captopril and acebutolol (all 
are used in the treatment of hypertension), minocycline (when used to treat acne), 
chlorpromazine (when used in the long-term treatment of schizophrenia), 
propylthiouracil (when used in long-term treatment of hyperthyroidism), and 
penicillamine and sulfasalazine (used to suppress the rheumatic disease process). In 
addition, one of the 'control drugs', salbutamol, is prescribed for maintenance of 
asthma. For these drugs, the self-controlled case series method may not be the 
most appropriate statistical analysis method to asses associations with risk of SLE 
because of the limited amount of unexposed baseline time. 
Although both the case-control study and the self-controlled case series utilised the 
same set of incident SLE cases from the GPRD, risk estimates of these two studies 
are not directly comparable. First of all, the measures obtained in the two analyses 
are different, namely an odds ratio for the case control study and an incidence rate 
ratio for the case series. In order to calculate the odds ratio, we considered 
exposures taking place before diagnosis of SLE. For the incidence rate ratio on the 
other hand, we considered prescriptions received at any point during a person's 
observation time in the GPRD, including time after diagnosis of SLE. In addition, the 
sample of cases contributing to the risk estimates was different in the two study 
designs. In the matched case-control study only discordant case-control pairs 
contributed· information, whereas in the case series only exposed cases were 
included. Despite these differences, it is helpful to compare results of both studies of 
SLE and ·prescription drugs in terms of direction of risk estimates, whether the 
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estimates are statistically significant, and size of the risk estimates (Le. whether 
exposures are mildly or strongly associated with risk of disease). These comparisons 
can provide useful information when int.erpreting results of both the case-control and 
case-series analyses. For instance, we suspected that the results of the matched 
case-control study were affected by bias. In the self-controlled case series, where 
these biases did not playa role, we observed different (lower) risk estimates. This 
finding made us believe that the risk observed in the case-control study may have 
been overestimated due to residual (unmeasured) confounding that could not be 
accounted for in the logistic regression models. We will further discuss potential 
sources of residual confounding in section 6.1.3.2. 
When comparing sex-specific risk estimates for carbamazepine from the case-control 
and case series analyses, results are inconclusive. In the case-control analyses, we 
observed an interaction with sex whereby women appeared to have an increased risk 
of SLE after carbamazepine exposure. No clear association was seen in men. In the 
self-controlled case series however the observed effect was in the opposite direction; 
no clear effect was seen in women whereas the relative incidence rate in men was 
strongly increased in both the high risk and washout periods. However, results of 
both analysis methods were based on a limited number of cases (the number of 
exposed male subjects in the case-control study: 3 cases and 10 controls, in the case 
series: 7 cases) and our findings may have been due to chance. Further studies 
investigating sex-specific risk of SLE associated with carbamazepine exposure will 
have to be conducted to clarify our conflicting results. 
Although the risk estimates obtained from this case series have to be interpreted 
with caution due to a limited number of exposed study subjects, the results 
contribute valuable information to the current body of knowledge on drug-induced 
SLE. Hypotheses of associations between drugs and risk of SLE that were identified 
from the literature were previously confirmed using a case-control approach. With 
our case series analysis we were able to furt:her confirm some of these pre-existing 
hypotheses. 
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6.1.3. Smile Plots and Systemic Lupus Erythematosus 
In sections 6.1.1 and 6.1.2 of this thesis, we evaluated pre-existing hypotheses of 
drugs that may induce SLE which were tdentified from the literature. We were able to 
confirm some of these hypotheses. In this section, we discuss results from a signal 
generation exercise in which we also investigated the association between 
prescription medicine and risk of SLE. The purpose of this exercise was twofold, 
namely: to investigate whether the smile plot method was capable of detecting 
known associations, and to investigate whether any other drugs, in addition to those 
hypothesised in the literature, were associated with risk of SLE. 
6.1.3.1. Main Findings 
We found a strong association between exposure to sunscreens and camouflagers 
and risk of SLE. Other BNF subchapters that were identified as potential signals were 
not as strongly associated with risk of disease. Among the identified BNF subchapters 
were those for corticosteroids (for topical local use, as well as systemic 
corticosteroids), drugs used in musculoskeletal diseases, and antiprotozoal drugs. 
When excluding recent exposures taking place in the year before diagnosis of SLE, 
some of these associations were still apparent, especially the association between 
sunscreens and camouflagers and risk of SLE. However, the risk estimates were 
lower compared to those including recent exposures. 
The risk estimate for the BNF subchapter which includes minocycline, a drug known 
to be associated with risk of SLE, only provided weak evidence for an association. 
When investigating risk associated with full BNF .code (i.e. a finer sub-categorisation 
of drugs), we were also not able to identify many of the known associations between 
drugs and risk of lUpus. 
6.1.3.2. Discussion 
The majority of signals we identified in this exercise involved drugs that are 
commonly prescribed to treat (early) symptoms of SLE. These 'signals' are most 
likely markers of disease rather than causative. factors in the aetiology of SLE. 
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Although we believe these BNF subchapters are not associated with risk of disease in 
a causal manner, the drugs are in some way connected with SLE and cannot be 
considered false-positive signals. Drug~ in three of the BNF subchapters that were 
identified as signals, subchapters 103, "1306 and 208, could not be directly linked to 
early symptoms of SLE and warranted further investigation. 
Although stomach ulcers are not a symptom of SLE, we did observe an association 
between the BNF subchapter for ulcer-healing drugs (subchapter 103) and SLE. Two 
of the subchapters encoding aspirin and non-steroidal anti-inflammatory drugs 
(NSAIDS, subchapters 407 and 1001) were also identified as a 'signal'/marker of 
SLE. Known and relatively common side effects of aspirin and NSAIDS include gastro-
intestinal side-effects, e.g. stomach ulcers. So, due to use of aspirin and NSAIDS, 
cases were at higher risk of developing gastro-intestinal conditions than their 
matched controls. These gastro-intestinal side effects were likely to have been 
treated with for instance ulcer-healing drugs. It is therefore not surprising we 
identified subchapter 103 as a 'signal'/marker of SLE. 
Two BNF subchapters, those for anticoagulants and protamine (208), and drugs 
treating acne and rosacea (1306), were observed to be associated with SLE. Unlike 
the previously discussed associations, the drugs in these subchapters could not be 
directly or indirectly linked to symptoms of SLE. With subchapter 208 we may have 
identified a previously unknown association. However, our observation may be a 
chance finding because only a limited number of cases and controls were exposed to 
the subchapter of interest. When the signal generation exercise was repeated using 
refined grouping of drugs, we no longer observed a signal for any of the BNF codes 
categorised under subchapter 208. There are two possible explanations for this 
negative finding; a true association may not exist, or perhaps the sample size was 
too limited (due to refined grouping) to detect an association. Further studies are 
needed to darify our findings. 
The subch.apter for drugs treating acne and rosacea (subchapter 1306) includes the 
drug minocycline, a drug that is known to be assoCiated with risk of SLE[62, 63]. We 
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believe our identification of subchapter 1306 as a signal most likely represents this 
association between minocycline and SLE. When we excluded recent exposures to 
subchapter 1306 from the analyses, the,association was also identified as a signal. In 
addition, when we repeated our signal 'generation exercise using refined grouping of 
drugs (grouping by full BNF codes instead of BNF subchapters), two of the three 
codes that include minocycline were identified as a signal. In our previously described 
case-control and self-controlled case series we had already identified this increased 
risk of SLE associated with minocycline use. The risk estimates in both of the 
previous analyses were higher compared to the estimates reported in the signal 
.' 
generation exercise. Due to the grouping of drugs by subchapter or full BNF code, we 
included drugs other than minocycline that were not associated with risk of SLE and 
may have caused a dilution of the effect of minocycline. However, further studies 
investigating -risk of SLE associated with each of the drugs comprised in subchapter 
1306 are needed, to ensure the identified signals do not represent a class effect. 
An important limitation of our signal generation analysis was the grouping of 
exposures based on BNF subchapter. Drugs with an opposite effect in the human 
body may be incorporated in the same subchapter. For example, the BNF subchapter 
for drugs used in diabetes (subchapter 601) contains both insulin (required for 
glucose absorption) and glucagon (which counteracts the effects of hypoglycaemia). 
An additional limitation of grouping by BNF subchapter is that it combines drugs with 
the same effect but a different mechanism of action into one exposure category. An 
example is the BNF subchapter for "Antisecretory drugs and mucosal protectants" . 
(subchapter 103). This subchapter includes proton pump inhibitors, which are used in 
the treatment of gastric and duodenal ulcers. The drug inhibits gastric acid secretion 
by blocking an enzyme system in a certain type of gastric cells. Another type of 
drugs, also used for the treatment of gastric and duodenal ulcers and categorised 
under subc~apter 103, is the H2-receptor antagonist. This drugs reduces gastric acid 
output by blocking an entirely different pathway in the cell; the histamine H2-
receptor. Other examples are the subchapter for Antiepileptics (408, including 
carbamazepine and an additional wide range of d(fferent drugs with often unknown 
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mechanism of action) and that for hypertension and heart failure (205, including 
hydralazine but also beta-blockers, calcium channel blockers, Angiotensin-converting 
enzyme (ACE) inhibitors). Combining .these different entities into one exposure 
category may result in 'dilution' of th-e effect which may explain why we did not 
identify the subchapters for hydralazine and carbamazepine as a signal. 
The strong association seen for sunscreens and camouflagers, which was also 
apparent when we excluded recent exposures from the analyses, indicated that a 
number of cases sought medical treatment for symptoms of SLE more than one year 
before the diagnosis. This raises questions about the accuracy of the SLE diagnosis 
date as recorded in the database. We also found an association (albeit less 
pronounced) for anti-malaria Is, which are drugs that may be used in the treatment of 
SLE. Again, the association was apparent when excluding recent exposures from the 
analyses. In our signal generation analyses we used the first occurrence of a medical 
code for SLE as the diagnosis date, but it may be more appropriate to redefine this 
diagnosis date to the date of a first prescription for disease specific treatment. In 
practice this may not always be feasible, as many of the treatments for SLE are non-
specific, i.e. also used for the treatment of a number of other conditions. 
All smile plots depicting the risk of SLE associated with various groups of drugs were 
based on risk estimates and p-values that were adjusted for confounding factors. The 
majority of point estimates suggested an increased risk of SLE, instead of being 
randomly dispersed around the null. It is highly unlikely that the majority of BNF . 
subchapters are truly associated with risk of SLE. A more plausible explanation is 
that residual confounding affected our risk estimates. In the previously discussed 
self-controlled case series of SLE and exposure to specific drugs, we already 
suggested there may be an effect of residual confounding in the case-control 
analysis. The findings of this signal generation exercise provide further evidence of 
an influence of unmeasured bias. 
A potential source of the residual confounding in this study is confounding by 
indication. It is possible that a GP preferentially prescribed a certain drug to 
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individuals who were predisposed to develop SLE, whereas others not likely to 
develop SLE may have received an alternative drug[70]. Although this source of 
confounding is an important problem in. many pharmacoepidemiological studies, it is 
unlikely that it influenced the majority of our risk estimates in the same direction, i.e. 
an overestimate of the risk. Another source of residual confounding may be related 
to a non-random difference between the case and control groups in terms of the 
proportion of individuals with contraindications for a specific drug. If the proportion of 
controls with contraindications for a drug is larger than this proportion among cases, 
we would find a spurious association between use of this drug and risk of SLE 
(because the odds of exposure would be lower in controls compared to cases). Again, 
it is unlikely that this source of bias affected all of the exposure categories in a 
similar way. 
A more plausible explanation for the apparent residual confounding in our study is 
related to a differential disparity between cases and controls in terms of health-
seeking behaviour. Behavioural factors are difficult to measure in computerised 
medical records. However, in the study of drugs and risk of SLE, these behavioural 
factors may playa large role: patients who are more prone to visit their GP are more 
likely to receive prescriptions to any drug and they are also more likely to be 
diagnosed with SLE. In our analyses, we adjusted for the effect of health-seeking 
behaviour by using the number of visits in the year before SLE diagnosis as a proxy. 
The time period of one year before diagnosis to measure this number of visits may 
not have been ideal. As illustrated by our analysis excluding drug exposures in the 
year before SLE index date, several cases had symptoms of SLE (such as photo-
sensitivity) long before the index date and occurrence of these symptoms may have 
affected a case's health-seeking behaviour. It would have therefore been more 
appropriate to measure health-seeking behaviour in a period before onset of SLE 
symptoms, for instance in the 2 years to 1 year before index date. However, many of 
the matched controls did not have two years or more of recorded data before the 
index date. Adjusting our analyses for health-seeking behaviour using this alternative 
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proxy variable would have resulted in the loss of a substantial number of controls 
from the analysis, and thereby a substantial loss of statistical power. 
Although there is no gold standard available against which we can check our results 
of the smile plot analysis, we can comment on sensitivity and specificity by referring 
to evidence from the literature and from our previously reported case-control and 
case series analyses (sections 4.1, 4.2, 6.1.1 and 6.1.2). In these previous analyses, 
we confirmed a number of associations that had also been reported in the literature. 
Of the confirmed associations, only one was identified as a signal using the 'Smile 
Plot' method, namely the subchapter for minocycline. Other BNF subchapters 
comprising drugs that are known to be associated with risk of SLE were not identified 
as signals in this smile plot analysis, i.e. a number of false negative associations 
were among our results. 
In summary, when we utilised the 'Smile Plot' method to generate signals of drug-
induced lupus we observed a number of highly specific associations between drugs 
and risk of SLE, most of which were not causal. In order to interpret our results we 
needed intricate knowledge of the disease, as well as an understanding of the 
indications and side-effects of drugs that were identified as signals. After ruling out 
the majority of potential signals because they were in fact markers of disease, there 
were' only two signals left that needed further scrutiny. One 'signal, for the BNF 
subchapter containing minocycline, has been previously reported in the literature and 
we therefore believe this signal is true-positive. The other signal may have been 
erroneously identified. Among the 87 exposures investigated, the number of false-
positive signals identified with this 'Smile Plot' analysis is not more than one, from 
which we can derive that the specificity of this method is high. On the other hand, a 
number of known associations were not identified in the smile plots. From these 
false-negative findings we conclude that the sensitivity of the method is currently not 
optimal. Be'tter hierarchical coding systems for drugs are needed to allow for 
appropriate grouping of drugs which will improve sensitivity of the method. 
112 
6.1.4. Signals of Drug-Induced SLE in the Yellow Card Database 
So far, we have discussed risk of SLE associated with prescription drugs based on 
data from the General Practice Research Database. In this section we discuss signals 
of drug-induced SLE which were observed in the Yellow Card database. Although 
both the GPRD and the Yellow Card database comprise data from the United 
Kingdom, the nature of the data collection process is entirely different. In the GPRD, 
data are collected on a daily basis as part of routine clinical practice. The Yellow Card 
database on the other hand contains spontaneous reports of suspected adverse drug 
reactions which are voluntarily sent in by health care professionals (and, more 
recently, by patients as well). 
6.1.4.1. Main Findings 
Numerous reports of drug-induced lupus have been submitted as part of the Yellow 
Card scheme. The majority of these reports listed hydralazine or minocycline as the 
suspected drug. The majority of cases (71%) were reported to recover when the 
drug suspected of causing lupus was withdrawn. Four individuals who developed SLE 
after being exposed to hydralazine were reported to have died from the disease. 
Missing information was a common factor among all Yellow Card reports: time to 
onset of SLE was missing on the vast majority of reports (83%), as well as 
information on duration of therapy (72%). 
6.1.4.2. Discussion 
The Yellow Card database does not contain information on the total number of 
persons exposed to drugs of interest at anyone time. In addition, spontaneous 
reporting databases such as the Yellow Card database are subject to substantial 
under-reporting[71]. Given this lack of denominator data and inaccurate numerator 
" data, it is not possible to calculate a quantitative risk measure of SLE associated with 
exposure to' the suspected drugs. It is also not informative to directly compare the 
number of reports for drug-induced lupus across the different suspected drugs, again 
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because denominator data is lacking, and the prevalence of use for each of the drugs 
is likely to be different. 
. 
Some methods have been employed to identify signals of adverse drug reactions in 
spontaneous reporting databases. Examples are the proportional reporting ratio 
(PRR) used by the MHRA to investigate data in the Yellow Card database[72], the 
Empirical Bayesian Geometric Mean (EBGM)[73] employed by the FDA to investigate 
the MedWatch data, as well as application of data mining algorithms to the 
spontaneous reporting data[74]. Despite the sometimes sophisticated statistical 
methodology, these methods are generally applied to poor quality data and can 
therefore not assess causality but merely signals of adverse drug reactions[8]. The 
above mentioned methods are beyond the scope of this thesis. Our analysis of the 
Yellow Card data was purely descriptive and provided a source of comparison for 
Signals identified from the literature and from the GPRD. 
Signals of drug-induced lupus identified from the Yellow Card database showed 
overlap with signals that have been reported in the literature. Unfortunately we were 
not given permission to view reports of drugs that were suspected of inducing lupus 
in less than nine occasions. We can therefore not comment on the completeness of 
the Yellow Card data as compared to information available in the literature. However, 
it should be noted that both the Yellow Card database as w-ell as the published 
literature collect data based on voluntary, non-systematic reporting mechanisms. 
Data from both sources are therefore likely to be incomplete and subject to biases , 
related to (for instance) the severity of the adverse event, the number of years a 
drug has been on the market, the frequency of use of a suspected drug, the 
background rate of the condition in the general population, etc. For example, 
consider the number of reports (N=20) for procainamide. Procainamide is prescribed 
for arrhythmias of the heart which occur relatively commonly. It is known that 
approximately 30% of procainamide users will develop lupus within one year of 
starting therapy[65]. If we would assume that all instances of procainamide-induced 
lupus were recorded in the Yellow Card database, an estimated 70 individuals would 
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have been exposed to procainamide in the UK during the nearly 25 years that the 
Yellow Card Scheme has been in operation. This number is very low and illustrates 
the problem of under-reporting. 
Compared to our previously discussed signal generation exercise utilising GPRD data, 
the Yellow Card data revealed a larger number of signals of drug-induced SLE. This is 
primarily due to the current limitations of the smile plot method as discussed in 
section 6.1.3. However, it should be noted here that healthcare professionals are 
encouraged to submit Yellow Card reports as soon as an adverse drug reaction is 
suspected (instead of reporting only those associations for which causality has been 
proven). Due to the nature of data collection, it is likely that false positive reports are 
included in the Yellow Card database. 
An important, strength of the Yellow Card data was the availability of information on 
disease outcome. In our earlier signal evaluation analyses of GPRD data, this 
information could not be derived because the GPRD medical coding dictionary does 
not include codes for disease remission. The Yellow Card data indicated that 
symptoms of lupus disappear after withdrawal of the suspected drug, which is an 
important confirmation of what has been reported in the literature. 
6.1.~. Risk of SLE Associated With Prescription Drugs: the Full Picture 
Numerous reports in the literature have suggested an association between certain 
prescription drugs and risk of SLE[22, 23, 25, 61-63, 65-67, 75-77]. We utilised data 
from the GPRD to evaluate these pre-existing hypotheses. Data were analysed using 
two different study designs; a matched case-control study and a self-controlled case 
series. Results of both these studies suggested an increased risk of SLE associated 
with minocycline, hydralazine and carbamazepine. In addition, the self-controlled 
case series suggested an increased risk of SLE associated with use of penicillamine 
and sulfasajazine. Results for other drugs of interest were inconclusive and need 
further investigation. 
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The case-control and the self-controlled case series designs each provided 
complimentary pieces of information regarding the hypothesised associations 
between drugs and risk of SLE. The matched case-control study was especially useful 
to investigate the effect of cumulative "dose on risk of SLE. The self-controlled case 
series on the other hand provided information on the timing of SLE in relation to 
exposure to drugs of interest. However, with both the statistical analysis methods we 
obtained wide confidence intervals around our point estimates due to the low 
incidence of SLE and the low exposure prevalence of the drugs of interest (i.e. low 
statistical power). At the present time, no larger data set than the GPRD is available 
.. 
to study the hypothesised associations. In the current age of computerised medical 
records it is thinkable that other (and larger) sources will become available in the 
future, perhaps through pooling of national data and linkage of several data 
sources[78]. If such data sources become available it will be possible to gain further 
understanding of the hypothesized associations and obtain more evidence to assess 
causality. 
A few limitations should be noted regarding the use of computerised medical records 
to study SLE. In chapter 2 of this thesis we already discussed some general 
limitations of the GPRD in terms of its validity. With regard to studying SLE, a few 
additional pOints are important to mention. The results of both the case-control and 
case series analysis methods are dependent on accurate recording of diagnosis date 
and prescription dates. As discussed in section 6.1.2, the exact SLE diagnosiS date is 
particularly difficult to establish when using computerised information. 
When studying the association between exposures and risk of disease, it is important 
to ensure only true cases of the disease of interest are included in the study. We 
therefore formulated strict criteria defining cases of SLE. The set of diagnostic codes 
we included in our definition may have excluded codes that were preferred by GPs to 
describe the symptoms of drug-induced lUpus. For instance, cutaneous lupus is not 
considered to be true SLE and was therefore not included in our case definition. 
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However, approximately 25% of cases of drug-induced lupus have shown symptoms 
of cutaneous lupus[23] and may have been recorded as such in the GPRD. 
Our analysis of the Yellow Card database provided an additional understanding of the 
association between drugs and risk of SLE. In the majority of reports, symptoms of 
SLE were observed to resolve after withdrawal of the suspected drug. In four reports 
of drug-induced SLE it was thought the patient died as a result of the adverse drug 
reaction. 
6.2. RISK OF HYPOTHYROIDISM ASSOCIATED WITH PRESCRIPTION 
DRUGS 
In section 6.1 we discussed associations between prescription medicines and risk of 
SLE. A numb~r of pre-existing hypotheses, identified from the literature, formed the 
basis of these investigations. First, we evaluated hypotheses using a matched case- . 
control and a case-only study design to analyse GPRD data. We then used the same 
data set to demonstrate the use of a novel method to detect signals of drug-induced 
disease. In addition, we described signals of drug-induced SLE in a spontaneous 
reporting database and compared these to our observations in GPRD data. 
In the current section, we will discuss a two phase study of drug related 
,-
hypothyroidism. Instead of relying on spontaneous reports or published literature to 
identify new signals of drug-induced disease, we generated signals using a subset of 
data from the GPRD. Newly identified signals were subsequently verified in a different 
data subset. The main purpose of this two pha~e study design was to provide an 
example of an entirely systematically performed drug safety investigation. This is in 
contrast to the current practice of pharmacovigilance, where all signal evaluation 
studies are preceded by identification of a signal in a non-standardised and 
subjective way.-
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6.2.1. Signal Generation 
6.2.1.1. Main Findings 
In our signal generation analyses of a. subset of drug related hypothyroidism cases 
and matched controls we did not identify BNF subchapters that were potentially 
causally associated with risk of disease. However, we did identify a BNF subchapter 
which is strongly associated with risk of iatrogenic drug related hypothyroidism; the 
subchapter for non-pharmacologic care products for the throat. We refined our case 
and control selection criteria to exclude those with diagnostic codes indicative of 
iatrogenic drug related hypothyroidism. When using the redefined case and control 
selection criteria, thyroid hormone prescriptions were found to be strongly associated 
with drug related hypothyroidism. This association was not causal, but rather an 
indication of_forthcoming drug related hypothyroidism. The date of first thyroid 
hormone prescription was therefore incorporated into the definition of diagnosis date. 
Using the new definition of diagnosis date, no signals of drug-induced drug related 
hypothyroidism were identified. 
6.2.1.2. Discussion 
When performing a signal generation exercise it is highly undesirable to identify 
spuri~us associations between drugs and adverse events. In th_~ worst case, falsely 
identified positive associations may lead to erroneous withdrawal of drugs from the 
market and denial of 'safe' medicines from patients who could have benefited from 
the drug. With respect to identification of spurious associations the Smile Plot method 
can be regarded as a useful method; it detected no false-positive associations of 
drug-induced hypothyroidism, and one potentially false-positive signal of drug-
induced lupus (discussed in section 6.1.3). 
As discussed in. section 6.1.3, an important limitation of the Smile Plot method, when 
utilised to identify signals of drug-induced disease, is the classification system we 
used to categorise drug exposures. Drug exposures were grouped by BNF subchapter 
because this claSSification system was incorporated in the GPRD drug dictionary. An 
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alternative classification system that is currently available and widely used is the 
Anatomical Therapeutic Chemical (ATC) classification[79]. This classification system 
arranges prescription drugs in five levels, according to the organ or system on which 
they act (which is the highest level) and their chemical, pharmacological and 
therapeutic properties. The ATC classification has been developed for the purpose of 
drug utilisation studies and not specifically to study drug safety. The hierarchical 
organisation of ATC codes is very similar to the BNF classification system (BNF also 
uses the target organ or system as the highest classification level) and because of 
these similarities we believe there will be little improvement in the sensitivity of the 
Smile Plot method when using ATC codes instead of BNF codes. 
In contrast to our earlier findings in the Smile Plots investigating drug-induced SLE, 
the point estimates for drug related hypothyroidism were generally dispersed around 
the no effect level (OR=l). This is a pattern one would expect to see when none of 
the investigated risk factors are truly associated with risk of disease. It is therefore 
unlikely that our risk estimates were affected by residual confounding, unlike our 
observation for signals of drug-induced SLE. 
Prior to redefinition of the diagnosis date, we observed subchapter 901 to be a 
potential signal of drug-induced drug related hypothyroidism. After redefinition, this 
subchapter was no longer identified as a signal but the 95°/~' confidence interval 
around the risk estimate excluded 1 and suggested an increased risk of drug related 
hypothyroidism associated with its use. Subchapter 901 includes drugs prescribed for 
anaemia and some other blood disorders. In hypothyroidism, anaemia is a common 
feature[26] and it is possible we identified subchapter 9.01 because it is prescribed 
for early symptoms of hypothyroidism. 
Approximately four percent of cases who were identified as incident received their 
-
first thyroxine prescription more than one year before a recorded diagnosis of 
hypothyroidism. These cases may in reality be prevalent cases who were 
misclassified as incident. This is possible when a hypothyroidism patient who is on 
thyroxine newly registers with a GP. It is plausible that a GP does not enter a medical 
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code for hypothyroidism retrospectively, but records such a code only when the 
patient develops new symptoms of the disease. Based on the computerised records 
this patient will appear to be newly diagnosed with hypothyroidism, despite having 
several prescriptions of thyroxine preceding the apparent 'diagnosis date'. We made 
a similar observation of potentially prevalent cases of SLE, based on prescriptions for 
anti-malarials that were received more than a year before the recorded diagnosis 
date. 
6.2.2. Signal Evaluation 
The main purpose of our two phase study design was to provide an example of an 
entirely systematically performed drug safety investigation. When we originally 
designed our study, we anticipated identifying signals of drug-induced 
hypothyroidism. These signals would subsequently be evaluated in a larger subset of 
the data. However, in the first phase of the study we did not observe signals of drug-
induced disease. In a real life setting, the drug safety study would have ended here. 
However, for the purpose of this thesis we did proceed with a signal evaluation 
phase. Two BNF subchapters for which the 95% confidence intervals suggested an 
association with risk of drug related hypothyroidism were selected for evaluation in 
the second phase of this study. When interpreting the results of this signal evaluation 
study it is important to keep in mind that these subchapters VIi-ere not identified as 
signals due to the threshold we defined to take account of multiple comparisons. 
6.2.2.1. Main Findings 
When investigating the BNF subchapter for "Drugs used in anaemias and some other 
blood disorders" in further detail, we found evidence for an increasing risk of drug 
related hypothyroidism with an increasing number of prescriptions for oral iron. This 
association was confined to individuals diagnosed with drug related hypothyroidism 
before the age of 55 and there was a statistically significant interaction between age 
group (younger or older than 55 years) and an iron cumulative dose of 4 or more 
prescriptions. In terms of exposure to hypnotics and anxiolytics, we found limited 
120 
evidence for an inverse association between cumulative dose and risk of drug related 
hypothyroidism. 
6.2.2.2. Discussion 
The weak evidence for an inverse dose-response relationship for hypnotics and 
anxiolytics may be in support of a causal association between use of these drugs and 
a decreased risk of drug related hypothyroidism. However, it is important to consider 
the clinical characteristics of drug related hypothyroidism when interpreting our 
results. Firstly, it should be noted that clinical manifestations of hypothyroid disease 
can be non-specific[27], which may cause substantial time to pass before a diagnosis 
of hypothyroidism is made. One of the common clinical manifestations of ," 
hypothyroidism is slowed mental processing[28]. Individuals with undiagnosed or 
subclinical hypothyroid disease[80] are therefore less likely to require the use of 
sedatives such as hypnotics and anxiolytics. When early symptoms of a disease 
influence the likelihood of being exposed to a certain drug, there is potential for bias. 
This particular type of bias is called protopathic bias[70] and may explain the inverse 
cumulative dose-response association we found between hypnotics and anxiolytics 
and the risk of drug related hypothyroidism. 
Hypothyroidism is reported to occur in approximately 1 per 1600 to 3 per 1000 
pregnancies [81, 82]. In addition, postpartum thyroiditis has been reported to occur 
in approximately 20 to 50 per 1000 pregnancies. In women developing postpartum 
hypothyroidism, a hyperthyroid stage is often seen 2 to 4 months postpartum, 
followed by a euthyroid and/or hypothyroid s.tage. Not all cases have disease 
remission [27]. When a woman is pregnant or planning a pregnancy, her GP will 
often prescribed supplements including oral iron and folic acid. This may explain why 
we observed an association between exposure to the subchapter for these drugs and 
a risk of drug related hypothyroidism among individuals less than 55 years of age, 
the majority of them being women of childbearing age. The prescriptions for oral iron 
and folic acid were most likely a marker for pregnancy instead of causative factors in 
the aetiology of drug related hypothyroidism. 
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6.2.3. Risk of Hypothyroidism Associated with Prescription Drugs: the Full 
Picture 
In our signal generation analysis we "did not identify BNF subchapters that were 
associated with risk of drug related hypothyroidism. In the subsequent signal 
evaluation analyses, the stratified analyses revealed a strong cumulative dose-
response association between the subchapter encoding supplements prescribed for 
pregnancy and risk of drug related hypothyroidism. This association reflects the 
increased risk of hypothyroidism during and immediately after pregnancy. The 
cumulative dose-response investigations for hypnotics and anxiolytics illustrated an 
example of protopathic bias. 
6.3. IMPLICATIONS FOR PHARMACOVIGILANCE 
6.3.1. Signal generation 
Using GPRD data for signal detection has a number of advantages compared to the 
use of spontaneous reporting databases. Firstly, GPRD data are collected routinely 
and in a prospective manner. Information is therefore less likely to be incomplete 
and/or subject to underreporting compared to data from spontaneous reporting 
databases. Secondly, the total number of individuals in the GPRD database receiving 
a prescription for a drug of interest can be determined, i.e. "denominator" data are 
available. In addition, the GPRD contains detailed information on unexposed 
individuals with and without the outcome of interest, as well as exposed individuals 
without the outcome of interest. This provides ~n opportunity to select appropriate 
comparison groups to perform (for instance) case-control or cohort studies. Lastly, 
the information captured in the GPRD is more detailed and complete than information 
on spontaneous reports. For instance, the GPRD can provide insight in timing of 
events (e.g. lag time between exposure and occurrence of a potential adverse 
event), underlying medical conditions and comorbidities, information on cumulative 
exposure and duration of exposure, and concurrent or past use of other drugs. 
However, for certain adverse events (e.g. SLE) it is difficult to assess whether the 
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symptoms resolved after withdrawal of a drug, because this type of information is 
not recorded. 
The large size of the GPRD and the relatively high incidence of hypothyroidism 
enabled us to create two data subsets without compromising substantially on study 
power and significance level. We were able to use one data subset for signal 
generation and to subsequently evaluate signals in the second data subset. In 
practice this may not always be the case, however. Adverse drug reactions that are 
identified during the post-marketing phases of a drug are likely to be rare, because 
any common events would have already been identified during the pre-marketing 
phases (when a relatively small numbers of individuals are exposed). Often the 
adverse drug reaction of interest (e.g. SLE) will be too rare to split the total set of 
cases recorded in the GPRD into subsets. When studying such rare events, we 
suggest using two separate large longitudinal databases with prospectively recorded 
patient-level data. One of the data sets (the smaller of the two) will serve to 
generate signals, and the other to evaluate newly identified signals. 
Our method to split the total set of cases with hypothyroid disease and matched 
controls was non-random (i.e. by geographical location of the patient's general 
practice). Random splitting of data would have essentially guaranteed similar results 
for bbth the signal generation and evaluation phases of our stud'y (if a difference was 
observed between the randomly split data subsets, this would· have been due to 
random variation). Several variables were considered for splitting the data non-
randomly. Age-group or sex were not deemed appropriate characteristics, because 
these factors were likely to be associated with both risk of hypothyroidism and 
likelihood of receiving a prescription for a drug of interest. We also did not split our 
data by calendar period. From previous analyses we knew that the incidence of 
hypothyroidism increased substantially over time during our study period[32], and 
prescription· patterns are also likely to have changed over time. Non-random splitting 
by geographical area seemed the most appropriate. Although the incidence of 
hypothyroidism varied across the United Kingdom during our study period[32], we 
123 
have no reason to believe that exposure to prescription drugs varied substantially 
between different regions. 
Identification of signals of ADRs invol~es considering both the apparent strength of 
the signal as well as the severity/importance of the adverse event[83]. Despite its 
current weaknesses in terms of grouping of exposures, we believe the Smile Plot 
method can be helpful in this decision making process. Firstly, the plots are based on 
data of much higher quality and completeness than data from spontaneous reporting 
databases. Secondly, the methods used to generate data pOints on the plot are well-
accepted and widely used statistical analysis methods (unlike the numerous data 
mining algorithms which are difficult to validate[71]. Lastly, the smile plots can be 
generated in relatively little time thereby providing timely results that are easy to 
interpret. 
In our signal generation studies of drug-induced hypothyroidism and drug-induced 
lupus, we chose the adverse event as the starting point of our study and conducted a 
matched case-control study to identify which exposures were associated with this 
adverse event. However, the focus of signal generation generally is to identify which 
adverse events are associated with a specific product (or class of drugs). In order to 
answer this question, one can generate signals of ADRs in association with a 
particular medicine. This can be easily done by adapting the analysis method 
described in section 3.5.5 of this thesis: instead of a conducting a case-control study 
(estimating odds ratios of the association between a specific ADR and several drug, 
exposures), one could conduct a cohort study. Risk ratios are estimated by 
comparing incidence of several diseases in the exposed group to the incidence of 
these diseases in the comparison group(s). The obtained risk ratios and 
corresponding P-values can then be plotted in a Smile Plot and a method to correct 
for multiple comparisons applied. 
In our earlier discussion of the Smile Plot method we identified the grouping of drug 
exposures to be the main limitation. The cohort study approach does not involve 
grouping of drug exposures, but instead involves grouping of diseases. This can be 
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done by using a well-developed and widely used hierarchical coding system of 
diseases: the leO classification. Although this classification system will likely have its 
own limitations but it may be superior to the drug classification systems available to 
date, resulting in a higher sensitivity of the Smile Plot method. An additional strength 
of using the cohort approach to generate Smile Plots is that the study design allows 
for several comparison groups. For example, one can have (1) an unexposed 
population based cohort, (2) a cohort of individuals who are exposed to a different 
drug of the same class or (3) a comparison cohort of unexposed individuals who have 
the same underlying condition for which the suspected drug is prescribed. Although 
cohort studies may be subject to bias and confounding in a similar way as case-
control studies, the use of well-selected different comparison groups can facilitate a 
better understanding of these biases and confounding. 
6.3.2. Signal evaluation 
Because causality can not be established based on signal generation studies, signal 
evaluation will always be an essential component of pharmacovigilance. One 
individual signal evaluation study will also not be sufficient to establish causality. In 
this thesis we presented two different methods to evaluate potential associations 
between drugs and adverse events; a case-control and a self-controlled case series 
approach. These methods can be applied to the same data source which is an 
efficient use of resources. In addition, when using the two- analysis methods 
alongside each other, we illustrated how the results of one study may facilitate. 
interpretation the results of the other study. 
Most signal evaluation studies will be of observational n-ature due to ethical and/or 
practical reasons. Observational studies will often be subject to bias and confounding. 
A particular type of bias which is of importance in observational studies of drug 
safety is confounding by indication. This type of bias may be overcome by removing 
the effect of difficult to measure factors which are likely to vary between a cases (or 
exposed individuals) and the comparison group. Inter-personal variations are 
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removed from the analysis when making within-person comparisons, for example by 
using the self-controlled case series method. 
Despite the large size of the GPRD, t~e sample size of SLE cases was too small to 
perform relevant subgroup analyses or to detect moderately increased risks. 
6.4. RECOMMENDATIONS FOR CLINICIANS AND DRUG SAFETY 
SCIENTISTS 
6.4.1.1. Recommendations for clinicians 
It is important for GPs to consider drug-induced lupus as a potential diagnosis when 
a patient on one (or more) of the drugs listed in Table 1-1 presents with lupus-like 
symptoms. We will publish the matched case-control study of the associations 
between prescription drugs and risk of SLE in an international peer-reviewed medical 
journal. This publication will further inform the medical community of potential risk of 
SLE associated with a wide range of drugs. Based on the findings presented in this 
thesis we do not recommend routine testing for autoantibodies in the blood of 
patients on drugs suspected of causing drug-induced lupus. The findings for drug-
related hypothyroidism presented in this thesis do not warrant any recommendations 
for endocrinologists or general practitioners. 
6.4.1.2. Recommendations for drug safety scientists 
The methods explored in this thesis provide a useful addition to the currently used 
set of methods to monitor safety of medicines. In terms of signal evaluation, use of 
the case-series method should be considered when studying a potential adverse 
event with an acute onset of symptoms. 
Further studies are needed to investigate sensitivity and specificity of Smile Plots 
-
when these.are generated from cohort study results. The smile plot method provides 
an easy to interpret visual aid for interpretation of large quantities of data and with 
improved. sensitivity and specificity this tool should not be disregarded in the 
detection of previously unknown adverse events. 
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Currently, the GPRD is not used to its full potential for the study of drug safety. 
Although the data are being utilised for evaluation of hypothesized drug- adverse 
event associations, no signal detection studies have been reported to date. Use of 
the GPRD for signal detection would "be an important improvement of the current 
practice of pharmacovigilance. 
6.5. CONCLUSION 
The GPRD is the largest primary care medical records database currently available. It 
is a powerful tool to study morbidity in primary care. However, intimate knowledge of 
the use of coding in General Practice and of the complexities of the database is 
needed to ensure that the best use is made of it. 
Known and ,suspected associations of drug-induced SLE were reproduced in the 
GPRD. However, in our study of drug-induced SLE both the disease and the 
exposures (Le. drug prescriptions) of interest were uncommon, resulting in a limited 
study power to detect moderately increased risks or to perform relevant subgroup 
Results from a matched case-control study indicated strong associations with risk of 
SLE for hydralazine, carbamazepine and minocycline. These associations were 
confirmed in a self-controlled case series but the risk estimates were lower compared 
to those observed in the case-control study. This difference in risk estimates is most 
likely due to an overestimate of risk in the case-control study, as a result of the 
effect of unmeasured confounders including health-seeking behaviour. Despite the. 
large size of the GPRD, the sample size of SLE cases was too small to investigate 
potential associations and bias using conventional stratification. 
Known associations between drugs and risk of SLE were not identified as signals 
when using the Smile Plot method. This signal generation method was found to have 
a high specifiCity as illustrated by the highly limited number of falsely identified 
positive associations for both drug-induced SLE and drug-induced hypothyroidism. 
However, the sensitivity of the Smile Plot method is low. Sensitivity may be improved 
when improved hierarchical classification systems for drugs become available. 
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Alternatively, smile plots may be created from risk estimates of a cohort study rather 
than a case-control study in order to avoid use of inadequate drug classification 
systems. 
Spontaneous reports of drug-induced SLE recorded in the UK Yellow Card database 
indicated that symptoms of SLE often resolve after withdrawal of the suspected drug. 
This is important information that could not be gathered from our studies utilising 
GPRD data. 
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APPENDIX I-A. MEDLINE AND EMBASE SEARCH STRATEGIES 
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system/ 
(GPRD or Genera l Practice Research Database or General Practice 
3 Database or VAMP or Value Added Medical Products or GP Research 
Database or GP Ddatabase).af. 
(accurac$ or quality or valid$ or systematic comparison or 
4 agreement between or complete$ or evaluat$ or reprduci$ or predict$ or sensit$ or specific$ or misdiagnos$ or compar$ or false 
positiv$ or false negativ$ or reference value) .af. 
5 (medical record$ or primary care record$ or patient record$ or 
cHagnos#s). af. 
6 1 or 4 
7 2 or 5 
8 3 and 6 and 7 
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1 Records" [MeSH] OR "Medica l record administrators" [MeSH] OR 
"records" [MeSH] OR "registries" [MeSH] OR "diagnosis" [MeSH] OR 
"documentation" [MeSH] 
GPRD OR "General Practice Research Database" OR "Practice 
2 Research Database" OR "General Practice Database" OR VAMP OR 
"Value Added Medical Products" OR "GP Database" OR "UK Database 
of Primary Care Records" 
"accurac*" OR "qualit*" OR "valid * " OR "systematic comparison" OR 
"agreement between" OR "complete* " OR "evaluat* " OR "reproduci*" 
OR "predictive value" OR "sensit* " OR "specific*" OR "misdiagnos* " 
OR "compar* " OR "false positiv*" OR "false negativ*" OR "reference 
3 va lue" OR "evaluation studies" [MeSH] OR "evaluation studies" [PT] 
OR "reproducibility of results" [MeSH] OR "validation studies" [PT] 
OR "software validation" [MeSH] OR "sensitivity and specificity" 
[MeSH] OR "predictive value of tests" [MeSH] OR "reference values" 
[MeSH] 
4 Search "Epidemiology"[MeSH] OR "epidemiology"[Subheading] OR 
epidemiol* 
5 # 1 AND # 2 AND # 3 
6 (#2 AND # 4) NOT # 5 
135 
APPENDIX 1-8: DATA EXTRACTION SHEET FOR GPRD 
LITERATURE REVIEW 
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APPENDIX II. OXMIS AND READ CODES FOR SYSTEMIC LUPUS 
ERYTHEMATOSUS (SLE) 
Medical codes for systemic lupus erythematosus . 
Oxmis codes 
7341AC 
7341C 
7341AD 
7341 
7341AA 
7341AB 
6954 
7341A 
Read codes 
Nyu4300 
NOOOOOO 
N000200 
H57y400 
M154.00 
M154z00 
K01x411 
F396100 
K01x400 
F371000 
M154700 
NOOO.OO 
NOOOzOO 
N000300 
N000400 
ACUTE SYSTEMIC LUPUS ERYTHEMATOSUS 
LUPUS ENDOCARDITIS 
LUPUS ERYTHEMATOSUS ACUTE 
LUPUS ERYTHEMATOSUS DISSEMINATED 
LUPUS ERYTHEMATOSUS SYSTEMIC 
NEPHRITIS LUPUS 
SYSTEMIC LUPUS ERYTHEMATOSUS 
SYSTEMIC LUPUS ERYTHEMATOSUS WITH RENAL 
[XlOTHER FORMS OF SYSTEMIC LUPUS ERYTHEMATOSUS 
DISSEMINATED LUPUS ERYTHEMATOSUS 
DRUG-INDUCED SYSTEMIC LUPUS ERYTHEMATOSUS 
LUNG DISEASE WITH SYSTEMIC LUPUS ERYTHEMATOSUS 
LUPUS ERYTHEMATOSUS 
LUPUS ERYTHEMATOSUS NOS 
LUPUS NEPHRITIS 
MYOPATHY DUE TO DISSEMINATED LUPUS ERYTHEMATOSUS 
NEPHROTIC SYNDROME IN SYSTEMIC LUPUS ERYTHEMATOSUS 
POLYNEUROPATHY IN DISSEMINATED LUPUS ERYTHEMATOSUS 
SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS 
SYSTEMIC LUPUS ERYTHEMATOSUS 
SYSTEMIC LUPUS ERYTHEMATOSUS NOS 
SYSTEMIC LUPUS ERYTHEMATOSUS WITH ORGAN OR SYS INVOLV 
SYSTEMIC LUPUS ERYTHEMATOSUS WITH PERICARDITIS 
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APPENDIX III. OXMIS AND READ CODES FOR HYPOTHYROIDISM, 
(INCLUDING AUTOIMMUNE THYROIDITIS) 
Medical codes for hypothyroidism (including autoimmune hypothyroiditis) 
Oxmis codes 
24S B 
244AC 
244 AG 
244 
24S E 
24S EA 
24S A 
Read codes 
Cyu1400 
Cyull00 
FyulS00 
COSOOOO 
COSO.OO 
COSOzOO 
C046.00 
COS2.11 
F144l00 
FllxSOO 
COS2.00 
COSy400 
COS1.11 
COS2.12 
C04 .. 13 
C04z.00 
F381400 
C04 .. 11 
C04zl00 
C04y.OO 
COSy.OO 
COS3.11 
COS1.00 
COS .. OO 
COSz.OO 
HASHIMOTO'S DISEASE 
HYPOTHYROIDISM ACQUIRED 
HYPOTHYROIDISM COMPENSATED 
MYXOEDEMA 
THYROIDITIS 
THYROIDITIS ACUTE 
THYROIDITIS AUTOIMMUNE 
[X]OTHER CHRONIC THYROIDITIS 
[X]OTHER SP CIFIED HYPOTHYROIDISM 
[X]SYSTEMIC ATROPHY AFFECTING THE CNS IN MYXOEDEMA 
ACUTE NON SUPPURATIVE THYROIDITIS 
ACUTE THYROIDITIS 
ACUTE THYROIDITIS NOS 
AUTOIMMUNE MYXOEDEMA 
AUTOIMMUNE THYROIDITIS 
CEREBELLAR ATAXIA DUE TO MYXOEDEMA 
CEREBRAL DEGENERATION DUE TO MYXOEDEMA 
CHRONIC LYMPHOCYTIC THYROIDITIS 
CHRONIC THYROIDITIS WITH TRANSIENT THYROTOXICOSIS 
DE QUERVAIN'S THYROIDITIS 
HASHIMOTO'S DISEASE 
HYPOTHYROIDISM 
HYPOTHYROIDISM NOS 
MYASTHENIC SYNDROME DUE TO HYPOTHYROIDISM 
MYXOEDEMA 
MYXOEDEMA COMA 
OTHER ACQUIRED HYPOTHYROIDISM 
OTHER AND UNSPECIFIED CHRONIC THYROIDITIS 
RIEDEL'S THYROIDITIS 
SUBACUTE THYROIDITIS 
THYROIDITIS 
THYROIDITIS NOS 
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APPENDIX IV. EXCLUSION CRITERIA FOR CASES WITH 
HYPOTHYROID DISEASE AND MATCHED CONTROLS 
A priori identified medical codes for potentially iatrogeniC hypothyroidism 
7110111 BILATERAL SUBTOTAL THYROIDECTOMY 
K0722 DISSECTION NECK WITH THYROIDECTOMY 
K0714FH FUND HOLDING PARTIAL THYROIDECTOMY 
K0722FH FUND HOLDING THYROIDECTOMY ABERRENT GLAN 
K0721FH FUND HOLDING TOTAL THYROIDECTOMY 
7110200 HEMITHYROIDECTOMY 
K0716 HEMITHYROIDECTOMY 
5A16.11 I131 RADIOTHERAPY 
K998 A 1-131 THYROID ABLATION 
5A16.12 IODINE 131 RADIOTHERAPY 
7110yOO OTHER SPECIFIED THYROIDECTOMY 
7110500 PARTIAL THYROIDECTOMY NEC 
K998 T RADIOIODINE THERAPY 
7110100 SUBTOTAL THYROIDECTOMY 
K998 THYROID ABLATION RADIOIODINE 
K072 THYROIDECTOMY 
7110600 THYROIDECTOMY NEC 
7110z00 THYROIDECTOMY NOS 
K071 D THYROIDECTOMY OF ABERRENT THYROID GLAND 
7110.00 THYROIDECTOMY OPERATIONS 
K071 THYROIDECTOMY PARTIAL 
K071 B THYROIDECTOMY SUBTOTAL 
7110000 TOTAL THYROIDECTOMY 
K0721 TOTAL THYROIDECTOMY 
Further medical codes for potentially iatrogeniC hypothyroidism 
BBaO.OO [MlCraniopharyngioma 
ZV10100 [VlPersonal history of malig neop of trachea/bronchus/lung 
ZV10016 [VlPersonal history of malignant neoplasm of oesophagus 
ZV10113 [VlPersonal history of malignant neoplasm of trachea 
ByuO.OO [Xl Malignant neoplasm of lip, oral cavity and pharynx 
PA37.00 Atresia of oesophagus with tracheo-oesophageal fistula 
7432400 Attention to artificial voicebox in larynx 
2121 BENIGN NEOPLASM LARYNX 
B721.00 Benign neoplasm of larynx 
B722.00 Benign neoplasm of trachea 
B710100 Benign neoplasm of upper 1/3 of oesophagus 
2109 BENIGN NEOPLASM PHARYNX 
B721z11 
B800900 
B810.00 
B810z00 
B800.00 
B800z00 
B800700 
B800800 
B800.12 
B811.00 
B801000 
BO ... 11 
744D100 
7433400 
7606100 
7606000 
Benign papilloma of larynx 
Carcinoma in situ of hypopharynx 
Carcinoma in situ of larynx 
Carcinoma in situ of larynx NOS 
Carcinoma in situ of lip, oral cavity and pharynx 
Carcinoma in situ of lip, oral cavity and pharynx NOS 
Carcinoma in situ of nasopharynx 
Carcinoma in situ of oropharynx 
Carcinoma in situ of pharynx 
Carcinoma in situ of trachea 
Carcinoma in situ of upper 1/3 oesophagus 
Carcinoma of lip, oral cavity and pharynx' 
Changing of tracheooesophageal valve 
Chondroplasty of larynx 
Closure of fistula of oesophagus NEC 
Closure of tracheooesophageal fistula 
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Further medical codes for potentially iatrogenic hypothyroidism 
PA36.00 Cong.absence of oesophagus with tracheo-oesophageal fistula 
PA32z00 Congenital oesophageal fistula NOS 
PA32111 Congenital tracheo-oesophageal fistula 
2262CP CRANIOPHARYNGIOMA 
ZD64700 Development of oesophageal vojce exercises 
7432200 Division of larynx stenosis and insertion of prosthesis 
7431100 Excision lesion larynx using lateral pharyngotomy approach 
7430.00 Excision of larynx 
7430z00 Excision of larynx NOS 
7431000 Excision of lesion of larynx using thyrotomy as approach 
7420.00 Excision of pharynx 
7420z00 Excision of pharynx NOS 
7606011 Excision of tracheooesophageal fistula 
7443.00 Exteriorisation of trachea 
7443z00 
7601211 
7422011 
7422212 
7432300 
7601212 
7430.11 
1619C 
743 .. 00 
743z.00 
2311A 
BOz .. OO 
B542z00 
B082.00 
150 A 
B220000 
Bl00.00 
B542100 
B08 .. 00 
B08z.00 
BOz2.00 
B21..00 
B21z.00 
B21y.00 
B066.00 
BO ... OO 
BOzz.OO 
B220100 
Bl0 .. 00 
Bl0z.00 
B06 .. 00 
B06z.00 
B06y.00 
BOzy.OO 
B08y.00 
Bl0y.00 
B06yzOO 
B062300 
BOzO.OO 
B083.00 
B067.00 
Bl01.00 
B220.00 
B220z00 
B22 .. 00 
B103.00 
149 AT 
B542.00 
B084.00 
B214.00 
7601111 
B901z00 
B901.00 
B907z00 
B920.00 
B920z00 
1619A 
1620A 
B920100 
B901900 
B906.00 
B906z00 
B901800 
Exteriorisation of trachea NOS 
Herzen oesophagectomy and interposition of jejunal loop 
Hynes pharyngoplasty 
Hynes pharyngoplasty 
Implantation of artificial voice box into larynx 
Judine oesophagectomy and interposition of jejunal loop 
Laryngectomy 
LARYNX CARCINOMA 
Larynx operations 
Larynx operations NOS 
LEIOMYOMA LARYNX 
Malig neop other/iii-defined sites lip, oral cavity, pharynx 
Malig neop pituitary gland or craniopharyngeal duct NOS 
Malignant neoplasm aryepiglottic fold, hypopharyngeal aspect 
MALIGNANT NEOPLASM OESOPHAGUS 
Malignant neoplasm of cartilage of trachea 
Malignant neoplasm of cervical oesophagus 
Malignant neoplasm of craniopharyngeal duct 
Malignant neoplasm of hypopharynx 
Malignant neoplasm of hypopharynx NOS 
Malignant neoplasm of laryngopharynx 
Malignant neoplasm of larynx 
Malignant neoplasm of larynx NOS 
Malignant neoplasm of larynx, other specified site 
Malignant neoplasm of lateral wall of oropharynx 
Malignant neoplasm of lip, oral cavity and pharynx 
Malignant neoplasm of lip, oral cavity and pharynx NOS 
Malignant neoplasm of mucosa of trachea 
Malignant neoplasm of oesophagus 
Malignant neoplasm of oesophagus NOS 
Malignant neoplasm of oropharynx 
Malignant neoplasm of oropharynx NOS 
Malignant neoplasm of oropharynx, other specified sites 
Malignant neoplasm of other sites lip, oral cavity, pharynx 
Malignant neoplasm of other specified hypopharyngeal site 
Malignant neoplasm of other specified part of oesophagus 
Malignant neoplasm of other specified site of oropharynx NOS 
Malignant neoplasm of palatopharyngeal arch 
Malignant neoplasm of pharynx unspecified 
Malignant neoplasm of posterior pharynx 
Malignant neoplasm of posterior wall of oropharynx 
Malignant neoplasm of thoracic oesophagus 
Malignant neoplasm of trachea 
Malignant neoplasm of trachea NOS 
Malignant neoplasm of trachea, bronchus and lung 
Malignant neoplasm of upper third of oesophagus 
MALIGNANT NEOPLASM PHARYNX 
Malignant neoplasm pituitary gland and craniopharyngeal duct 
Malignant neoplasm, overlapping lesion of hypopharynx 
Malignant neoplasm, overlapping lesion of larynx 
McKewown total oesophagectomy 
Neop of uncertain behaviour lip, oral cavity and pharynx NOS 
Neop of uncertain behaviour of lip, oral cavity and pharynx 
- Neop of uncertain behaviour of trachea, bronchus or lung NOS 
Neop uncertain behaviour pituitary and craniopharyngeal duct 
Neop uncertain behaviour pituitary and craniopharyngeal NOS 
NEOPLASM MALIGNANT LARYNX 
NEOPLASM MALIGNANT TRACHEA 
Neoplasm of uncertain behaviour of craniopharyngeal duct 
Neoplasm of uncertain behaviour of hypopharynx 
Neoplasm of uncertain behaviour of larynx 
Neoplasm of uncertain behaviour of larynx NOS 
Neoplasm of uncertain behaviour of oropharynx 
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Further medical codes for potentially iatrogenic hypothyroidism 
B901.12 Neoplasm of uncertain behaviour of pharynx 
B907000 Neoplasm of uncertain behaviour of trachea 
B907.00 Neoplasm of uncertain behaviour trachea, bronchus and lung 
BI0z.11 Oesophageal cancer 
ZT12100 Oesophageal voice _ 
ZD64800 Oesophageal voice injection exercises 
ZD64900 Oesophageal voice insufflation exercises 
K291 OESOPHAGECTOMY 
7602z11 
ZC65900 
PA32100 
150 C 
7431200 
7444000 
7423000 
7440000 
7431.00 
7431z00 
7442000 
7442.00 
7442z00 
7442200 
7442100 
7433500 
7422211 
7433z00 
7444z00 
7433.00 
7423.00 
7444.00 
744CzOO 
7437z00 
7426z00 
744C.00 
7437.00 
7430yOO 
7420yOO 
7443yOO 
PA3y.00 .' 
7431yOO 
7433yOO 
743y.00 
742y.00 
7444yOO 
744CyOO 
7437yOO 
7426yOO 
7602yOO 
7440yOO 
7441yOO 
7432yOO 
7422yOO 
7601yOO 
7602.00 
7602z00 
7440.00 
7440z00 
7602.11 
7602000 
7602500 
7602200 
7602300 
7602400 
7602100 
7420100 
7420.11 
K2841 
K2843 
7420000 
7420300 
7420300 
7422.11 
K2862 
7422200 
7422100 
7422000 
149 C 
Oesophagectomy NEC 
Oesophagostomy feeding 
Oesophagotracheal fistula 
OESOPHAGUS CARCINOMA 
Open destruction of lesion of larynx 
Open destruction of lesion of trachea 
Open excision of lesion of pharynx 
Open excision of lesion of trachea 
Open extirpation of lesion of larynx 
Open extirpation of lesion of larynx NOS 
Open insertion of tubal prostheSiS in trachea 
Open placement of prostheSis in trachea 
Open placement of prosthesis in trachea NOS 
Open removal of tubal prostheSiS from trachea 
Open renewal of tubal prosthesis in trachea 
Operation on cartilage of larynx NEC 
Orticochea pharyngoplasty 
Other open operation on larynx NOS 
Other open operation on trachea NOS 
Other open operations on larynx 
Other open operations on pharynx 
Other open operations on trachea 
Other operation on bronchus or trachea NOS 
Other operation on larynx NOS 
Other operation on pharynx NOS 
Other operations on bronchus or trachea 
Other operations on larynx 
Other specified excision of larynx 
Other specified excision of pharynx 
Other specified exteriorisation of trachea 
Other specified oesophageal atresia, stenosis or fistula 
Other specified open extirpation of lesion of larynx 
Other specified open operation on larynx 
Other specified operations on larynx 
Other specified operations on pharynx 
Other specified other open operation on trachea 
Other specified other operation on bronchus or trachea 
Other specified other operation on larynx 
Other specified other operation on pharynx 
Other specified partial excision of oesophagus 
Other specified partial excision of trachea 
Other specified plastiC operation on trachea 
Other specified reconstruction of larynx 
Other specified repair of pharynx 
Other specified total excision of oesophagus 
Partial excision of oesophagus 
Partial excision of oesophagus NOS 
Partial excision of trachea 
Partial excision of trachea NOS 
Partial oesophagectomy 
Partial oesophagectomy and end to end anastomosis of oesoph 
Partial oesophagectomy and interposition of colon NEC 
Partial oesophagectomy+anastom oesophagus to transp jejunum 
Partial oesophagectomy+anastomosis oesophagus to jejunum NEC 
Partial oesophagectomy+interposition microvasc attach colon 
Partial oesophagectomy+interposition microvasc attach jejun 
Partial pharyngectomy 
Pharyngectomy 
PHARYNGECTOMY PARTIAL 
PHARYNGECTOMY TOTAL 
Pharyngolaryngectomy 
Pharyngolaryngooesophagectomy 
Pharyngolaryngooesophagectomy 
Pharyngoplasty 
PHARYNGOPLASTY 
Pharyngoplasty using lateral pharyngeal flap 
Pharyngoplasty using posterior pharyngeal flap . 
Pharyngoplasty using posterior pharyngeal implant 
PHARYNX CARCINOMA 
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Further medical codes for potentially iatrogenic hypothyroidism 
K289 PHARYNX OPERATION 
742z.00 
7441z00 
7441.00 
7422300 
7432.00 
7432z00 
7422.13 
7422900 
7422500 
7422611 
7422700 
7422600 
7422800 
7441000 
7441200 
7441.11 
7441100 
7441300 
7422z00 
7601213 
150 B 
B561500 
ZT12211 
7601100 
7601.00 
7601z00 
7601.11 
7601000 
7601000 
7601400 
7601200 
7601300 
7420011 
7420400 
1620C 
K249 AA 
7502C 
J10y200 .. 
H5y0400 
ZT12200 
5B76.00 
Pharynx operations NOS 
Plastic operation on trachea NOS 
Plastic operations on trachea 
Plastic repair of pharynx NEC 
Reconstruction of larynx 
Reconstruction of larynx NOS 
Reconstruction of pharynx operations 
Reconstruction of pharynx with colon pull-up 
Reconstruction of pharynx with distant pedicle flap 
Reconstruction of pharynx with free flap 
Reconstruction of pharynx with free jejunal transfer 
Reconstruction of pharynx with microvascular transfered flap 
Reconstruction of pharynx with stomach pull-up 
Reconstruction of trachea & anastomosis HFQ 
Reconstruction of trachea NEC 
Reconstruction of trachea operations 
Reconstruction of trachea using graft 
Reconstruction of trachea with skin flap 
Repair of pharynx NOS 
Roux oesophagectomy and interposition of jejunal loop 
SARCOMA OESOPHAGUS 
Secondary and unspec malig neop paratracheal lymph nodes 
T-E voice - Tracheo-oesophageal voice 
Tot oesophagectomy+interposition microvasc attached jejunum 
Total excision of oesophagus 
Total excision of oesophagus NOS 
Total oesophagectomy 
Total oesophagectomy and anastomosis of pharynx to stomach 
Total oesophagectomy and anastomosis of pharynx to stomach 
Total oesophagectomy and interposition of colon NEC 
Total oesophagectomy and interposition of jejunum NEC 
Total oesophagectomy+interposition microvasc attached colon 
Total pharyngectomy 
Total pharyngectomy 
TRACHEA CARCINOMA 
TRACHEA OPERATION 
TRACHEO-OESOPHAGEAL FISTULA 
Tracheo-oesophageal fistula 
Tracheo-oesophageal fistula following tracheostomy 
Tracheo-oesophageal voice 
U-S therapy - larynx lesion 
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APPENDIX V. DESCRIPTION OF BNF SUBCHAPTERS 
BNF subchapter Drug indications 
Gastrointestinal system (chapter 1) 
101 dyspepsia and gastro-oe~ophageal reflux disease 
102 antispasmodics and other drugs altering gut motility 
103 
104 
105 
106 
107 
109 
ulcer-healing drugs 
acute diarrhoea 
chronic bowel disorders 
laxatives 
local preparations for anal and rectal disorders 
drugs affecting intestinal secretions 
Cardiovascular system (chapter 2) 
201 positive inotropic drugs 
202 
203 
204 
205 
206 
207 
208 
209 
211 
212 
213 
diuretics 
anti-arrhytmic drugs 
beta-ad reno receptor blocking drugs 
hypertension and heart failure 
nitrates, calcium-channel blockers and other antianginal drugs 
symptathomimetics 
anticoagulants and protamine 
anti platelet drugs 
antifibrinolytic drugs and haemostatics 
lipid-regulating drugs 
local sclerosants 
Respiratory system (chapter 3) 
301 bronchodilators 
302 corticosteroids 
303 cromoglicate and related therapy and leukotriene receptor antagonists 
304 
306 
307 
308 
309 
310 
antihistamines, hyposensitisation, and allergic emergencies 
oxygen 
mucolytics 
aromatic inhalations 
cough preparations 
systemic nasal decongestants 
.350 miscellaneous care products for the respiratory system 
Central nervous system (chapter 4) 
401 hypnotics and anxiolytics 
402 drugs used in psychoses and related disorders 
403 antidepressant drugs 
405 drugs in the treatment of obesity 
406 
407 
408 
409 
410 
Infections (chapter 5) 
501 
502 
503 
504 
505 
drugs used in nausea and vertigo 
analgesics 
antiepileptics 
drugs used in parkinsonism and related disorders 
drugs used in substance dependance 
antibacterial drugs 
antifungal drugs 
antiviral drugs 
antiprotoloal drugs 
antihelminthics 
Endocrine system (chapter 6) 
601 drugs used in diabetes 
602 thyroid and antithyroid drugs 
603 
604 
corticosteroids 
sex hormones 
.' 
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BNF subchapter 
605 
606 
Drug indications 
hypothalamic and pituitary hormones and anti-oestrogens 
drugs affecting bone metabolism 
607 other endocrine drugs 
Obstetrics, gynaecology and urinary tract disorde"rs (chapter 7) 
701 drugs used in obstetrics . 
702 treatment of vaginal and vulval conditions 
703 
704 
750 
contraceptives 
drugs for genito-urinary disorders 
Malignant disease and immunosuppression (chapter 8) 
801 
802 
cytotoxic drugs 
drugs affecting the immune response 
803 sex hormones and hormone antagonists in malignant disease 
Nutrition and blood (chapter 9) 
901 anaemias and some other blood disorders 
902 
904 
905 
906 
907 
908 
910 
911 
fluids and electrolytes 
oral nutrition 
minerals 
vitamins 
bitters and tonics 
metabolic disorders 
Musculoskeletal. and joint diseases (chapter 10) 
1001 drugs used in rheumatic diseases and gout 
1002 
1003 
Eye (chapter 11) 
1103 
1104 
1105 
1106 
1107 
1108 
1150 
drugs used in neuromuscular disorders 
drugs for the relief of soft-tissue inflammation 
anti-Infective eye preparations 
corticosteroids and other anti-inflammatory preparations 
mydratics and cycloplegics 
treatment of glaucoma 
local anaesthetics 
miscellaneous opthalmic preparations 
Ear, nose and oropharynx (chapter 12) 
1201 drugs acting on the ear 
1202 
1203 
Skin (chapter 13) 
1301 
1302 
1303 
1304 
1305 
1306 
1307 
1308 
1309 
1310 
1311 
1312 
1314 
drugs acting on the nose 
drugs acting on the oropharynx 
management of skin conditions 
emollient and barrier preparations 
topical local anaesthetics and antipruritics 
topical local corticosteroids 
preparations for eczema an psoriasis 
acne and rosacea 
preparations for warts and calluses 
sunscreens and camouflagers 
shampoos and other preparations for scalp and hair conditions 
anti-infective skin preparations 
skin cleansers and antisceptics 
antiperspirants 
herbal preparations 
1315 soap and cleansers 
Immunological products and vaccines (chapter 14) 
1404 vaccines and antisera 
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BNF subchapter Drug indications 
1405 immunoglobulins 
Anaesthesia (chapter 15) 
1501 
1502 
general anaesthesia 
local anaesthesia 
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APPENDIX VI. DRUGS BY BNF CODE 
Drugs included in BNF code 1.03.05.00 
AMOXICILliN+CLARITHROM & LAN SOP 
CLARITHROMYCINmetronid + lanzop 
LANSOPRAZOLE 
OMEPRAZOLE 
RABEPRAZOLE 
Drugs included in BNF code 3.04.01.01 
ACRIVASTINE 
CETIRIZINE 
FEXOFENADINE 
LORATADINE 
TERFENADINE 
Drugs included in BNF code 4.07.01.00 
ACETYLSAliCYliC ACID 
ACETYLSAliCYliC ACID/ CODEINE PHOSPHATE 
AMBUCETAMIDE/PARACETAMOL 
ASPIRIN 
ASPIRIN /CALCIUM CARBONATE /CITRIC ACID 
ASPIRIN 600MG/GLYCINE 300MG 
ASPIRIN E/C 
ASPIRIN PAED 
ASPIRIN SACHETS 
ASPIRIN/CAFFEINE CIT./CODEINE PHOSPHATE 
ASPIRIN/CAFFEINE/DEXTROPROPOXYPHENE 
ASPIRIN/CHLORMEZANONE 
ASPIRIN/CODEINE 
ASPIRIN/CODEINE/PAEDIATRIC 
ASPIRIN/PAPAVERETUM 
ASPIRIN+ CAFFEINE 
ASPIRIN+ CODEINE & CAFFEINE 
ASPIRIN+ GLYCINE 
ASPIRIN+ OTHERS 
ASPIRIN+ PARACETAMOL 
ASPIRIN+NA BICARB&CITRIC AC 
ASPRIN E/C 
CAF/COD/NICOT/PARACETAMOL(ACETAMINOPHEN) 
CAFF/HOMATROP/PARACETAMOL(ACETAMINOPHEN) 
CARISOPRODOL/PARACETAMOL (ACETAMINOPHEN) 
CHLORMEZANONE+-PARACETAMOL 
CODEINE 30/PARACETAMOL SOO/ACETAMINOPHEN 
CODEINE COMPOUND SOLUBLE 
CODEINE PHOSPHATE+ ASPIRIN & CAFFEINE 
CODEINE PHOSPHATE+ADDITIONAL INGREDS 
CODEINE PHOSPHATEPARACET,DOXYLAMI,CAF 
CODEINE/PARACETAMOL (ACETAMINOPHEN) 
CLARITHROMYCIN+LANSOP & AMOXI 
ESOMEPRAZOLE 
LANSOPRAZOLE+AMOXI & CLARITH 
PANTOPRAZOLE 
ASTEMIZOLE 
DESLORATADINE 
LEVOCETIRIZINE 
MIZOLASTINE 
ACETYLSAliCYliC ACID 300MG/GLYCINE 133MG 
ALOXIPRIN 
AMBUCETAMIDE+ PARACETAMOL 
ASPIRIN /CAFFEINE /QUININE SULPHATE 
ASPIRIN 300MG/LYSINE 24SMG 
ASPIRIN DISPERSIBLE 
ASPIRIN M/F 
ASPIRIN SIR 
ASPIRIN/ANHYDROUS CITRIC ACID/CALCIUM 
ASPIRIN/CAFFEINE DISPERSIBLE 
ASPIRIN/CAFFEINE/DEXTROPROPOXYPHENE NAPS 
ASPIRIN/CODEI/PARACETAMOL(ACETAMINOPHEN) 
ASPIRIN/CODEINE PHOSPHATE/CAFFEINE 
ASPIRIN/ETHOHEPTAZINE CITRAT/MEPROBAMATE 
ASPIRIN/PARACETAMOL (ACETAMINOPHEN) 
ASPIRIN+ CODEINE 
ASPIRIN+ CYCliZINE 
ASPIRIN+ METHOCARBAMOL 
ASPIRIN+ PAPAVERETUM 
ASPIRIN+ALOXIPRIN &CAFFEINE 
ASPIRINCALCIUM CARBONATE 
BENORILATE 
CAFF/CODEINE/PARACETAMOL (ACETAMINOPHEN) 
CAFFEINE/CODEINE/DIPHENHYDRAMINE 
CHLORMEZANONE+ ASPIRIN 
CO-CODAPRIN 
CODEINE COMPOUND 
CODEINE PHOSPHATE+ ASPIRIN 
CODEINE PHOSPHATE+ PARACETAMOL 
CODEINE PHOSPHATEPARACET,DIPHENH,CAFF 
CODEINE. SOLUBLE 
CODEINE/PARACETAMOL (ACETAMINOPHEN)8/S00 
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CODEINE/PARACETAMOL(ACETAMINOPHEN)/CITRA 
CODYDRAGESIC 
CO-METHIAMOL 
DEXTROPROPOXYPHENE HCL+ PARACETAMOL 
DEXTROPROPOXYPHENE NAPSYLATE+ ASPIRIN & 
CAFFEINE 
DICHLORALPHENAZONE/ISOMETHEPTENE MUCATE 
DIHYDROCODEINE TARTRATE/ASPIRIN 
ETHOHEPTAZINE CITRATE/ASPIRIN 
FENOPROFEN 
ISOMETHEPTENE MUCATE+ PARACETAMOL 
MEPROBAMATE+ETHOHEPTAZINE&ASPIR 
MORAZONE HYDROCHLORIDE+ PARACETAMOL 
NAPROXENSODIUM 
PAPAVERETUM+ ASPIRIN 
PARACETAMOL (ACETAMINOP)/CODEINE 450/8.1 
PARACETAMOL (ACETAMINOPHEN) 
PARACETAMOL (ACETAMINOPHEN)/CODEINE 
PARACETAMOL(ACETA/DYHYDROCODEINE500/20MG 
PARACETAMOL(ACETAM/PHENYLEP/DEXTROMETHOR 
PARACETAMOL(ACETAMINOPHEN)/CAFF/CODEINE 
PARACETAMOL(ACETAMINOPHEN)/OXYPHENBUTAZO 
PARACETAMOL/ ACETAMINOPHEN 
PARACETAMOL/ ACETAMINOPHEN/CAFFEINE 
PARACETAMOL+ ASPIRIN 
PARACETAMOL+ ASPIRIN & CODEINE 
PARACETAMOL+ CHLORMEZANONE 
PARACETAMOL+ CODEINE & CAFFEINE 
PARACETAMOL+ DEXTROPROPOXYPHENE 
PARACETAMOL+ DIPHENHYDRAMINE 
PARACETAMOL+ METHIONINE 
PARACETAMOL+ PHENYLEPHRINE 
PARACETAMOL+ PSEUDOEPHEDRINE 
PARACETAMOL+ SODIUM SALICYLATE 
PARACETAMOL+ADDITIONAL INGREDS 
PARACETAMOL+DIPHEN,EPHED&CAFF 
PARACETAMOL+GUAIFEN&PHENYLEPHR 
PARACETAMOL+PHENYLEPH VIT C+CAF 
PARACET AMOL + PH ENYLEPH RN E&CAFFI N 
PARACETAMOL+PHENYLPROP&DIPHENHY 
PARACETAMOL+PHENYLPROPANOLAMINE 
PARACETAMOL+PROMETH&DEXTRO'PHAN 
PARACETAMOL+PSEUDOEPH&DIPHENHYD 
PARACETAMOLCODEINE,DIPHENHY,CAF 
PARACETAMOLCODEINE,HYOSCINE,CAF 
PENTAZOCINE+ PARACETAMOL 
PHENYLEPHRINE+ADDITIONAL INGREDS 
PROMETHAZINE HYDROCHLORIDE+ PARACETAMOL 
PSEUDOEPHEDRINE+ PARACETAMOL 
SODIUM SALICYLATE 
CODEINE/PARACETAMOL(ACETAMINOPHEN)ls/s00 
CO-DYDRAMOL 
CO-PROXAMOL 
DEXTROPROPOXYPHENE NAPSYLATE/ASPIRIN 
DEXTROPROPOXYPHENE/PARACETAMOL (ACETAMIN 
DICHLORALPHENAZONE+ PARACETAMOL 
DIHYDROCODEINE+ PARACETAMOL 
ETHOHEPTAZINE/PARACETAMOL(ACETAMINOPHEN) 
IBUPROFEN 
MENTHOL 
METHOCARBAMOL+ ASPIRIN 
MYOLGIN 
NEFOPAM 
PARACETAMOL 
PARACETAMOL (ACETAMINOPH)/CODEINE 500/10 
PARACETAMOL (ACETAMINOPHEN) PAEDIATRIC 
PARACETAMOL& ASCORBIC ACID 
PARACETAMOL(ACETA/DYHYDROCODEINEsOO/30MG 
PARACETAMOL(ACETAMINOPH)/MEPROBAMATE/CAF 
PARACETAMOL(ACETAMINOPHEN)/DICHLORALPHEN 
PARACETAMOL(ACETOMINOPHEN)CAFFEI/CODEINE 
PARACETAMOL/ ACETAMINOPHEN SOLUBLE 
PARACETAMOL/ ACETAMINOPHEN/CO 
PARACETAMOL+ ASPIRIN & CAFFEINE 
PARACETAMOL+ CAFFEINE 
PARACETAMOL+ CODEINE 
PARACETAMOL+ CODEINE PHOSPHATE 
PARACETAMOL+ DIHYDROCODEINE 
PARACETAMOL+ ISOMETHEPTENE 
PARACETAMOL+ PENTAZOCINE 
PARACETAMOL+ PROMETHAZINE HCL 
PARACETAMOL+ SODIUM BICARBONATE 
PARACETAMOL+ VITAMIN C 
PARACETAMOL+DIPHEN & PHENYL 
PARACET AMOL + DIPH EN, PSU EDO, PHOLC 
PARACETAMOL+NaBICARB &: CAFFEINE 
PARACETAMOL+PHENYLEPH&ASCORB AC 
PARACETAMOL+PHENYLPROP &DEXTROM 
PARACETAMOL+PHENYLPROP&PHENYLTO 
PARACETAMOL+PROMETH HCL COL/FR 
PARACETAMOL+PSEUDOEPH&ASCORBIC 
PARACETAMOL+PSEUDOEPH+PHOLCODIN 
PARACETAMOLCODEINE,DOXYLAMI,CAF 
PARACETAMOLPSEUDOEPH&OTHERS 
PHENYLBUTAZON/PARACETAMOL(ACETAMINOPHEN) 
PHENYLPROPANOLAMINE+ PARACETAMOL 
PROMETHAZINE HYDROCHLORIDE+PARACET COL/FREE 
SALICYLAMIDE/PARACETAMOL 
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Drugs included in BNF code 5.01.03.00 
BLENMIX 
CH LORTETRACYCLIN E 
CHLORTETRACYCLINE HYDROCHLORIDE 
CLOMOCYCLINE 
DEMECLOCYCLINE HYDROCHLORIDE 
DEMECLOCYCLINE+CHLORTET & TETRACYC 
DOXYCYCLINE HCI 
DOXYCYCLINE MONOHYDRATE 
METACYCLINE 
MINOCYCLINE 
OXYTETRACYCLINE 
OXYTETRACYCLIN E/PROCAIN E HYDROCH LORID E 
TETRACYCLINE 
TETRACYCLINE HCI/AMPHOTERICIN 
TETRACYCLINE HYDROCHLORIDE 
TETRACYCLINE/NOVOBIOCIN 
TETRACYCLINE+ AMPHOTERACIN 
TETRACYCLINE+ PANCREATIC ENZYMES 
AMOXICILLIN+CLARITHROM & LANSOP 
CLARITHROMYCIN 
CLARITHROMYCIN+LANSOP & AMOXI 
ERYTHROMYCIN 
ERYTHROMYCIN ETHYL SUCCINATE 
ERYTHROMYCIN ETHYLSUCCINATE 
ERYTHROMYCIN LACTOBIONATE 
ERYTHROMYCIN STEARATE 
ERYTHROMYCINSPRINKLE 
SPIRAMYCIN 
Drugs included in BNF code 5.01.05.00 
BROMHEXINE HCL/OXYTETRACYCLINE HCL 
CHLORTETRACYCLINE HCI/DEMECLOCYCLINE HCI 
CHLORTETRACYCLINE+DEMECLOCYC&TETRACYC 
DEMECLOCYCLINE 
DEMECLOCYCLINE HYDROCHLORIDE DROPS 
DOXYCYCLINE 
DOXYCYCLINE HYCLATE 
LYMECYCLINE 
METHACYCLINE HYDROCHLORIDE 
NYSTATIN+ TETRACYCLINE HCL 
OXYTETRACYCLIN E/EPH EDRIN E/IPECACUAN HA 
OXYTETRACYCLINE+ BROMHEXINE HCL 
TETRACYCLINE HCI 
TETRACYCLINE HCL/PANCREATIC CONCENTRATE 
TETRACYCLINE/CHLORTETRACY/DEMECLOCYCLINE 
TETRACYCLINE/PROCAINE HYDROCHLORIDE 
TETRACYCLINE+ NYSTATIN 
TETRACYCLINE+CHORTET&DEMECLOCYC 
AZITHROMYCIN 
CLARITHROMYCIN SOOMG VIAL IN 
CLARITHROMYCINmetronid + lanzop 
ERYTHROMYCIN E/C 
ERYTHROMYCIN ETHYL SUCCINATE S/F 
ERYTHROMYCIN ETHYLSUCCINATECOATED 
ERYTHROMYCIN SACHET S/F 
ERYTHROMYCINESTOLATE 
LANSOPRAZOLE+AMOXI & CLARITH 
TELITHROMYCIN 
AMOXICILLIN+CLARITHROM & LAN SOP ERYTHROMYCIN ETHYLSUCCINATE 
AZITHROMYCIN ERYTHROMYCIN ETHYLSUCCINATECOATED 
t-;:;C-;-LA:;R~I~TH:-;-;R;;-;O;;-;M-::Y"'"'C~-;-I;-;-N-------------t-;::E;:;;RYT~HROMYCIN LACTOBIONATE 
CLARITHROMYCIN SOOMG VIAL IN ERYTHROMYCIN SACHET S/F 
CLARITHROMYCIN+LANSOP & AMO'-X'-I -------+-:E=R-:-:YT:::H7.RO":O:7M7.Y7:C:::cIN:c-::S::OTE::-A:-::RA:7.::T:::-E---'---------"1 
CLARITHROMYCINmetronid + lanzop ERYTHROMYCINESTOLATE 
~RYTHROMYCIN 
f--------------------=--------------t-;--:-:::;;-;;;~~-;;-;-,;;-~ -----------~------------j 
ERYTHROMYCIN E/C LANSOPRAZOLE+AMOXI & CLARITH 
ERYTHROMYCIN ETHYL SUCCINATE SPIRA~YCIN 
ERYTHROMYCIN ETHYL SUCCINATE S/F TELITHROMYCIN 
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Drugs included in BNF code 5.04.01.00 
AMODIAQUINE 
CHLOROQUINE 
CHLOROQUINE PHOSPHATE 
CHLOROQUINEPHOSPHATE 
DAPSONE+ PYRIMETHAMINE 
HYDROXYCHLOROQUINE SULPHATE 
MEFLOQUINE HYDROCHLORIDE 
PROGUANIL 
PROGUANIL HYDROCHLORIDE 
PYRIMETHAMINE 
PYRIMETHAMINE+ SULFADOXINE 
QUININE DIHYDROCHLORIDE 
QUININEBISULPHATE 
QUININEHCL 
TETRACYCLINE 
Drugs included in BNF code 6.03.02.00 
BETAMETHASONE 
BETAMETHASONE VALERATE 
DEFLAZACORT 
DEXAMETHASONE SODIUM PHOSPHATE 
HYDROCORTISONE ACETATE 
HYDROCORTISONE NA SUCCINATE 
HYDROCORTISONE SODIUM SUCCINATE 
METHYLPREDNISOLONE ACETATE 
PREDNISOLONE 
PREDNISOLONE E/C 
PREDNISOLONEACETATE 
PREDNISONE 
TRIAMCINOLONE ACETONIDE 
ATOVAQUONE+PROGUANIL HYDROCHLR 
CHLOROQUINE AND PROGUANIL 
CHLOROQUINE SULPHATE F/C 
CHLOROQUINESULPHATE 
HALOFANTRINE 
MEFLOQUINE 
PRIMAQUINE PHOSPHATE 
PROGUANIL AND CHLOROQUINE 
PROGUANIL+ ATOVAQUONE 
PYRIMETHAMINE+ DAPSONE 
QUININE BISULPHATE 
QUININE SULPHATE 
QUININEDIHYDROCHLORIDE 
QUININESULPHATE 
BETAMETHASONE SODIUM PHOSPHATE 
CORTISONE ACETATE 
DEXAMETHASONE 
HYDROCORTISONE 
HYDROCORTISONE NA PHOSPHATE 
HYDROCORTISONE SODIUM PHOSPHATE 
METHYLPREDNISOLONE 
METHYLPREDNISOLONE SODIUM SUCC 
PREDNISOLONE ACETATE 
PREDNISOLONE SODIUM PHOSPHATE 
PREDNISOLONESTEAGLATE 
TRIAMCINOLONE 
Drugs included in BNF code 10.01.01.00 
ACECLOFENAC ACEMETACIN 
ACETYLSALICYLIC ACID ALOXIPRIN 
ASPIRIN ASPIRIN+ GLYCINE 
ASPIRIN+NA BICARB&CITRIC AC AZAPROPAZONE 
BENORILATE BENOXAPROFEN 
CELECOXIB CHOLINE MG TRISALICYLATE 
CODEINE PHOSPHATE/IBUPROFEN DEXKETOPROFEN 
DICLOFENAC DICLOFENAC POTASSIUM 
DICLOFENAC SODIUM DICLOFENAC SODIUM (3ML) 
DICLOFENAC SODIUM M/R DICLOFENAC& MISOPROSTOL 
DICLOFENACDISPERSIBLE DICLOFENACSODIUM 
DIFLUNISAL ETODOLAC 
FENBUFEN FENCLOFENAC 
FENOPROFEN FENOPROFEN (AS CALCIUM SALT) 
FENOPROFEN DISPERSIBLE FEPRAZONE 
FLUFENAMIC ACID FLURBIPROFEN 
IBUPROFEN IBUPROFEN F/C 
IBUPROFEN SIR IBUPROFEN& CODEINE 
IBUPROFEN(AS LYSINE) IBUPROFEN/CODEINE PHOSPHATE 
INDOMETACIN INDOMETHACIN 
.' 
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INDOPROFEN 
LORNOXICAM 
MELOXICAM 
NAPROXEN 
NAPROXEN+MISOPROSTOL(combin) 
PARACETAMOL(ACETAMINOPHEN)/OXYPHENBUTAZO. 
PHENYLBUTAZONE 
PHENYLBUTAZONE/AL HYDROXI/MG TRISILICATE 
PH ENYLBUT AZON E/PARACETAMOL(ACET AM INOPH EN 
PIROXICAM(BETA-CYCLODEXTRIN) 
SALSALATE 
SODIUM SALICYLATE 
SUPROFEN 
TENOXICAM 
TOLFENAMIC ACID 
TOLMETIN (AS SODIUM SALT) 
KETOPROFEN 
MEFENAMIC ACID 
NABUMETONE 
NAPROXEN& MISOPROSTOL 
OXYPHENBUTAZONE 
PHENYLBUTAZON/PARACETAMOL(ACETAMINOPHEN) 
PHENYLBUTAZONE ALKA 
PHENYLBUTAZONE/LIGNOCAINE 
PIROXICAM 
SALICYLAMIDE/PARACETAMOL 
SALSALATE (SALICYL SALICYLATE) 
SULINDAC 
SUTOPROFEN 
TIAPROFENIC ACID 
TOLMETIN 
Drugs included in BNF code 10.01.03.00 
URANOFIN 
CHLOROQUINEPHOSPHATE 
ETANERCEPT 
INFLIXIMAB 
METHOTREXATE SODIUM 
SODIUM AUROTHIOMALATE 
SULPHASALAZINE 
AZATHIOPRINE 
CICLOSPORIN 
HYDROXYCHLOROQUINE SULPHATE 
LEFLUNOMIDE 
PENICILLAMINE 
SULFASALAZINE 
Drugs included in BNF code 10.01.04.01 
AZAPROPAZONE 
DICLOFENAC 
KETOPROFEN 
PIROXICAM 
Drugs included in BNF code 11.04.02.00 
r-:-' . 
ADRENALINE ACID TARTRATE+ ZN SULPH & BORIC 
ANTAZOLINE SULPHATE/NAPHAZOLINE NITRATE 
ANTAZOLINE+ NAPHAZOLINE 
1---:-:-.-.--.. ---.-------.---
ANTAZOLINE+ XYLOMETAZOLINE 
~ELASTINE 
EMEDASTINE DIFUMARATE 
HAMAMELIS WATER 
1--- -
INDOMETHACIN DROPS 
~ETOTIFEN 
LEVOCABASTiN E 
r.--, 
LODOXAMIDE 
NAPHAZOLINE HCI DROPS 
NAPHAZOLINE HYDROCHLORIDE 
COLCHICINE 
INDOMETACIN 
NAPROXEN 
SULINDAC 
NAPHAZOLINE HYDROCHLORIDE+ HAMAMELIS 
NAPHAZOLINE/WITCH HAZEL/BORIC A/GLYCEROL 
NEDOCROMIL SODIUM 
-----_. 
OXYPHENBUTAZONE 
o"XYPHENBUTAZ-ONE+ CHLORAMPHENICOL 
SODIUM BICARBONATE DROPS 
SODIUM BICARBONATE OPHTHALMIC 
SODIUM CROMOGLICATE 
SODIUMCROM OG LYCATE(EYE) 
TETRAHYDROZOLINE HCI 
TETRAHYDROZOLINE/BENZALI<ONIUM 
XYLOMETAZOLINE HYDROCHLORIDE+ ANTAZOLINE 
SULPH. 
ZINC S!JLPHATE/HAMAMELIS/BENZALKONIUM CI 
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Drugs included BNF code 13.02.01.02 
ALLANTOIN+ HEXACHLOROPHENE 
ALMOND OIL+ LIQUID PARAFFIN 
AQUEOUS 
ARACHIS OIL+ LIQUID PARAFFIN 
CETOMACROGOL 
DEIONISED WATER+GLYCERIN+BENZ ALC 
DIMETICONE& BENZYL ALCOHOL 
EMOLLIENT 
EMOLLIENT + HYDROXYBENZOATES 
EMOLLIENT +H-A LANOLIN+PRESERV 
EMOLLIENTHYPOALLERGENIC LAN 
ESSENTIAL FATTY ACIDSESTERIFIED 
HYDROUS 
LIGHT LIQUID PARAFFIN+ ISOPROPYLMYRISTATE 
LIGHT LIQUID PARAFFIN+BENZALCHLOR&TRICLOS 
LIQUID PARAFFIN+ ACET WOOL ALCOHOLS 
LIQUID PARAFFIN+ ISOPROPYLMYRISTATE 
LIQUID PARAFFIN BENZ CHL & ISOP MYR 
MINERAL OIL+LANOLIN &HYDROXBENZ 
PARAFFIN AND WOOL FAT+CETOSTEARYL ALCOHOL 
PROPYLENE GLYCOL+ UREA & OTHER INGRD 
SIMPLE 
SODIUM PYRROLIDONE 
SOYA+ LAUROMACROGOLS 
TANNIC ACID+ MENTHOL&PHENOL 
UREA 
UREA+ SODIUM CHLORIDE 
UREAWITH LAUROMACROGOIS 
WHITE SOFT PARAFFIN 
WHITE SOFT PARAFFIN+COCONUT OIL+GLYCERL 
WOOL ALCOHOLS 
ZINC OXIDE 
ZINC OXIDE+ LANOLIN 
ALMOND OIL 
AMMONIA+ PHENOL 
ARACHIS OIL 
Aveeno 
CHAMOMILE+LANOLIN &HYDROXBENZ 
DEIONISED WATER+GLYCERIN+PRO.GLYCOL 
E45 
EMOLLIENT + CHLOROCRESOL 
EMOLLIENT + LACTIC ACID 
EMOLLIENT +LANOLIN &HYDROXBENZ 
EMULSIFYINGOINT + PHENOXYETHANOL 
HERBAL EMOLLIENT 
LIGHT LIQUID PARAFFIN 
LIGHT LIQUID PARAFFIN+ALMOND OIL 
LIQUID PARAFFIN 
LIQUID PARAFFIN+ BENZALKONIUM CL 
LIQUID PARAFFIN+ANTIMICROBIALS 
LUBRICANT+ PARAFFIN 
OILY 
PETROLEUMWHITE 
PYRROLIDONE CARBOXYLIC ACID 
SODIUM LAURYL ETHER SULPHATE+ OTHERS 
SOYA 
SOYA+ TAR 
TOCOPHERYL 
UREA+ LACTIC ACID 
UREACETRI+CHLOROCRS+DEME 
Vaseline Dermacare 
WHITE SOFT PARAFFIN+ LIQUID PARAFFIN 
WHITE SOFT PARAFFIN+LIGHT LIQ PARRAFIN 
YELLOW SOFT PARAFFIN PARAFFIN AND WAX 
ZINC OXIDE+ C.L.O. & LANOLIN 
Drugs included in BNF code 13.04.00.00 
ALCLOMETASONE DIPROPIONATE 
BECLOMETASONE+ CHLORTETRACYCLINE 
BECLOMETHASONE DIPROPIONATE 
BENZALKONIUM/SALICYLIC ACI/TRIAMCINOLONE 
BETAMETHASONE 
BETAMETHASONE BENZOATE 
BETAMETHASONE DIPROPIONATE& SALICYLIC ACID 
BETAMETHASONE DIPROPIONATEDUOPACK 
BETAMETHASONE IN WHITE SOFT PARAFFIN 
BETAMETHASONE PREPARATION 
BETAMETHASONE VAL/WHITE SOFT PARAFFIN 
BETAMETHASONE VALERATE/CHLORHEXIDINE 
BETAMETHASONE VALERATE/WEAK TAR PASTE 
BETAMETHASONE VALERATE+ CLOTRIMAZOLE 
BETAMETHASONE VALERATE+ NEOMYCIN 
BETAMETHASONE/CHLORHEXIDINE/PARAFFIN 
BECLOMETASONE 
BECLOMETASONE+ CLIOQUINOL 
BECLOMETHASONE/CLIOQUINOL 
BETAMETHASONE 
BETAMETHASONE (AS SODIUM PHOSPHATE) 
BETAMETHASONE DIPROPIONATE 
BETAMETHASONE DIPROPIONATE + FLUOCIN, GENT + SAL 
AC 
BETAMETHASONE IN EMULSIFYING OINTMENT 
BETAMETHASONE IN WHITE SOFT PARAFFIN OIL 
BETAMETHASONE VAL 0.1 %/NEOMYCIN SUL 0.5% 
BETAMETHASONE VALERATE 
BETAMETHASONE VALERATE/NEOMYCIN SULPHATE 
BETAMETHASONE VALERATE+ CLIOQUINOL 
BETAMETHASONE VALERATE+ FUSIDIC ACID 
BETAMETHASONE/CHLORHEXIDIN/CETOMACROGOL 
BETAMETHASONE/CLIOQUINOL 
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BETAMETHASONE/COAL TAR/WHITE SOFT PARAFF 
BETAMETHASONE/UREA/LAVENDER/CETOMACROGOL 
CALAMINE 20.88%/HYDROCORTISONE 0.5% 
CHLORHEXIDINE/HYDROCORTISONE/NYSTATIN 
CHLORTETRACYCLINE/CLOBETASONE BUTYRATE 
CLIOQUINOL 
CLIOQUINOL/HYDROCORTISONE ACETATE 
CLIOQUINOL+ FLUOCINOLONE 
CLIOQUINOL+ HYDROCORTISONE 
CLOBETASOL PROPIONATE+ NEOMYCIN 
CLOBETASONE BUTYRATE+ OXYTET & NYSTATIN 
CLOTRIMAZOLE+ HYDROCORTISON E 
CORTICOSTEROIDS 
CROTAMITON+ HYDROCORTISONE 
DESOXIMETASONE 
DESOXIMETASONE+ NEOMYCIN 
DIFLUCORTOLONE VALERATE 
DIMETHICONE IN CLOBETASOL PROPIONATE 
DITHRANOL/CLOBETASOL PRO PI/PARAFFIN SOFT 
ECONAZOLE+ TRIAMCINOLONE 
FLUOCINOLONE 
FLUOCINOLONE ACETONIDE 
FLUOCINOLONE ACETONIDE+ CLIOQUINOL 
FLUOCINOLONE7CETOMACROGOL B/CLIOQUINOL 
FLUOCINONIDE 
FLUOCORTOLONE ACETONIDE 
FLUOCORTOLONE/FLUOCORTOLONE HEXANOATE 
FLURANDRENOLONE+ CLIOQUINOL 
FRAMYCETIN SULPH/HYDROCORTISONE ACETATE 
FUSIDIC ACID/HYDROCORTISONE ACETATE 
GENTAMICIN+ HYDROCORTISONE 
HALQUINOL/TRIAMCINOLONE 
HYDROCORTISON E 
HYDROCORTISONE 1% IN WEAK COAL TAR PASTE 
HYDROCORTISONE BUTYRATE+ CHLORQUINALDOL 
HYDROCORTISONE IN CETOMACROGOL FORMULA A 
HYDROCORTISONE IN DIMETHICONE 
HYDROCORTISONE IN WATER-MISCIBLE BASIS 
HYDROCORTISONE NON-GREASY 
HYDROCORTISONE/NEOMYCIN 
HYDROCORTISONE/TYROTHRICIN 
HYDROCORTISONE+ CLIOQUINOL 
HYDROCORTISONE+ CROTAMITON 
HYDROCORTISONE+ ECONAZOLE NITRATE 
HYDROCORTISONE+ FUSIDIC ACID 
HYDROCORTISONE+ MICONAZOLE NITRATE 
HYDROCORTISONE+ NYSTATIN &CHLORHEX 
HYDROCORTISONE+ PRAMOCAINE HCL 
HYDROCORTISONE+ UREA 
HYDROCORTISONE+ UREA & NaCI 
HYDROCORTISONE+NEOMYC+NYSTAT+POLYM 
HYDROCORTISONE+NYSTAT +DIMETICONE+ 
MICONAZOLE+ HYDROCORTISONE 
NEOMYCIN SULPHATE/HYDROCORTISONE 
NYSTATIN/TRIAMCINOLONE ACETONIDE 
NYSTATIN+'HYDROCORT &CHLORHEX 
NYSTATIN+NEOMY+BACITRAC+H.C. 
BETAMETHASONE/SALICYCLIC ACID 2% 
BUDESONIDE 
CALAMINE/HYDROCORTISONE 1% 
CHLORQUINALDOL/HYDROCORTISONE 
CHLORTETRACYCLINE/HYDROCORTISONE/PARAFF 
CLIOQUINOL 3%/HYDROCORTISONE ACET 0.5% 
CLIOQUINOL+ BETAMETHASONE 
CLIOQUINOL+ FLURANDRENOLONE 
CLOBETASOL PROPIONATE 
CLOBETASONE BUTYRATE 
CLOBETASONE/NYSTATIN/OXTETRACYLINE 
CLOTRIMAZOLE+BETAMATHASONE 
CORTICOSTEROIDS 0.02%/HEPARINOID 0.2%/SA 
DESONIDE 
DESOXIMETASONE& SALICYLIC ACID 
DESOXYMETHASONE 
DIFLUCORTOLONE VALERATE FATTY 
DITHRANOL 0.1% IN CLOBETASONE BUTYRATE 
ECONAZOLE+ HYDROCORTISONE 
FLUCLOROLONE ACETONIDE 
FLUOCINOLONE ACE 0.025%/NEOMYCIN SU 0.5% 
FLUOCINOLONE ACETONIDE/NEOMYCIN SULPHATE 
FLUOCINOLONE ACETONIDE+ NEOMYCIN 
FLUOCINOLONE/LAVENDER OIL/CETOMACROGOL 
FLUOCORTOLONE 
FLUOCORTOLONE HEXANOATE & PIVALATE 
FLURANDRENOLONE 
FLUTICASONE 
FRAMYCETIN+ HYDROCORTISONE 
FUSIDIC ACID+ HYDROCORTISONE 
HALCINONIDE 
HEPARIN SODIUM/HYDROCORTISONE ACETATE 
HYDROCORTISONE 1% IN COAL TAR MILD 
HYDROCORTISONE BUTYRATE 
HYDROCORTISONE IN AQUEOUS CREAM 
HYDROCORTISONE IN COAL TAR PASTE 
HYDROCORTISONE IN SILICONE BARRIER 
HYDROCORTISONE IN WHITE SOFT PARAFFIN 
HYDROCORTISONE/CHLORTETRACYCLINE/PARAFFI 
HYDROCORTISON E/N EOMYCIN/ZINC BACITRACIN 
HYDROCORTISONE+ CALAMINE 
HYDROCORTISONE+ CLOTRIMAZOLE 
HYDROCORTISONE+ DIMETICONE 
HYDROCORTISONE+ FRAMYCETIN 
HYDROCORTISONE+ GENTAMICIN 
HYDROCORTISONE+ NEOMYCIN 
HYDROCORTISON E+ OXYTETRACYCLIN 
HYDROCORTISONE+ SODIUM FUSIDATE 
HYDROCORTISONE+ UREA & LACTIC ACID 
HYDROCORTISONE+K.HYDROXYQUNINOLINE 
HYDROCORTISONE+NEOMYCIN&BACITRACIN 
METHYLPREDNISOLONE+ NEOMYCIN 
MOMETASONE 
NEOMYCIN SULPHATE+NYSTAT +BACITRA+H.C. 
NYSTATIN+CLOBETASOL&NEOMYCIN 
NYSTATIN+HYDROCORT &NEOMYCIN 
OXYTETRACYCLINE+ HYDROCORTISONE 
161 
OXYTETRACYCLINE+HYDROCORT &NYSTATIN 
TRIAMCINOLONE 0.1 %/CHLORTETRACYCLINE 3% 
TRIAMCINOLONE ACETONIDE 
TRIAMCINOLONE ACETONIDE+ NYSTATIN 
TRIAMCINOLONE ACETONIDE+GRAMICIDIN+NEOMYCIN 
TRIAMCINOLONE/GRAMICIDIN/NEOMYCIN/NYSTAT. 
UREA 10%/HYDROCORTISONE 1% 
SODIUM FUSIDATE+ HYDROCORTISONE 
TRIAMCINOLONE ACETONID/CHLORTETRACYCLINE 
TRIAMCINOLONE ACETONIDE/HALQUINOL 
TRIAMCINOLONE ACETONIDE+CHLORTETRACYCLINE 
TRIAMCINOLONE ACETONIDE+NEOMY+NYSTAT +GRAMIC 
TRIAMCINOLONE+NEOMYC&UNDECYLENATE 
UREA+HYDROCORT&LACTIC AC 
Drugs included in BNF code 13.06.01.02 
BENZOYL PEROXIDE+ ERYTHROMYCIN 
CLINDAMYCIN PHOSPHATE 
ERYTHROMYCIN+ BENZOYL PEROXIDE 
ISOTRETINOIN+ ERYTHROMYCIN 
TETRACYCLINE 
BENZOYL PEROXIDE+ MICONAZOLE NITRATE 
ERYTHROMYCIN 
ERYTHROMYCIN+ ZINC ACETATE 
MICONAZOLE+ BENZOYL PEROXIDE 
Drugs included in BNF code 13.06.02.01 
DOXYCYCLINE HYCLATE 
ERYTHROMYCIN+ TRETINOIN 
MINOCYCLINE 
ERYTHROMYCIN 
ERYTHROMYCINESTOLATE 
TETRACYCLINE 
Drugs included in BNF code 13.08.01.00 
AMINOBENZOIC ACID 
AMINOBENZOIC ACID/ PADIMATE-O/ UVB SPF 10 
AVOBENZONE/ EtHex P-METHOXYCINNAMATE 
EtHex P-METHOXYCINNAMATE/ AVOBENZONE/ TITA 
METHOXYCINNAMATE/ OXYBENZONE/ Et Hex SALIC 
PADIMATE-O 3.2% 
P-METHOXYCINNAMATE/ AVOBENZONE/ TITANIUM D 
P-METHOXYCINNAMATE/ METHOXYDIBENZ/ FACIAL 
SUN PROTECTION MILK/FACTOR 6 
SUN PROTECTION/FACTOR 4 
SUN PROTECTION/LIPS/FACTOR 8 
SUN PROTECTON/SPF 12 
TITANIUM DIOXIDE 
AMINOBENZOIC ACID/ PADIMATE-O 
AMINOBENZOIC ACID/ PADIMATE-O/ UVB SPF 25 
AVOBENZONE/ OXYBENZONE/ PADIMATE/ TITANIUM 
ETHYL p-DIMETHYL AMINOBENZ/ TITANIUM DIOX 
MEXENONE 
P-METHOXYCINNAMATE/ AVOBENZONE/ TITANIUM 
P-METHOXYCINNAMATE/ METHOXYDIBEN/ TITANIUM 
SUN PROTECTION 
SUN PROTECTION/FACIAl.:/SPF 8 
SUN PROTECTION/FACTOR 8 
SUN PROTECTION/SPF 8 
TITANIUM DIOX/RED FERR OXIDE/BURNT SUGA 
TITANIUM DIOXIDE PASTE 
Drugs included in BNF code 13.08.01.01 
Almay SPF12, SPF30 and SPF30 
Ambre Solaire SPF25 and SPF60 
Delph Children's SPF30 
Ambre Solaire HP SPFI0 and SPF12 
Ambre Solaire SPF60/sun intol skin 
Delph SPF15, SPF20, SPF25 and SPF30 
E45 SUN SPF15 E45 Sun Block SPF25 and SPF50 
ETHYLHEXYL-P-METHOXYCINNAMATE+ AVOBENZONE ETHYLHEXYL-P-METHOXYCINNAMATE+ AVOBENZONE+ 
HYDROQUINONE+PADIMATE-O+OXYBENZO 
METHOXYCINNAMATE+AVOBENZONE&TITANIUM 
METHYLBENZYLIDENE CAMPHOR+ AVOBENZONE+ 
TITANIUM 
OXYBENZONE+ PADIMATE 0 
TITANIUM 
METHOXYCINNAMATE+ AVOBENZONE 
METHYL PHENYLBENZOXAZOLE 
METHYLBENZYLIDENE CAMPHOR+ 
BUTYLMETHOXYDIBENZO 
PADIMATE 0+ AMINO BENZOIC ACID 
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PADIMATE 0+ OXYBENZONE 
Piz Buin SPF12, SPF20 and SPF30 
Roc total sunblock SPF16 and SPF25 
Spectra ban Ultra SPF28 
Sunsense Ultra SPF60 
Uvistat SPF10, SPF15, SPF20 and SPF8 
PADIMATE O+OXYBENZONE&M'CINNAM 
Roc 
Spectra ban 15, Spectraban 25 
Sun E45 SPF15, SPF25 and SPF50 
Uvistat Babysun SPF22 
Drugs included in BNF code 13.10.01.02 
CHLORTETRACYCLINE 
CHLORTETRACYCLINE+ HYDROCORTISONE 
GENTAMICIN 
OXYTETRACYCLINE 
TETRACYCLINE 
CHLORTETRACYCLINE HYDROCHLORIDE 
FUSIDIC ACID 
METRON IDAZOLE 
SODIUM FUSIDATE 
Drugs included in BNF code 13.10.02.00 
4-NITROPHENOL 
AMPHOTERICIN 
BENZOIC ACID§< SALICYLIC ACID 
BIFONAZOLE 
CHLORPHENESIN 
CLOTRIMAZOLE 
DICHLOROPHEN+ TRICLOSAN 
ECONAZOLE NITRATE 
HYDROCORTISONE+ CLOTRIMAZOLE 
KETOCONAZOLE 
MICONAZOLE NITRATE 
NYSTATIN 
NYSTATIN/ZINC OXIDE 
NYSTATIN+ TOLNAFTATE 
SALICYLIC ACID 
SA~ICYLIC ACID/METHYL HYDROXYBENZOATE 
SULCONAZOLE NITRATE 1 % 
TIOCONAZOLE 
TOLNAFTATE 1 %/ ZINC NAPHTHENATE 8% 
UNDECENOIC ACID 2.5%/ DICHLOROPHEN 0.25% 
WHITFIELDS 
ZINC UNDECENOATE 20%/ UNDECENOIC ACID 5% 
AMOROLFINE 
BENZOIC ACID 
BENZOIC ACIDCOMPOUND 
BUCLOSAMIDE/SALICYLIC ACID 
CHLORQUINALDOL 
CLOTRIMAZOLE+ HYDROCORTISONE 
ECONAZOLE 
HALQUINOL 
HYDROCORTISONE+NEOMYC+NYSTAT +POLYM 
MICONAZOLE 
NATAMYCIN 
NYSTATIN/CLIOQUINOL 
NYSTATIN+ CHLORHEXIDINE HCL 
NYSTATIN+ ZINC OXIDE 
SALICYLIC ACID/BENZOIC (WHITFIELD'S) 
SULCONAZOLE NITRATE __ 
TERBINAFINE 
TOLNAFTATE 
UNDECENOATES 
UNDECENOIC ACIDDIBROMPROPAMIDINE 
ZINC UNDECENOATE 
Drugs included in BNF code 15.01.04.01 
CLOMETHIAZOLE 
DROPERIDOL 
FENTANYL+ DROPERIDOL 
MIDAZOLAM 
TEMAZEPAM 
DIAZEPAM 
DROPERIDOL+ FENTANYL 
LORAZEPAM 
PROMETHAZINE HYDROCHLORIDE 
TRIMEPRAZINE TARTRATE 
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